	Page
UNITED STATES I	DISTRICT COURT
NORTHERN DISTRIC	T OF CALIFORNIA
IN RE: ROUNDUP PRODUCTS	
LIABILITY LITIGATION)
) Case No.
) 16-md-02741-VC
THIS DOCUMENT RELATES TO ALI	Ц)
CASES)
)
VIDEOTAPED DEPOSITION OF A	AARON EARL BLAIR, Ph.D
WASHINGTO	N, D.C.
MONDAY, MARCH	H 20, 2017
8:59 A	.M.
Reported by: Leslie A. Todd	

Page 2 Deposition of AARON EARL BLAIR, Ph.D., held at the offices of: HOLLINGSWORTH, LLP 1350 I Street, N.W. Suite 1000 Washington, DC 20005 (202) 898-5800 Pursuant to notice, before Leslie Anne Todd, Court Reporter and Notary Public in and for the District of Columbia, who officiated in administering the oath to the witness.

Page 3 1 APPEARANCES 2 3 ON BEHALF OF PLAINTIFFS: 4 MICHAEL MILLER, ESQUIRE mmiller@millerlawfirmllc.com 5 NANCY GUY ARMSTRONG MILLER, ESQ. JEFFREY TRAVERS, ESOUIRE 6 JTravers@millerfirmllc.com MILLER FIRM, LLC 7 108 Railroad Avenue 8 Orange, Virginia 22960 9 (540) 672-4224 10 11 -and-12 KATHRYN M. FORGIE, ESQUIRE kathryn.forgie@andruswagstaff.com 13 AIMEE H. WAGSTAFF, ESQUIRE (Telephonically) aimee.wagstaff@andruswagstaff.com 14 ANDRUS WAGSTAFF, PC 7171 West Alaska Drive 15 Lakewood, Colorado 80226 (310) 339-8214 16 17 ON BEHALF OF MONSANTO COMPANY: 18 ERIC G. LASKER, ESQUIRE elasker@hollingsworthllp.com 19 JOSEPH G. HOLLINGSWORTH, ESQUIRE jhollingsworth@hollingsworthllp.com 20 ELYSE A. SHIMADA, ESQUIRE eshimada@hollingsworthllp.com 21 HOLLINGSWORTH, LLP 1350 I Street, N.W., Suite 1000 22 23 Washington, DC 20005 24 (202) 898-5800 25

Page 4 A P P E A R A N C E S (Continued) ON BEHALF OF THE WITNESS: DAVID S. GREENE, ESQUIRE LAW OFFICES OF DAVID S. GREENE, LLC 611 Rockville Pike Suite 225 Rockville, Maryland 20852 (301) 279-7600 ALSO PRESENT: DANIEL HOLMSTOCK (Videographer)

Page 5 1 CONTENTS EXAMINATION OF AARON EARL BLAIR, Ph.D. 2 PAGE 3 By Mr. Miller 11, 263, 296 4 By Mr. Lasker 89, 293 5 6 7 8 9 EXHIBITS 10 (Attached to transcript) BLAIR DEPOSITION EXHIBITS 11 PAGE 12 No. 1 Curriculum Vitae of Aaron Earl Blair, February 6, 2017 18 13 14 No. 2 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, 15 16 Preamble, Lyon, France 2006 23 No. 3 IARC Monographs on the Evaluation of 17 Carcinogenic Risks to Humans, Volume 18 19 112 36 45 20 No. 4 Document titled "Glyphosate" 21 Article entitled "Carcinogenicity of No. 5 22 Tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate" 66 23 No. 6 International Agency for Research on 24 25 Cancer, World Health Organization paper 71

٦

				Page 6
1		E	XHIBITS CONTINUED	
2			(Attached to transcript)	
3	BLAI	R DEP	OSITION EXHIBIT	PAGE
4	No.	7	NAPP Poster Presentation, Bates	
5			MONGLY00340901 to MONGLY00340902	80
6	No.	8	E-mail string re IARC - NAPP	
7			Epidemiology Study Abstract re:	
8			Glyphosate and NHL, Bates	
9			MONGLY02365099 to MONGLY02365101	82
10	No.	9	Environmental Health Perspectives,	
11			IARC Monographs: 40 Years of	
12			Evaluating Carcinogenic Hazards to	
13			Humans, Bates MONGLY01154782 to	
14			MONGLY01154819	85
15	No.	10	E-mail re Monograph Meeting	98
16	No.	11	E-mail string re Monograph Meeting	99
17	No.	12	Volume 112 - Overview of assignments	104
18	No.	13	Handwritten notes	122
19	No.	14	E-mail string re Minutes from NAPP	
20			Meeting on October 20	130
21	No.	15	E-mail re Proposal to analyze	
22			Glyphosate exposure and NHL risk in	
23			NAPP	133
24				
25				

		I	Page 7
1	E	XHIBITS CONTINUED	
2		(Attached to transcript)	
3	BLAIR DEF	POSITION EXHIBIT	PAGE
4	No. 16	OCRC: An Detailed Evaluation of	
5		Glyphosate Use and the Risk of Non-	
6		Hodgkin Lymphoma in the North	
7		American Pooled Project (NAPP)	145
8	No. 17	Article entitled "Cancer Incidence	
9		Among Glyphosate-Exposed Pesticide	
10		Applicators in the Agricultural Health	1
11		Study"	152
12	No. 18	Article entitled "Differences in the	
13		Carcinogenic Evaluation of Glyphosate	
14		Between the International Agency for	
15		Research on Cancer and the European	
16		Food Safety Authority"	158
17	No. 19a	DRAFT - Risk of total and cell	
18		Specific non-Hodgkin Lymphoma and	
19		pesticide use in the Agricultural	
20		Health Study	165
21	No. 19b	DRAFT - Lymphoma risk and	
22		pesticide use in the Agricultural	
23		Health Study	165
24			
25			

Page 8 1 EXHIBITS CONTINUED 2 (Attached to transcript) 3 BLAIR DEPOSITION EXHIBIT PAGE 4 No. 20 Article entitled "Non-Hodgkin PAGE 5 Lymphoma and Occupational Exposure to Agricultural Pesticide Chemical Groups PAGE 6 Agricultural Pesticide Chemical Groups PAGE 7 and Active Ingredients: A Systematic PAGE 8 Review and Meta-Analysis" PAGE 9 No. 21 E-mail re: A second thought about the PAGE 10 Rejection of the NHL manuscript 200 11 No. 22 E-mail string re Interview with Betty PAGE 13 Jibben and the Farm Journal 217 14 No. 24 E-mail string re Quick question from 210 15 Carey Gillam 220 16 No. 26 E-mail string re IARC 228 19 No. 26 E-mail string re Maeting on Glyphosate 228 20 No. 28 E-mail string re Pesticide Exposure 23 21 No. 29 E-mail string re Pesticide Exposure </th <th></th> <th></th> <th></th> <th></th> <th></th>					
2(Attached to transcript)3BLAIR DEPOSITION EXHIBITPAGE4No. 20Article entitled "Non-Hodgkin5Lymphoma and Occupational Exposure to6Agricultural Pesticide Chemical Groups7and Active Ingredients: A Systematic8Review and Meta-Analysis"9No. 21E-mail re: A second thought about the10Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty21113Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22015Carey Gillam22016No. 25E-mail string re IARC22519No. 26E-mail string re IARC22519No. 28E-mail string re Meeting on Glyphosate2302105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23224No. 30E-mail string re EPA and glyphosate235				Pa	age 8
3BLAIR DEPOSITION EXHIBITPAGE4No. 20Article entitled "Non-Hodgkin5Lymphoma and Occupational Exposure to6Agricultural Pesticide Chemical Groups7and Active Ingredients: A Systematic8Review and Meta-Analysis"9No. 21E-mail re: A second thought about the10Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty21714No. 24E-mail string re Quick question from21615Carey Gillam22016No. 25E-mail string From Marie-Monique22117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate2302105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	1		E	XHIBITS CONTINUED	
4No. 20Article entitled "Non-Hodgkin5Lymphoma and Occupational Exposure to6Agricultural Pesticide Chemical Groups7and Active Ingredients: A Systematic8Review and Meta-Analysis"9No. 21E-mail re: A second thought about the10Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty21713Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22015Carey Gillam22016No. 25E-mail string From Marie-Monique22117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	2			(Attached to transcript)	
5Lymphoma and Occupational Exposure to6Agricultural Pesticide Chemical Groups7and Active Ingredients: A Systematic8Review and Meta-Analysis"1789No. 21E-mail re: A second thought about the1010Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty21713Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22015Carey Gillam22016No. 25E-mail string From Marie-Monique21117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 28E-mail string re Meeting on Glyphosate23022No. 29E-mail string re Pesticide Exposure23123and Cancer23224No. 30E-mail string re EPA and glyphosate235	3	BLAI	IR DEP	OSITION EXHIBIT	PAGE
6Agricultural Pesticide Chemical Groups7and Active Ingredients: A Systematic8Review and Meta-Analysis"1789No. 21E-mail re: A second thought about the10Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty1313Jibben and the Farm Journal21714No. 24E-mail string re Quick question from15Carey Gillam22016No. 25E-mail string From Marie-Monique17Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	4	No.	20	Article entitled "Non-Hodgkin	
7and Active Ingredients: A Systematic8Review and Meta-Analysis"1789No. 21E-mail re: A second thought about the10Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty21713Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22016No. 25E-mail string From Marie-Monique22117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 28E-mail string re Meeting on Glyphosate23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	5			Lymphoma and Occupational Exposure to	
8Review and Meta-Analysis"1789No. 21E-mail re: A second thought about the10Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty21714No. 24E-mail string re Quick question from22016No. 25E-mail string From Marie-Monique22117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 28E-mail string re Meeting on Glyphosate23022No. 29E-mail string re Pesticide Exposure23224No. 30E-mail string re EPA and glyphosate235	6			Agricultural Pesticide Chemical Groups	
9No. 21E-mail re: A second thought about the Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty21713Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22016No. 25E-mail string From Marie-Monique22117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 28E-mail string re Meeting on Glyphosate23022No. 29E-mail string re Pesticide Exposure23224No. 30E-mail string re EPA and glyphosate235	7			and Active Ingredients: A Systematic	
10Rejection of the NHL manuscript20011No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty21713Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22015Carey Gillam22016No. 25E-mail string From Marie-Monique22117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	8			Review and Meta-Analysis"	178
11No. 22E-mail string dated September 16, 201621012No. 23E-mail string re Interview with Betty1313Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22015Carey Gillam22016No. 25E-mail string From Marie-Monique22117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	9	No.	21	E-mail re: A second thought about the	
12No. 23E-mail string re Interview with Betty13Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22015Carey Gillam22016No. 25E-mail string From Marie-Monique22117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate2302105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23224No. 30E-mail string re EPA and glyphosate235	10			Rejection of the NHL manuscript	200
13Jibben and the Farm Journal21714No. 24E-mail string re Quick question from22015Carey Gillam22016No. 25E-mail string From Marie-Monique21117Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate212105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure2323and Cancer23224No. 30E-mail string re EPA and glyphosate235	11	No.	22	E-mail string dated September 16, 2016	210
14No. 24E-mail string re Quick question from15Carey Gillam22016No. 25E-mail string From Marie-Monique17Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate2302105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23224No. 30E-mail string re EPA and glyphosate235	12	No.	23	E-mail string re Interview with Betty	
15Carey Gillam22016No. 25E-mail string From Marie-Monique17Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate2302105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	13			Jibben and the Farm Journal	217
16No. 25E-mail string From Marie-Monique17Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate212105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure2323and Cancer23224No. 30E-mail string re EPA and glyphosate235	14	No.	24	E-mail string re Quick question from	
17Robin/On behalf of Kathleen Guyton22118No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate2302105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	15			Carey Gillam	220
18No. 26E-mail string re IARC22519No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate2302105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	16	No.	25	E-mail string From Marie-Monique	
19No. 27WHO Q&A on Glyphosate, 1 March 201622820No. 28E-mail string re Meeting on Glyphosate2302105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23223and Cancer23224No. 30E-mail string re EPA and glyphosate235	17			Robin/On behalf of Kathleen Guyton	221
20No. 28E-mail string re Meeting on Glyphosate2105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23and Cancer23224No. 30E-mail string re EPA and glyphosate235	18	No.	26	E-mail string re IARC	225
2105/16/16 at 10AM23022No. 29E-mail string re Pesticide Exposure23and Cancer23224No. 30E-mail string re EPA and glyphosate235	19	No.	27	WHO Q&A on Glyphosate, 1 March 2016	228
22No. 29E-mail string re Pesticide Exposure23and Cancer23224No. 30E-mail string re EPA and glyphosate235	20	No.	28	E-mail string re Meeting on Glyphosate	
23and Cancer23224No. 30E-mail string re EPA and glyphosate235	21			05/16/16 at 10AM	230
24 No. 30 E-mail string re EPA and glyphosate 235	22	No.	29	E-mail string re Pesticide Exposure	
	23			and Cancer	232
25	24	No.	30	E-mail string re EPA and glyphosate	235
	25				

٦

			Page 9
1		EXHIBITS CONTINUED	
2		(Attached to transcript)	
3	BLAIR DE	POSITION EXHIBIT	PAGE
4	No. 31	E-mail string re Glyphosate and NHL	
5		Presentation (ISEE Conference)	239
6	No. 32	E-mail string re Glyphosate and NHL	
7		Presentation (ISEE Conference)	243
8	No. 33	E-mail string re Your Departure	
9		6ZHHOW: IAD-LHR 1 Mar 2015 18:30	246
10	No. 34	OCRC: A Detailed assessment of	
11		glyphosate use and the risks of non-	
12		Hodgkin lymphoma overall and by	
13		major histological sub-types:	
14		Findings from the North American	
15		Pooled Project, June 10, 2016	250
16	No. 35	E-mail string re EU glyphosate review	255
17	No. 36	Article entitled "Increased Cancer	
18		Burden Among Pesticide Applicators an	d
19		Others Due to Pesticide Exposure"	266
20	No. 37	EHP ISEE - Conference Abstracts,	
21		2015 Conference	274
22			
23			
24			
25			

Page 10 1 PROCEEDINGS 2 _____ 3 THE VIDEOGRAPHER: We are now on the 4 record. My name is Daniel Holmstock. I'm the 5 videographer for Golkow Technologies. Today's date is March 20th, 2017, and the time is 8:59 a.m. 6 7 This deposition is being held at the law 8 offices of Hollingsworth, LLP, at 1350 I Street, Northwest, in Washington, D.C., in the matter of 9 In Re Roundup Products Liability Litigation, MDL 10 11 No. 2741. The case is pending before the United States District Court of the Northern District of 12 California. 13 14 Our deponent today is Dr. Aaron Blair. 15 Counsel, would you please identify 16 yourselves and whom you represent. 17 MR. MILLER: Yes, good morning. I'm Michael Miller, and I represent the plaintiffs, 18 together with my law partner Nancy Miller, law 19 partner Jeff Travers, and an attorney from Denver 20 21 Kathryn Forgie. 22 MS. FORGIE: With Andrus Wagstaff. 23 MR. LASKER: David? MR. GREENE: I'm sorry. David Greene. 24 Ι represent Dr. Blair. 25

Page 11 1 MR. HOLLINGSWORTH: Joe Hollingsworth. I 2 represent Monsanto, 3 MS. SHIMADA: Elyse Shimada. I represent 4 Monsanto. 5 MR. LASKER: Eric Lasker for Monsanto. THE VIDEOGRAPHER: Anybody via telephone, 6 7 please identify. 8 MS. WAGSTAFF: Good morning, everyone. 9 This is Aimee Wagstaff from Andrus Wagstaff, and I 10 represent the plaintiffs in this matter. 11 THE VIDEOGRAPHER: Anybody else via 12 telephone? 13 Okay. Our reporter is Leslie A. Todd, who will now administer the oath. 14 15 WHEREUPON, 16 AARON EARL BLAIR, Ph.D., called as a witness, and having been first duly sworn, 17 18 was examined and testified as follows: 19 DIRECT EXAMINATION 20 BY MR. MILLER: Good morning, Dr. Blair. 21 0 22 А And good morning. MR. LASKER: Mike, as you said, just 23 before we get started, a statement on the record. 24 25 This is Eric Lasker for Monsanto.

Page 12

1	Based upon discussions we had with
2	Dr. Blair's counsel when this deposition was
3	subpoenaed and subpoenaed by plaintiffs, it is our
4	understanding that Dr. Blair has been produced solely
5	as a fact witness to provide testimony about his
б	factual knowledge and his experiences in connection
7	with issues for which he will be questioned, and not
8	to offer any expert opinions in this litigation. And
9	we have prepared for the deposition accordingly.
10	MR. MILLER: Well, and we agree to the
11	extent that we we have not retained Dr. Blair as
12	an expert. I don't believe Monsanto has retained
13	Dr. Blair as an expert, but as we get into the
14	deposition, and we both know Dr. Blair was part of a
15	committee that formulated opinions, and we'll only
16	ask about opinions that were formulated within that
17	process and not for expert opinion as he sits here
18	today. We certainly are not asking that.
19	So let's get going and see if we can
20	complete our day.
21	MR. LASKER: As questions are asked, we
22	will object or not according to our understanding.
23	MR. MILLER: As the rules allow.
24	BY MR. MILLER:
25	Q All right. Good morning, Dr. Blair.

Page 13 1 А Good morning. 2 How are you, sir? 0 3 А Okay. 4 Good. What -- would you please state 0 5 your name on the record. 6 Aaron Earl Blair. А 7 0 All right, sir. And Aaron Earl Blair, and you're a doctor? 8 9 А Ph.D. Ph.D. You've got -- I'm going to start 10 0 11 and go through a little bit of your credentials, if I may, sir. 12 13 А Sure. Okay. You graduated in 1965 with a 14 0 degree in biology from Kansas Wesleyan University? 15 16 Α Yes. Master of Science degree in '67 from 17 0 18 North Carolina State University? 19 А Yes. 20 And a Ph.D. in genetics at North Carolina 0 State University? 21 22 Α Yes. 23 And then in 1976, you got a MPH. What is 0 24 an MPH? Masters in Public Health. 25 А

Page 14 1 0 And that's -- your CV says epidemiology? 2 А Correct. Okay. And what is epidemiology? 3 0 4 The study of causes and distribution of Α 5 diseases. Have you -- have you been professionally 6 0 7 since 1976 studying the causes of diseases? 8 А Yes. 9 And explain it to me, if you would. 0 10 Where and how have you been studying the causes of 11 diseases since 1976? 12 The study of disease in human А 13 populations, evaluating various factors that might be related to the initiation or etiology of those 14 15 diseases. 16 0 As the -- you say you've spent your 17 professional life with this doctorate degree studying 18 the causes of diseases. Have you studied the causes 19 of cancer? 20 А Yes. 21 And within the broad field of studying 0 22 the causes of cancer, have you studied the causes of 23 non-Hodgkin's lymphoma? 24 А Yes. I'm a lay person. Tell me what is 25 0

Page 15 non-Hodgkin's lymphoma. 1 2 Lymphatic and hematopoietic tumors have a Α variety of different specific diseases. 3 One is 4 Hodgkin's disease, you've probably heard of. It's a 5 lymphoma. Non-Hodgkin's lymphoma is all the lymphomas that aren't Hodgkin's disease. 6 7 0 So non-Hodgkin's lymphoma is a form of 8 cancer. You have to answer --9 А Yes. And non-Hodgkin's lymphoma is a form of 10 0 11 cancer in the blood? 12 Α Yes. So any kind of blood cancer that is not 13 0 14 Hodgkin's lymphoma would be called non-Hodgkin's 15 lymphoma? 16 No. It is --А 17 All right. Explain to me why I'm --0 18 -- any type of lymphoma --А 19 0 I see. 20 -- that isn't Hodgkin's disease is Α 21 non-Hodgkin's lymphoma. 22 So there can be other blood cancers such 0 23 as leukemia? 24 Α Yes. 25 I understand. Thank you for that 0

Page 16 correction. 1 2 Now, it sounds like you spend an awful lot of time at the National Cancer Institute. 3 Is 4 that right? 5 Α Yes. What is the National Cancer Institute? 6 Ο 7 А It is one of the institutes, the National 8 Institutes of Health devoted to studying cancer. 9 And you started there in 1976? 0 10 А Yes. 11 0 I think we're about the same age. How 12 many years ago was that? Quite a few. 13 Α Yeah. Thanks for clearing that up. 14 0 15 And how long did you stay there, from 1976 until when? Are you still there or are you 16 retired or --17 18 I am retired now, but I have an emeritus А position, which means I go in a couple of days a week 19 20 and do what I've always done. I just don't get paid. Sounds like an interesting promotion, 21 0 Dr. Blair. 2.2 23 All right. So you started there in 1976. 24 You were a staff fellow for the Environmental 25 Epidemiology Branch at the National Cancer Institute?

Page 17 Correct. 1 А 2 Went on 1978 to '82, became the acting 0 chief of the occupational study section of the 3 4 Environmental Epidemiology Branch, National Cancer 5 Institute? 6 А Yes. 7 0 Describe for us what it is you are doing 8 there and --Studying various sorts of exposures that 9 Α occur in occupations and to see if they are related 10 11 to cancer. 12 Would farming be one of those occupations 0 that you've studied for the causes of cancer? 13 14 Α Yes. 15 Wouldn't that be true for your entire 0 16 profession -- professional career? 17 That was one of the early things I А 18 started doing was studies of farmers. 19 Did there come a time when you saw an 0 20 increase in cancers in farmers? 21 Α Yes. All right. Let's go on then. You became 22 0 23 the chief of the occupational study section in 1982, 24 right? Α 25 Yes.

Page 18 Okay. Remained the chief for, and I will 1 0 2 do this math, 14 years until 1996? Sounds right. 3 А 4 Okay, sir. And I have -- you have a copy 0 5 of your CV there. I have a copy here. If you want to look at it, feel free. 6 7 And what I will do, I will mark as 8 Exhibit 1 a copy of your CV or curriculum vitae, 9 okay? (Blair Exhibit No. 1 was marked for 10 11 identification.) 12 BY MR. MILLER: And hand it to you. And you can let me 13 0 know if this is -- all right. Thank you, sir. 14 MR. MILLER: A copy for counsel. 15 16 MR. LASKER: Thank you. Yeah, do that. 17 BY MR. MILLER: 18 Is this your CV, sir? 0 19 Α Yes. 20 Okay. So we were down here, we were 0 looking at some of your professions. You were at the 21 National Cancer Institute after receiving your 2.2 23 Ph.D. --24 MR. LASKER: Mike, for the record, are 25 these highlights your highlights on the document?

Page 19 1 MR. MILLER: Yes. Yes. Yes, they are. 2 Thanks for asking. 3 MR. LASKER: That's the document that you 4 will be using for the deposition? 5 MR. MILLER: I -- I think we're allowed to do that, if I recall, under the rules. б 7 MR. LASKER: Okay, that's fine. MR. MILLER: Yeah. I'm just highlighting 8 to aid the jury along the way. 9 BY MR. MILLER: 10 These highlights aren't yours, are they, 11 0 12 Dr. Blair? 13 А No. Okay. It's all important, isn't it? 14 0 15 Your whole body of work, do you feel like it's 16 important? 17 Oh. Yes, sure. Α 18 All right. So after being the chief for 0 14 years at the Occupation and Environmental 19 20 Epidemiology Branch, you went on to become in 2004 a senior investigator. Please tell us what that means. 21 22 А It means I stepped down as head of the 23 unit and just retained a position at the National 24 Cancer Institute, and that is a senior position. 25 Okay. And then you retired from 0

Page 20 full-time work there in 2007. 1 2 Yes. А 3 And have been working for free as a 0 4 professor emeritus there ever since. 5 А Yes. 6 0 Very good. All right. 7 And the reason I'm asking about your background, sir, there came a time when this 8 9 organization asked you to do some scientific work for them. Is that fair? 10 11 MR. LASKER: Objection to form. 12 THE WITNESS: Yes. BY MR. MILLER: 13 Q Who is WHO? 14 15 А World Health Organization. 16 0 Okay. So the World Health Organization, 17 what did they ask you to do? What did they ask you 18 to do, sir? Are you asking about a particular time 19 Α 20 or --You know, that's a fair question. When 21 0 was the first time the World Health Organization 22 23 contacted Aaron Blair and asked him to perform some 24 professional services? I -- I don't --25 А

Page 21 1 MR. LASKER: Objection to form. 2 You can answer. 3 THE WITNESS: I don't actually remember 4 the earliest year that it was, but I have served on 5 various World Health Organization groups over the 6 years. BY MR. MILLER: 7 8 Could you just let the jury know some of 0 9 those groups that you served at the request and for the World Health Organization. 10 11 А Well, the main one is the International Agency for Research on Cancer, which is part of the 12 World Health Organization. 13 Okay. And is that also referred to as 14 0 15 IARC? 16 А Correct. 17 Okay. So -- and that stands for 0 International Association --18 19 Α Agency. 20 I'm sorry. International Agency for the Q Research on Cancer? 21 22 А Correct. And that is an organization which is part 23 0 24 of the World Health Organization. 25 А Yes.

Page 22 0 And how many times have you served as an 1 2 TARC volunteer? 3 You know, I don't actually remember Α 4 the -- the number. Seven maybe. 5 Okay. And I'm going now to your CV to 0 page 3, and it shows that you served on IARC as early 6 7 as 1985. 8 Does that sound about right, Dr. Blair? 9 Sounds about right. А 10 0 Okay. And you were at -- you were 11 involved in an IARC monograph. I guess we will stop there. What's a monograph? 12 13 А Just a publication, a book. 14 Okay. So it's an International Agency 0 15 for the Research of Cancer book on the evaluation of carcinogenic -- I guess that's cancer? 16 17 А Yes. 18 -- of cancer risks to humans. 0 19 Α Yes. 20 And you -- Volume 35, these books come 0 21 out from the World Health Organization in volumes, I 22 quess? 23 Yes. Α 24 Okay. So Volume 35 was probably one of 0 25 the first ones that you worked on.

Page 23 1 Α Yes. 2 So off and on, as requested by World 0 Health Organization, it would be fair to say you've 3 4 been involved in working with them since 1985, right? 5 А Yes. 6 MR. LASKER: Objection to form. 7 BY MR. MILLER: Or about -- is that 32 years? I'm real 8 0 9 bad with math. Sound about right? 10 Α Sounds right. 11 0 Okay. All right. So that was Volume 35. Did there come a time when you were asked 12 to be involved with the World Health Organization, 13 the International Association of Cancer, to what has 14 now become Volume 112 of the monographs? 15 16 А Yes. 17 MR. LASKER: Objection to form. 18 BY MR. MILLER: 19 And I'm going to put a copy under the 0 20 highlighter -- and that is my highlighting, so we all know -- I'll tell you what I will do, I will use a 21 non-highlighted copy and a highlighter to work with. 22 23 (Blair Exhibit No. 2 was marked for 24 identification.) 25 BY MR. MILLER:

Page 24 1 Q And a copy for you, Doctor. 2 MR. MILLER: And a copy for counsel. 3 All right. Here, Doctor. Q 4 Α Thank you. All right. So what we have here, can you 5 0 identify this document, which is Exhibit 2, please? 6 7 А Well, it is one of the monographs. 8 Okay. And I just want to ask you a few 0 9 questions about the front page of this document. So it says -- again, we've been talking about it, but 10 11 it's a World Health Organization, right? 12 Α Yes. 13 And it's the International Agency for 0 14 Research on Cancer. 15 А Yes. Also known as IARC, right? 16 Q 17 А Yes. 18 All right. Now, this is a preamble. 0 What is a preamble? 19 20 Sort of the beginning discussion of what А follows in the monograph. 21 22 Okay. And they meet in a place called Q 23 Lyon, France? 24 А Correct. 25 All right. And this preamble was written 0

Page 25 in 2006. Have you reviewed this before? 1 2 Yes. Not -- not recently. Α Well, I know, and I'm not -- it's not a 3 0 4 test, but I just want to go over a couple of things 5 with you. 6 And will go, if you would, sir, to the 7 first page of the preamble, and it says here that the IARC was established in two -- in 1965. 8 9 Is that your understanding? 10 Α Yes. 11 0 All right. It says: Through the IARC" -- I'm sorry, I will quote exactly. 12 13 "Through the monographs program, IARC seeks to identify the causes of human cancer." 14 That's true, isn't it, sir? 15 16 Α Yes. 17 Okay. And some terms, so the jury and I 0 can understand them. In this preamble they tell us, 18 the World Health Organization, that a cancer hazard 19 is an agent that is capable of causing cancer under 20 some circumstances. While a cancer risk is an 21 estimate of carcinogen -- carcinogenic effects 22 23 expected from exposure to a cancer hazard. 24 I mean, is that what we should understand? 25

Page 26 1 А Yes. 2 Okay. All right. And there's in the Q preamble a discussion of the selection of agents for 3 4 review by IARC, and I want to ask you about it. 5 It says: "Agents are selected for review" -- is that for review to see if they cause 6 7 cancer? 8 Α Yes. -- "on the basis of two main criteria: 9 0 There is evidence of human exposure, and there is 10 11 some evidence or suspicion of carcinogenicity." 12 Is that your understanding, Dr. Blair? 13 А Yes. 14 Okay. And IARC has in this preamble a 0 15 discussion of what they will review as they consider these issues, right, sir? 16 17 Α Yes. 18 Okay. And it talks about with regard to 0 epidemiological studies -- now, first, let's stop 19 20 there. What is an epidemiological study? 21 It's a study of -- in humans to evaluate 22 Α 23 risk of disease or risk factors. 24 To find out if some agent may cause some 0 condition? 25

Page 27 1 А Right. 2 Okay. 0 3 MR. LASKER: Object to form. 4 BY MR. MILLER: 5 0 What is a cancer bioassay? It's an experimental study. Usually it 6 А means studies in animals. 7 8 Okay. What do we mean by "mechanistic 0 and other relevant data"? 9 What are the biologic processes that 10 Α 11 might lead from an exposure to development of cancer. 12 Yes, sir. 0 13 "Only reports that have been published or accepted for publication in openly available 14 scientific literature are reviewed." 15 16 Is that true, sir? 17 А Yes. And why is that true? Why -- why does 18 0 IARC only review those publications that have been 19 20 published in available scientific literature or have 21 been accepted for publication? 22 MR. LASKER: Objection to form. 23 BY MR. MILLER: 24 0 You can answer. Because these materials are then 25 А

Page 28 1 available to anyone. 2 And IARC also reviews those exposure 0 data? 3 4 Yes. Α 5 And exposure data means how are humans 0 exposed to that agent, right? 6 7 Α Yes. Okay. And IARC extends invitations to 8 0 scientists around the world to participate in the 9 creation of a monograph for a book, right? 10 11 А Yes. 12 And it -- in this preamble it tells us: 0 "Before an invitation is extended, each potential 13 applicant participant, including the IARC 14 Secretariat, completes a WHO declaration of interest 15 to report financial interests, employment, and 16 consulting, and individual and institutional research 17 18 support related to the subject of the meeting." 19 Is that your understanding? 20 А Yes. So before these folks are invited to be 21 0 on this IARC panel, they have to declare their 22 23 interests? 24 Α Yes. 25 MR. LASKER: Objection to form.

Page 29 1 BY MR. MILLER: 2 And it says in this monograph preamble Q 3 that a working group -- and I want to ask you, what 4 is a working group? 5 It's the group of people invited to Α 6 perform this activity. 7 0 And the working group meets at IARC for 8 seven to eight days to discuss and finalize the text and to formulate the evaluation. 9 10 Is that your experience? 11 Roughly that number of days, yes. Α Excuse me. All right. Page 8. I want 12 0 to ask you about this if I can. 13 14 It says: "Regarding occurrence and 15 exposure, data that indicate the extent of past and 16 present human exposure, the sources of exposure, the 17 people most likely to be exposed, and the factors 18 that contribute to exposure are reported." 19 Is that your experience, sir? 20 А Yes. 21 And one more sentence here. 0 It says, quote: Information is presented on the range of 22 23 human exposure, including occupational and 24 environmental exposure. 25 Occupational exposure I guess would mean

Page 30 1 being exposed to the agent at work? 2 MR. LASKER: Objection to form. 3 THE WITNESS: Yes. 4 BY MR. MILLER: 5 And environmental exposure means what, 0 б sir? 7 А Usually not exposed at work. In other 8 ways. 9 All right. And I'm -- I just want to ask 0 you a few more questions. Page 9, there's a whole 10 11 section, and I'm not going to read it, but that IARC considers the quality of studies considered, right? 12 13 А Yes. 14 Okay. And then on page 10, IARC 0 15 considers meta-analysis? 16 А Yes. 17 Now, could you tell the jury what is a 0 18 meta-analysis? 19 It is a quantitative or statistical way Α of summing up results from several studies. 20 21 0 Okay. And does IARC not only consider meta-analysis that are available in the public 22 23 literature, but does IARC in fact do their own 24 meta-analysis? 25 А Sometimes.

Page 31 1 0 Okay. And we're going to get to the IARC 2 monograph on Roundup in a minute, but now I will jump out of turn and ask, did they -- did IARC working 3 4 group do a meta-analysis on Roundup --5 MR. LASKER: Objection to form. б BY MR. MILLER: 7 0 -- and the epidemiology concerning the issue of Roundup in non-Hodgkin's lymphoma? 8 9 I'm not sure I remember. А All right. We will take a look in a 10 0 minute then. Thank you. 11 12 And does IARC also review pooled 13 analysis? 14 Α Yes. Okay. All right. And IARC looks at 15 0 temporal effects, right, sir? 16 17 А Yes. 18 So they analyze both the detailed 0 analysis of both relative and absolute risk in 19 20 relation to temporal variables. Now, that's a 21 mouthful. 22 Detailed analysis of both relative and 23 absolute risk. What is a relative risk? It would be the calculation of a rate in 24 Α 25 one group compared to a rate in another.

Page 32 1 0 I see. Perhaps a group who's been exposed to an agent compared to a group that has not 2 3 been exposed to an agent? 4 Α Yes. 5 Okay. And an absolute risk would --0 would be what, sir? 6 The rate of occurrence of disease in a 7 Α 8 group. Yes, sir. They consider age at first 9 0 exposure, time since first exposure, duration of 10 11 exposure, cumulative exposure, peak exposure, when appropriate and time sense -- cessation of exposures 12 are reviewed and summarized when available. Is that 13 14 right, sir? 15 Α Yes. All right. Going, if we would, to 16 Q 17 page 11 in the preamble for IARC, it tells us that 18 they use a criteria to establish causality, right, 19 sir? 20 MR. LASKER: Objection to form. BY MR. MILLER: 21 22 Q You can answer. 23 А Yes. And in their criteria for cruality --24 0 25 causality, excuse me, in making its judgment, the

Page 33 working group considers several criteria for 1 2 causality. Hill, 1965. 3 Do you see that, sir? 4 А Yes. 5 And that is Sir Bradford Hill? 0 6 А Yes. Okay. It says in the preamble for IARC: 7 0 8 "If the risk increases with exposure, this is considered a strong indication of causality." 9 Is that true, sir? 10 11 Α Yes. IARC also considers studies of cancer in 12 0 13 experimental animals? 14 А Yes. 15 Page 15. In the preamble they discuss 0 that IARC considers mechanistic and other relevant 16 17 data. Is that right, sir? 18 А Yes. Okay. And that would include 19 0 20 toxicokinetic data. 21 Now, what does toxicokinetic data mean, Dr. Blair? 2.2 23 Α Sort of the processes of chemicals 24 interacting with human systems. 25 Okay, sir. And they consider data on Q

Page 34 mechanisms of carcinogens? 1 2 А Yes. And what is that? 3 0 4 Various pathways appear to lead to Α 5 carcinogenicity. 6 And after -- even before this seven- to 0 7 nine-day working group meeting in France, does the 8 working group review materials in the time before that? 9 10 MR. LASKER: Object -- objection to form. 11 THE WITNESS: The individuals on the working group --12 13 MR. MILLER: Yes. THE WITNESS: -- review materials before 14 15 then. 16 BY MR. MILLER: 17 Okay. And for what period of time 0 approximately do individuals in the working group 18 review material? 19 20 A couple of months. Three months. It's А a while. 21 22 Okay. And then after they review, there 0 23 is a determination made whether the agent being 24 reviewed is carcinogenic or not. Is that fair? 25 MR. LASKER: Objection to form.

Page 35 1 THE WITNESS: Yes. 2 BY MR. MILLER: 3 And there are different categories. 0 4 There's 1, 2A, 2B, 3, that sort of thing? 5 Α Yes. 6 Q Okay. Category 2A is the agent is 7 probably carcinogenic to humans, right? 8 Α Yes. 9 And carcinogenic means causes cancer, 0 10 right? 11 Α Yes. Okay. So -- and we're going to talk 12 0 13 about it in more detail, but you were selected for 14 the working group that looked at Roundup, right? 15 MR. LASKER: Objection to form. BY MR. MILLER: 16 17 You can answer. 0 18 Α Yes. And your group -- I think there were 17 19 Q 20 scientists on that group? Sounds about right. 21 А Yeah, I understand. We'll look at it in 22 0 23 a sec. But that group decided that Roundup and 24 25 glyphosate was probably carcinogenic to humans,

Page 36 1 right? 2 MR. LASKER: Objection to form. 3 THE WITNESS: Yes. 4 BY MR. MILLER: 5 You have to answer again. 2A, "yes" is 0 6 the answer? 7 А Yes. Okay. All right. And so we're going to 8 0 9 look at how that process was played out and see if we can understand it. 10 11 Α Okay. 12 I want to look at Exhibit 3, which is --0 13 one moment. Okay. Exhibit 3, Dr. Blair, is a list of 14 15 participants for the IARC Monograph on Evaluation of Carcinogenic Risk to Humans, which included a review 16 17 of glyphosate, okay? I have a copy for you and a 18 copy for counsel. So it will be Exhibit 3. 19 Here. MR. MILLER: All right. Counsel. 20 (Blair Exhibit No. 3 was marked for 21 identification.) 22 23 BY MR. MILLER: All right, Dr. Blair. This is a list of 24 0 25 participants for the IARC Monograph on the Evaluation

Page 37 of Carcinogenic Risk to Humans, right, sir? 1 2 А Yes. 3 So it's Volume 112 of these monographs 0 4 we've been talking about, right? 5 А Yes. And one of the things that -- one of the 6 0 7 agents that IARC Volume 112 looked at was glyphosate, right? 8 9 А Yes. 10 0 And the meeting occurred in Lyon, France, 11 March 3rd through 10th, 2015, right? 12 А Yes. And the list of participants -- I would 13 0 like to go over it for -- if I could, included Aaron 14 15 Blair, National Cancer Institute, retired --16 That's you, right, sir? 17 А Yes. -- from the United States of America, and 18 0 you were the overall chair of the group, weren't you? 19 20 А Yes. 21 Okay. How much did they pay you for 0 22 that? 23 We're not paid. Α 24 It's a volunteer assignment, isn't it? 0 25 А Yes.

Page 38 So you reviewed all these materials for 1 0 months. Right? 2 3 MR. LASKER: Objection to form. 4 THE WITNESS: Yes. 5 BY MR. MILLER: 6 You flew to France. 0 7 А Yes. 8 Spent seven to nine days -- I'm sorry, it 0 9 looks like seven days reviewing these materials with these other scientists, and you volunteered and did 10 11 it all for free. 12 Other than travel expenses. Α 13 0 Okay. They paid your airfare. Okay. 14 Thank you. 15 All right. Let's look at -- did all 17 16 of these people do this as volunteers? 17 Α Yes. 18 Okay. I want to look at some of them. 0 Also from America, Gloria Jahnke. 19 Am I 20 pronouncing that right? I'm not sure. 21 Α She's from the National Institute of 22 0 23 Environmental Health Sciences of the United States? 24 Yeah. А 25 Do you know her? 0

Page 39 1 Α No. 2 Q Okay. 3 Other than through this meeting, I mean. А 4 Yes, I understand. You spent seven days Q 5 with her. Charles Jameson from CWJ Consulting, LLC, 6 7 United States. He is a subgroup chair in cancer in 8 experimental animals. 9 Do you see that, sir? 10 А Yeah. 11 So how many subgroups are there or were 0 there in this particular group? 12 13 Α Four. 14 Okay. And there were people from the 0 15 Environmental Protection Agency who volunteered and 16 served on this panel that concluded that glyphosate 17 was a probable cause of human cancer. 18 MR. LASKER: Objection to form. 19 THE WITNESS: Yes. 20 BY MR. MILLER: One of them is Matthew Martin, right? 21 Ο 22 А Yes. And Matthew Martin is -- was employed in 23 0 24 2015 by the United States Environmental Protection 25 Agency, right?

Page 40 MR. LASKER: Objection to form. 1 2 THE WITNESS: Yes. 3 (Counsel conferring.) 4 BY MR. MILLER: 5 Oh, I skipped somebody. Peter -- I'll 0 never pronounce this right, Peter Egeghy? 6 I don't know. 7 А 8 I don't know either. From the United 0 States Environmental Protection Agency, unable to 9 10 attend. 11 Now, would he participate either by phone or not have participated, or how does that work? 12 13 Well, I -- I think everyone is there. Α 14 Okay. All right. So if you're not 0 15 there, you don't vote, or how does that work, do you 16 know? 17 I don't know of an example where someone А was not there and voted. 18 19 Okay. From Canada, John McLaughlin, 0 University of Toronto. 20 21 Α Yes. 22 Q Do you know him? 23 Α Yes. 24 I mean before the meeting. 0 25 Α Yes.

Page 41 1 Q Okay. How do you know him? We're both epidemiologists doing the same 2 Α 3 work. 4 Yes, sir. All right. Q 5 And from Mississippi State University, Matthew K. Ross. My wife wouldn't let me -- I would б be in trouble if I didn't bring out Mississippi State 7 8 University. 9 Do you know him? 10 Α Yes. 11 0 All right. And what sort of professional is he? 12 He's a toxicologist, a bioassay person. 13 Α And from Texas A&M, Ivan Rusyn, he was a 14 0 15 sub -- subgroup chair in mechanism. Did you know him professionally before? 16 17 А Yes. Do you know any of these people socially? 18 0 A few. 19 Α 20 Okay. Who? 0 21 Andrea 't Mannetje; John McLaughlin. Α Ιf "socially" means sometimes I see them not strictly in 22 23 a professional meeting. 24 Have dinner after a meeting or something? 0 25 Occasionally. Α

Page 42 Yeah, sure. 1 0 All right. From California Environmental 2 3 Protection Agency, Lauren Zeise. Do you know what 4 her profession is? 5 А No. 6 Okay. So those were the members. 0 7 Now, these people were the ones that 8 ultimately voted that Roundup or glyphosate was a 9 probable human carcinogen for non-Hodgkin's lymphoma. Was the vote unanimous? 10 11 MR. LASKER: Objection to form. 12 BY MR. MILLER: 13 0 You can answer. I actually don't remember for sure. 14 A Ι 15 think so. 16 I just want to say one thing --17 0 Please do. -- these are the people who voted. 18 А You've just underlined a whole bunch of them. 19 20 Yes, sir. 0 21 They all voted. Α Oh, I understand, sir. Yes, sir. 22 Q Ι 23 wasn't trying to suggest otherwise. Everyone on here 24 voted, right? 25 Α Yes.

Page 43 1 0 And you think it was unanimous, but you're not a hundred percent sure. Is that fair? 2 3 А Yeah. Now, I want to ask you, an invited 4 0 5 specialist, what is an invited specialist? 6 It may be that someone brings special Α expertise so it would be of value to the working 7 8 group. And the World Health Organization decided 9 0 that there was an invited specialist they wanted to 10 11 invite for this issue of glyphosate. Is that fair? 12 MR. LASKER: Objection to form. THE WITNESS: Or for the other pesticides 13 being evaluated. 14 BY MR. MILLER: 15 16 Q Sure. 17 Α I don't know why they did it. Yes, sir, I understand. You didn't make 18 0 the invitation? 19 20 I did not make the invitation. Α But an invitation was extended to 21 0 Christopher Portier, who was from the Agency for 22 Toxic Substances and Disease Registry in the United 23 24 States. 25 Α Yes.

Page 44 1 0 Do you know Dr. Portier? 2 Α Yes. Okay. Also present was a gentleman by 3 0 4 the name of Jesudosh -- I'm sorry if I'm pronouncing 5 it wrong -- Jesudosh Rowland from the United States Environmental Protection Agency. 6 7 Do you see that, sir? 8 Yes. А 9 Do you know him? Q No. You know, he was at the meeting. 10 Α Ι 11 probably met him --12 Right, I understand. 0 -- at the meeting, but -- yeah. 13 А 14 I understand. And there were observers 0 at the meeting. Now, what's the function of an 15 16 observer? 17 That usually means they are sort of Α 18 stakeholders in the issue being evaluated. 19 Q Okay. 20 A few who were invited to come. А 21 And the Monsanto Company was allowed to 0 have an observer at the meeting, weren't they, sir? 22 23 Yeah. Α 24 That was a Dr. Thomas Sorahan, right? 0 25 Yes. Α

Page 45 Do you know Dr. Sorahan? 1 0 2 А T do. 3 And did he -- was he allowed to speak up 0 4 at the meeting? 5 А Yes. 6 0 Okay. Did he object to or complain about 7 the unanimous decision to declare glyphosate a probable human carcinogen for non-Hodgkin's lymphoma? 8 9 MR. LASKER: Objection to form. I don't think I remember 10 THE WITNESS: 11 this for sure, but typically invited specialists are asked to comment on specific things, not on the 12 13 formal evaluation. BY MR. MILLER: 14 15 I understand. All right. 0 16 (Counsel conferring.) 17 BY MR. MILLER: 18 All right. So after this selection of 0 these 17 people IARC put together, you were the 19 20 chairman. After months of review, a seven-day 21 meeting, there was a report issued. Is that fair to 22 say? 23 Yes. Α 24 (Blair Exhibit No. 4 was marked for identification.) 25

Page 46 1 BY MR. MILLER: 2 Okay. Let's take a look at what I 0 3 believe to be the IARC report for glyphosate. And I 4 marked it as Exhibit 4, and I have a copy for you and 5 counsel. And I put 4 on it so you know when somebody goes back to it later, you're going to know what 6 number it is. 7 8 MR. MILLER: Counsel, here you go. BY MR. MILLER: 9 This is a report from IARC for 10 0 11 glyphosate? 12 Α Okay. Yes. 13 0 Yes? Okay. And glyphosate is the active ingredient 14 15 in Roundup? 16 А Yes, sir. 17 Okay. And I want to ask you a few 0 questions about the report, spend a little time going 18 19 over it. 20 I'm not going to ask you about the molecular structure. I didn't do very well in high 21 school chemistry. You'll forgive me. 22 23 If you would go to page 4. 24 The report says that: "Glyphosate is 25 widely used for household weed control throughout the

Page 47 world. In the USA, glyphosate was consistently 1 ranked as the second most commonly used pesticide 2 3 (after 2,4-D) in the home and garden market sector 4 between 2001 and 2007, with an annual use of 2,000 to 4,000 tonnes." And you cite the authority for that 5 6 comment. 7 That was your understanding after researching the matter? 8 9 That's my understanding. А 10 MR. LASKER: Objection to form. Lacks 11 foundation. 12 BY MR. MILLER: 13 Ο All right. I want to go to page 45 of 14 this report. 15 IARC studied obviously the drug in humans 16 and studied it in exposed humans. That's a fair 17 statement? 18 А Yes. MR. LASKER: Objection to form. 19 20 BY MR. MILLER: 21 Okay. You looked at the study, one of --0 22 was it about a thousand studies you guys looked at in 23 this process? 24 MR. LASKER: Objection to form. 25 THE WITNESS: I don't actually know what

Page 48 the total number across all types of studies is. 1 Ιt was a lot, but I -- I don't know if that's the right 2 3 number or not. 4 BY MR. MILLER: 5 Can you give me an estimate? 0 Not really because I'm on the 6 А 7 epidemiology panel. 8 Q Okay. 9 And I sort of look at it. I mean the Α monograph lists all of them --10 11 0 Right. 12 -- that we looked at. Α 13 Right, right. Okay. So you not only 0 14 chaired the entire panel but you subchaired the epidemiology section. 15 16 I was on the epidemiology --Α 17 I'm sorry. Well, was there a subchair? 0 There was. 18 А Who? 19 Q 20 А I don't remember. 21 Okay, fair enough. 0 22 The report says: "The baseline frequency 23 of binucleated cells with micronuclei" -- excuse me -- "was significantly higher in subjects from the 24 three regions where there had been aerial spraying 25

Page 49 with glyphosate formulations." 1 2 Do you remember reading the Bolognesi 3 study? 4 MR. LASKER: Objection to form. And 5 objection to using this witness just as a basis for reading in portions of the document and not having a 6 7 set of questions with respect to that. BY MR. MILLER: 8 9 0 You can answer. This is a toxicologic study. I'm an 10 А 11 epidemiologist. Different subgroups evaluate different components. I'm really familiar with 12 epidemiology, not so much the other. 13 That's fair. All right. All right. 14 0 15 Thank you. Let's look at the epidemiology then. 16 Ι 17 think that probably would make more sense. There's a 18 table in the report with the epidemiology on it, 19 isn't there? 20 А Yes. 21 (Counsel conferring.) 2.2 BY MR. MILLER: 23 Okay. Going to page 78 of your report, Ο "Cancer in Humans." We're on page 78. Do you see 24 25 this, Doctor?

Page 50 1 It says: "There is limited evidence in 2 humans for the carcinogenicity of glyphosate. A positive association has been observed for 3 4 non-Hodgkin's lymphoma." 5 What does a "positive association" mean, б sir? 7 MR. LASKER: Objection to form. 8 BY MR. MILLER: 9 Yeah, you can answer. I'm sorry. 0 It means there were studies that showed 10 Α 11 an excess risk for people exposed. 12 And that would include the 0 13 epidemiological studies that were done. 14 А Yes. 15 MR. LASKER: Objection to form. 16 BY MR. MILLER: And we'll take a look at a lot of them, 17 0 18 but all right. 19 Your report goes on to say: "There is 20 strong evidence that exposure to glyphosate or 21 glyphosate-based formulations is genotoxic based on studies in humans in vitro and studies in 2.2 23 experimental animals." 24 That's what your 17-expert committee found? 25

Page 51 MR. LASKER: Objection to form. 1 2 THE WITNESS: Yes. BY MR. MILLER: 3 4 You also concluded: "There is strong 0 5 evidence that glyphosate and glyphosate-based formulations, and aminomethylphosphonic acid can act 6 to induce oxidative stress based on studies in 7 experimental animals and in studies in humans in 8 vitro." 9 Now, that's a mouthful, so I've got to 10 11 ask you, why did you mention aminomethylphosphonic acid? 12 13 MR. LASKER: Objection to form. 14 THE WITNESS: Again, this comes from the 15 subgroups with a discipline that I'm not as knowledgeable about. 16 17 BY MR. MILLER: 18 0 Okay. And I think this is a breakdown product, 19 Α 20 but I'm not sure. I understand. Well, we'll pass that off 21 0 to people that study the breakdown products. 22 Okay. MR. LASKER: Objection to form to that 23 24 last comment. BY MR. MILLER: 25

Page 52 To be clear, though, before we leave the 1 0 "Conclusion" section, this report is in March of 2 2015, right? 3 4 Yes, sir. А 5 And "the positive association has been 0 observed for non-Hodgkin's lymphoma," IARC has not 6 7 retracted that statement in any way, shape or form as we sit here in March of 2017? 8 9 Not to my knowledge. А 10 0 And there's been requests by Monsanto 11 Corporation to retract that, hasn't there? 12 MR. LASKER: Objection to form. 13 THE WITNESS: I understand that to be 14 true. 15 BY MR. MILLER: 16 Q Now, let's look at some of the 17 epidemiology in the -- all right. There we go. 18 Table 2.2 is a table about the epidemiology -- well, let's look at it. And it's 19 20 quite a long one here. 21 Okay. Table 2.2 is -- I got it from here -- is case-control studies of leukemia and 22 23 lymphoma and exposure to glyphosate, right, sir? 24 Α Yes. 25 Okay. Now, I'm not going to ask about 0

Page 53 leukemia. But the first study in 1992, Cantor did 1 not show any statistical significance, right, sir? 2 3 Α Correct. 4 Explain to a lay person what "statistical 0 5 significance" means. 6 In statistical analyses, there is a Α 7 phenomenon known as noise, which means if you do 8 different studies, you don't get exactly the same 9 response. And statistical approaches are used to decide if it is sort of outside the bounds of what 10 11 you would anticipate to occur being just from noise. 12 Okay. So whenever -- explain to us -- in 0 parentheses here, this 0.7-1.9, what does that tell 13 14 us? 15 The estimate of 1.1 says that is an Α estimate of elevated risk from this exposure. 16 It's 17 like a 10 percent increase, but it's not very big. 18 And these other two numbers, 0.7 to 1.9, said we 19 have -- I think in this case it's a 95 percent 20 confidence interval that the real true estimate is somewhere between those two numbers. 21 22 Yes, sir. So then moving on in time, the Q 23 next study we see on your chart for non-Hodgkin's 24 lymphoma is a study by De Roos in 2003, right? 25 А Yeah.

Page 54 And what Dr. De Roos and others did --1 0 and this is an epidemiological report from a 2 peer-reviewed journal? 3 4 Α Yes. 5 0 What do we mean by "a peer-reviewed iournal"? 6 7 Α You send a manuscript to a scientific journal, and they send it out if they think it might 8 be worthy of fitting in that journal to other 9 scientists to review it and make comments about its 10 11 quality. Okay. And Dr. De Roos and others in this 12 0 13 peer-reviewed journal studied people who were exposed 14 to glyphosate in Nebraska, Iowa, Minnesota, Kansas, from the period 1979 to 1986, right? 15 16 Α Yes. 17 And what they found was that there was 0 over a doubling of the risk of non-Hodgkin's lymphoma 18 19 for people who had been exposed to glyphosate, right? 20 MR. LASKER: Objection to form. 21 THE WITNESS: Yes. 2.2 BY MR. MILLER: 23 And because our numbers here, 1.1 to 4.0 0 are higher than 1.0, they've taken chance out of it 24 25 at 95 percent, right?

Page 55 MR. LASKER: Objection to form. 1 2 THE WITNESS: Yes. BY MR. MILLER: 3 4 Is it -- is this finding of a doubling of 0 5 the risk of non-Hodgkin's lymphoma, is it statistically significant? 6 7 Α Yes. MR. LASKER: Objection to form. 8 BY MR. MILLER: 9 Is this one of the pieces of evidence 10 0 11 upon which your committee based their opinion there was a positive association between exposure to 12 13 glyphosate and non-Hodgkin's lymphoma? 14 А Yes. 15 (Counsel conferring.) BY MR. MILLER: 16 17 All right. So I'm going to go -- the Lee 0 study was also about non-Hodqkin's lymphoma. 18 Is that right, sir? 19 20 А Yes. And it showed an increased risk of 40 21 0 percent but could not rule out chance. Is that fair 22 or am I misinterpreting it? 23 24 Α Correct. 25 0 Okay.

Page 56 MR. LASKER: Objection to form to the 1 last question. 2 BY MR. MILLER: 3 4 And then in 2001, there was a large 0 5 study -- well, strike that. 6 There was a study from Canada called the 7 McDuffie study, right, sir? 8 А Yes. 9 Would you describe it as -- for a Ο case-control study -- a large study or not? 10 11 Α Yes. And they examined people who had been 12 0 13 exposed to glyphosate from 1991 to 1994, right, sir? They examined cases who occurred in that 14 А time period, I think, who might have been exposed. 15 16 0 Yes, sir. And they did exposure, 17 unexposed. They did people that had been exposed for 18 zero to two days and for people who had been exposed to greater than two days in that time period, right? 19 20 Α Yes. 21 And for people that had been exposed to Ο zero to two days, they found no increased risk of 22 23 non-Hodgkin's lymphoma, right? 24 MR. LASKER: Objection. 25 THE WITNESS: That actually is the

Page 57 reference population. 1 2 BY MR. MILLER: 3 That's the reference population? 0 4 А So it's set at 1.0. 5 Oh, I see. Of course. All right. 0 6 But for people that were exposed for 7 greater than two days, they found a doubling of the 8 risk of non-Hodgkin's lymphoma from exposure to 9 Roundup or glyphosate? 10 Α Yes. 11 MR. LASKER: Objection to form. 12 BY MR. MILLER: 13 And they found that was statistically 0 14 significant, that is to say it did not occur by 15 chance? 16 MR. LASKER: Objection to form. THE WITNESS: Outside the realm of 17 18 chance. BY MR. MILLER: 19 20 Yes, sir. Q 21 Α Yes. 22 0 Okay. How would you pronounce this, 23 Karunanayake? I'm sorry. I don't know how to 24 pronounce that. 25 I'm sorry, I can't quite read it. Α Okay.

Page 58 1 0 K-A-R-U-N-A-N-A-Y-A-K-E. 2 I don't know. А Okay. He did a study out of Canada in --3 0 4 for exposure period from '91 to '94, published in 5 2012, did not find a statistically significant increased risk in his study. Is that fair? 6 7 А Yes. The next year, 2013, Kachuri, et al, in 8 0 six provinces in Canada, studying multiple myeloma. 9 Is multiple myeloma a form of 10 11 non-Hodgkin's lymphoma? 12 Non-Hodgkin's lymphomas had Α No. different definitions over time. When this study was 13 done, it was not a form of non-Hodgkin's lymphoma. 14 All right, sir. 15 0 16 All right. Excuse me. Continuing on 17 your table of epidemiological studies, we have 18 Hardell and Eriksson in 1999 do a study on non-Hodgkin's lymphoma from northern and middle 19 20 Sweden during a three-year period, '87 to '90. 21 Do you see that, sir? 22 Α Yes. 23 Now, they found under ever used 0 24 qlyphosate univariate analysis -- what is a 25 univariate analysis?

Page 59 Just looking at the relationship in a 1 А statistical analysis that includes glyphosate and not 2 much of anything else. 3 4 All right. And what is an ever 0 5 glyphosate multivariate analysis? 6 They have included other factors that Α 7 they think might be related to this cancer. 8 0 I see. 9 And what they concluded was, just using glyphosate, they had a doubling of the risk, but it 10 11 was not statistically significant. Is that a fair 12 assessment? 13 MR. LASKER: Objection to form. 14 THE WITNESS: Yes. 15 BY MR. MILLER: 16 0 And if ever used glyphosate as a 17 multivariate analysis, they had an over 500 percent 18 increased risk, but again, not statistically significant, right? 19 20 MR. LASKER: Objection to form. 21 THE WITNESS: Correct. 2.2 BY MR. MILLER: 23 So then we go to the Hardell study in Ο 24 Sweden, 2002 -- and all these are peer reviewed or 25 they wouldn't be in your table, right?

Page 60 Yes. 1 А 2 And what they do, they take Sweden, four Q northern counties, and they take studying 3 4 non-Hodgkin's lymphoma and Hodgkin's lymphoma, and 5 what they conclude -- I'm sorry. They don't. I've just been corrected. 6 7 Non-Hodgkin's lymphoma and hairy cell, 8 right, which is a form of non-Hodgkin's --9 Hairy cell leukemia. Α Yes, which is a form of non-Hodgkin's 10 0 11 lymphoma? 12 Depends on the time frame, but I think it Α was at that time. I'm not sure. 13 14 Okay. And they find a 300 percent 0 15 increased risk statistically significant? 16 MR. LASKER: Objection to form. 17 THE WITNESS: Yes. 18 BY MR. MILLER: Okay. Meaning that they've eliminated 19 0 20 chance to the 95 percent. 21 Α Yes. 22 Q Okay. 23 MR. LASKER: Objection to form. 24 BY MR. MILLER: 25 All right. So now we go to the next page 0

Page 61 of your table where you report on the study of 1 Eriksson, an epidemiological study on non-Hodgkin's 2 lymphoma published in 2008, and exposure to any 3 4 glyphosate, they've got a doubling of the risk of 5 non-Hodgkin's lymphoma statistically significant, 6 right? 7 MR. LASKER: Objection to form. THE WITNESS: Yes. 8 MR. LASKER: You're just going to read 9 10 from one of those? There's two. 11 BY MR. MILLER: 12 0 They go on to look at days of use. Do 13 you see that, sir? Less than ten days use? 14 Α Yes. 15 Greater than ten days use? Q 16 А Yes. 17 So for less than ten days use, they have 0 a nonstatistically significant increased risk of 18 69 percent, right? 19 20 MR. LASKER: Objection to form. 21 THE WITNESS: Yes. 22 (Interruption in the proceedings.) 23 MR. MILLER: Do you need to take a break? 24 THE WITNESS: No. 25 MR. LASKER: And for the record, for this

Page 62 whole line of questioning, we make an objection to 1 testimony of studies based upon a table as opposed to 2 the studies themselves. So objection based on lack 3 4 of foundation as well. 5 BY MR. MILLER: 6 0 Okay. So for the Eriksson study, less 7 than ten days use, 69 percent increased risk, not statistically significant, correct? 8 Correct. 9 Α 10 MR. LASKER: Objection to form. 11 BY MR. MILLER: Well, tell us what the findings were for 12 0 13 less than ten days use from the Eriksson study. 14 So you just read what the findings were. Α 15 He's objected to me reading. He wants 0 16 you to explain it. There was a 1.69 relative risk 17 Α Oh. calculated for less than 10 years use that was not 18 statistically significant. 19 20 For ten days use. 0 21 For less than ten days use, it was not Α statistically significant. 22 23 All right, sir. 0 24 And for greater than ten days per year use, what did the Eriksson study reveal about 25

Page 63 1 non-Hodgkin's lymphoma after exposure to ten days of 2 glyphosate? 3 MR. LASKER: Objection to form. 4 THE WITNESS: For this category of use, 5 it was -- the relative risk was 2.36, which was statistically significant. 6 7 BY MR. MILLER: And 2.36 would be how much of an increase 8 0 in risk? 9 MR. LASKER: Objection to form. 10 11 THE WITNESS: It's better if you just say the relative risk. It's the relative risk is 2.36. 12 BY MR. MILLER: 13 Okay. Would it be --14 0 15 А It's more than doubling. 16 Q It's more than doubling. All right. 17 And what is dose response? As level of exposure goes up, the risk or 18 А relative risk goes up. 19 20 Did we see dose response here in the 0 21 Eriksson study for non-Hodgkin's lymphoma in exposure 2.2 to Roundup? 23 MR. LASKER: Objection to form, calls for 24 expert opinion. 25 THE WITNESS: Yes.

Page 64 1 BY MR. MILLER: 2 And the preamble to IARC said dose 0 3 response was strong evidence of causality; is that 4 true? 5 Α Yes. 6 All right. Let's go to lymphatic -- I'm 0 7 sorry, lymphocytic lymphoma B-cell. Do you see that? 8 Α Yes. 9 Exposure to glyphosate? Q 10 А Yes. 11 MR. LASKER: Objection to form. BY MR. MILLER: 12 13 0 Tell us what the findings were by Eriksson. 14 15 For this subgroup of lymphoma, the А relative risk was 3.35, which was statistically 16 17 significant, because the confidence interval, the 18 lower level was greater than 1.0. 19 And I know you don't like to put a 0 20 percentage on it, but would that be a 300 percent 21 increased risk? 22 MR. LASKER: Objection to form. 23 THE WITNESS: Roughly. 24 BY MR. MILLER: Yes, sir. Okay. 25 0

Page 65 And unspecified non-Hodgkin's lymphoma 1 and exposure to glyphosate, what were the findings, 2 and were they statistically significant? 3 4 Α The relative risk was 5.63, and the 5 confidence interval did not include 1.0, so it was statistically significant. 6 7 0 Would that be synonymous with a five times risk? 8 9 Roughly. Α MR. LASKER: Objection to form. 10 11 Objection to the selective questioning regarding the 12 table. BY MR. MILLER: 13 14 There was a study called Orsi, but is it 0 15 fair to say none of his findings were statistically significant; is that accurate? 16 I'm looking. None were statistically 17 Α 18 significant on this page. Study from the Czech Republic, the Cocco 19 0 20 study on the issue of B-cell lymphoma. And, first, 21 B-cell lymphoma is a form of non-Hodgkin's lymphoma? 22 Α Yes. 23 And this study, what were the findings of 0 24 this study, Dr. Blair? 25 Α The relative risk was 3.1, and the

Page 66 confidence interval was less -- the lower amount was 1 less than 1.0, so it was not statistically 2 significant. 3 4 And even though it was not statistically 0 5 significant, does this inform us or aid us in reaching the conclusions the panel was charged with 6 7 or -- or not? How does that play out? All studies inform us. 8 А There was -- we've looked at the 9 0 Okay. 10 big thick hundred-and-some-page report of IARC on There was also a shorter summary of the 11 qlyphosate. findings published in Lancet. Do you remember that? 12 13 Α Yes. 14 And Lancet is a peer-reviewed journal? 0 15 Α Yes. And would it be fair to say -- or you 16 Q tell me, is Lancet a prestigious medical journal? 17 18 Lancet Oncology is a prestigious journal. Α 19 0 Yeah. (Blair Exhibit No. 5 was marked for 20 identification.) 21 2.2 BY MR. MILLER: 23 And so I want to look at the IARC 0 24 findings published in Lancet Oncology, and I've marked them as Exhibit 5. And I got a copy for you 25

Page 67 and a copy for counsel. 1 2 Do you want to take a break? 3 А No. 4 Okay. All right. So what we're looking 0 5 at, Doctor, is from the Lancet Oncology, right? 6 Α Yes. 7 0 And it was published hard copy May 2015; 8 published online, it tells us, March 20th, 2015. 9 Do you see that? 10 Α Yes. 11 Okay. And it's carcinogenicity of 0 several things, which we're not involved in, but one 12 of them we are, and that's glyphosate, right? 13 14 Α Yes. 15 Okay. And it tells us there were 17 0 16 experts from 11 countries who met at the 17 International Agency for the Research on Cancer to 18 assess the carcinogenicity of these products, including glyphosate, right? 19 20 Α Correct. 21 Okay. There was only one cancer that the 0 22 committee found to be associated with glyphosate, 23 right? 24 MR. LASKER: Objection to form. 25 THE WITNESS: Yes.

Page 68 1 BY MR. MILLER: 2 And that's non-Hodgkin's lymphoma? 0 3 Correct. А 4 And the mechanistic evidence was what, 0 5 sir? 6 MR. LASKER: Objection to form. Lacks foundation. 7 8 BY MR. MILLER: 9 I'm sorry. You can answer. He objects, 0 10 but you can answer. 11 Α That it was genotoxic and had another possible effect with oxidative stress. 12 13 Did you help author this article in 0 Lancet? 14 15 Yes. А 16 0 Okay. You say here: "Glyphosate" -- and 17 I'm on page 2 -- "is a broad spectrum" -- there it is 18 right there -- "broad spectrum herbicide currently with the highest production volume of all herbicides. 19 20 It is used in more than 750 different products for agriculture, forestry and home application. Its use 21 has increased sharply with the development of 22 23 genetically modified glyphosate-resistant crop 24 varieties." 25 And that was part of the research that

Page 69 you folks developed in preparing this report? 1 2 MR. LASKER: Objection to form. BY MR. MILLER: 3 4 You can answer. Q 5 А It was part of the evidence we reviewed. Okay. And we've just been talking about 6 0 them, but I want -- "case-control studies" -- those 7 8 are the studies that we just talked about, right? 9 А Yes. Okay. "-- of occupation exposure in the 10 0 11 United States, Canada, and Sweden, reported increased risk for non-Hodgkin's lymphoma that persisted after 12 13 adjustment for other pesticides." What does that mean? 14 15 MR. LASKER: Objection to form. 16 THE WITNESS: It means that's the multivariate analysis. You include other things that 17 18 might include a disease in the analysis until you 19 know which is doing what. 20 BY MR. MILLER: Okay. Now, for the first time we're 21 0 talking about a study here, the AHS study. I want to 22 23 ask you about it: "The AHS cohort did not show a 24 significantly increased risk of non-Hodgkin's 25 lymphoma."

Page 70 1 So there was a study that did not show the association between -- between glyphosate and 2 3 non-Hodgkin's lymphoma, right? 4 Α Yes. 5 MR. LASKER: Objection to form. BY MR. MILLER: 6 7 0 And in fact, you were the author of that study, or one of them, right, sir? 8 9 One of the authors. Α And in spite of being the author of the 10 0 11 study that didn't show the association, you voted that in fact there was an association based on the 12 13 totality of the evidence, right, sir? 14 MR. LASKER: Objection to form. 15 THE WITNESS: Yes. 16 BY MR. MILLER: 17 Okay. All right. "And glyphosate has 0 been detected in the blood and urine of agricultural 18 workers indicating absorption." 19 20 What does that mean, sir? 21 MR. LASKER: Objection to form, lacks foundation. 2.2 23 BY MR. MILLER: 24 0 You can answer. 25 If it's in the blood, it had to get there А

Page 71 1 somehow. 2 Q Sure. 3 So it had to be absorbed through some Α 4 tissue. 5 After you and your working group 0 volunteered, looked at all of this material, 6 7 concluded there was a positive association between 8 glyphosate and non-Hodgkin's lymphoma, did Monsanto 9 attack you and other members of the IARC panel? MR. LASKER: Objection to form. 10 11 THE WITNESS: I don't think I quite know how to answer that. 12 BY MR. MILLER: 13 14 I understand. Let's take a look at this 0 15 document, and it will I think help -- helps us look at it. 16 17 This is going to be marked as 18 Exhibit 10 -- is it 10 already? MR. LASKER: 10? 19 20 MR. MILLER: Six. Oh, it's six. Wrote 21 the wrong one. Hardest part of my job. 22 All right. Six. It shall be marked as 23 Exhibit 6. And I have a copy for you, Doctor, and a 24 copy for counsel. Here you go. (Blair Exhibit No. 6 was marked for 25

Page 72 identification.) 1 2 BY MR. MILLER: 3 This has been produced by IARC on these 0 4 issues, and I want to ask you a little bit about it, 5 okay? 6 Have you seen this before, Doctor? Well, I -- I think so. 7 А Well, let's look at it. If at any time 8 0 you want to stop and read it, it's okay with me. All 9 right. I don't want to -- I don't want to go too 10 11 fast and don't expect you to have read everything. 12 But this is promulgated by IARC. It 13 says: "Originally prepared as a confidential 14 briefing for government councilmembers on IARC 15 evaluation of glyphosate and requests for meetings from CropLife." 16 17 Do you know who CropLife is? 18 It's an organization that includes many А pesticide manufacturers on it. 19 20 And IARC says here in point number 2 Ο that: "Monsanto rejected and attacked the IARC 21 findings, calling it junk -- junk science, and 22 23 immediately requested that the World Health 24 Organization retract the International Agency for the Research of Cancer evaluation, and privately lobbied 25

Page 73 the USEPA to reject IARC's findings." 1 2 You see that? 3 Α Yes. 4 MR. LASKER: Objection to form, 5 foundation, hearsay. 601, 801. BY MR. MILLER: 6 7 Q Have you been aware --8 THE REPORTER: I'm sorry? 9 MR. LASKER: I'm sorry. 601, 602, 801. 10 BY MR. MILLER: 11 0 Have you felt some of this pressure from IARC -- excuse me -- from Monsanto? 12 13 Well, I know -- I've seen this. А 14 Okay. I didn't know that. Okay. 0 15 I mean, I've seen that sort of А 16 information, yes. 17 Yes. 0 18 MR. LASKER: Same objection. BY MR. MILLER: 19 20 Did you help prepare this or do you know 0 who did? 21 22 Α No. 23 Probably Kathy Geiten, you think, or --0 MR. LASKER: Objection to form. 24 25 THE WITNESS: I don't know.

Page 74 1 BY MR. MILLER: 2 Okay. On 4d, Monsanto claimed, guote: 0 3 The data evaluated do not represent, quote, real 4 world exposures. 5 But IARC writes: "This ignores the fact 6 that cancer epidemiology based on real world exposures associated with cancer risk in humans is 7 8 the cornerstone of IARC Monograph evaluation." 9 That's true, isn't it? 10 MR. LASKER: Objection to form. 11 Counsel, the witness has already said he 12 doesn't -- is not sure he has seen this document and he did not write the document. 13 BY MR. MILLER: 14 15 0 You can answer. 16 А Epidemiology is based on real world 17 exposures. That's what humans get. 18 And is epidemiology the cornerstone of 0 what IARC Monographs are about? 19 20 It is at least one of them. Α 21 And are -- and is epidemiology, is it 0 based on real world exposures? 2.2 23 Yes. Α 24 Okay. They go on to say that: "Other 0 25 members of the working group and IARC Secretariat are

Page 75 1 now being subject to intimidating letters from 2 Monsanto lawyers." 3 Did you get a letter from Monsanto 4 lawyers about this? 5 MR. LASKER: Same objection. BY MR. MILLER: 6 It's okay to answer. 7 0 8 А No. Did Monsanto lawyers call you? 9 Q I don't think so. 10 Α 11 0 Okay. You have spoken to one of the lawyers that represents plaintiffs at one time, 12 13 right, just to be fair about all this? 14 Α Yes. 15 But you're not an expert for either side 0 16 in this case, are you? 17 А No. Okay. Are you aware that Monsanto has 18 0 been lobbying the House of Representatives to cut off 19 20 funding for IARC because of this? MR. LASKER: Objection to form. 21 2.2 BY MR. MILLER: 23 You can answer. 0 24 Α Yes. 25 How do you feel about that? 0

Page 76 1 MR. LASKER: Objection to form. 2 THE WITNESS: I don't see why that's 3 pertinent. 4 BY MR. MILLER: 5 I -- pertinent in the sense that if 0 scientists are being intimidated for their 6 conclusions, that's probably relevant in this 7 lawsuit. 8 9 MR. LASKER: Objection to form. THE WITNESS: Do I have to answer? 10 11 BY MR. MILLER: 12 No. If you don't want to, I will 0 13 withdraw the question. Okay? MR. MILLER: All right. Why don't we 14 15 take a five-minute break and --THE VIDEOGRAPHER: The time is 10:14 a.m. 16 17 We're going off the record. 18 (Recess.) THE VIDEOGRAPHER: The time is 19 20 10:33 a.m., March 20th, 2017, and we are on the record with video 2. 21 2.2 BY MR. MILLER: 23 So what we were just talking about off 0 24 record, and we shared with your counsel, it's a 25 protective order that the court wants us to have

Page 77 witnesses sign before they look at documents. 1 We 2 haven't had any problems. There are lots of experts 3 on both sides who have signed it. They've looked at 4 documents. 5 I will be frank with you, Dr. Blair, my experts have already seen the document I'm going to б 7 show you, so you wouldn't be the only one that looked at it. I have lots of fellows and gals who have 8 9 looked at it. But we all know you're a man of honor, you sign this, you're not going to show it to 10 11 anybody. So that's all we're asking. 12 А So that's not my question. 13 0 What's your question? My question is I don't -- I do sign it, I 14 Α 15 never tell anyone, it gets leaked, and I get accused because people know I had it. What's my protection? 16 17 Well, I mean, I see your point. I mean, 0 18 I'm in the same boat. I've signed --19 There is none. А 20 Well, I guess honesty is your protection. 0 You really won't leak it, so you won't -- I've 21 seen -- and you guys can speak to this, but I've seen 22 23 one litigation one lawyer who leaked something, and 24 Zyprexa comes to mind, and there is some sort of 25 coding in the documents or something, I don't know,


Page 78 but they will know it's not you. We're not going to 1 give you a copy. You're going to leave without a 2 3 copy anyway, so you couldn't leak it. 4 MR. GREENE: Dr. Blair, I've had a number 5 of cases where we've had confidentiality agreements because of documents being produced in my cases by 6 7 the defendant, and my clients have signed it. It's 8 just part of the discovery process. And I've never 9 had any repercussions from anybody or anything dealing with these agreements. 10 11 I would suggest, as your counsel, that you can sign this. 12 13 THE WITNESS: Okay. Okay. 14 MR. MILLER: Okay, great. Do you need a 15 pen? 16 THE WITNESS: I need a pen. 17 MR. MILLER: Yes, sir. Here you go, sir. MR. GREENE: Mr. Miller, can I keep a 18 copy of it? 19 20 MR. MILLER: Absolutely. Absolutely. THE WITNESS: This is me here, right? 21 22 MR. MILLER: Yes, sir. THE WITNESS: (Witness signs document.) 23 24 MR. MILLER: All right. Thank you, 25 Doctor.

Page 79 1 All right. You've got it. Okay. 2 Here you go, Jeffrey. You're in charge 3 of those, and if you want, we will send a copy of the 4 signed one. 5 MR. GREENE: Just out of curiosity, do б you want me to sign something? 7 MR. MILLER: I don't think you have to. 8 I don't think it's required. 9 MR. LASKER: Actually, it probably is. MR. MILLER: Okay. Well, then hand it on 10 11 down. MR. LASKER: Since you're not counsel of 12 13 record. MR. GREENE: (Counsel signs document.) 14 15 (A discussion was held off the record.) BY MR. MILLER: 16 All set? 17 0 All right. Doctor, thank you for your 18 patience. 19 20 I want to ask you a little bit about the 21 North American Pooled Project, the NAPP. It's "Pooled analyses of case-control studies of 22 23 pesticides and agriculture exposures, 24 lymphohematopoietic cancers" --25 А Yes.


Page 80 -- "and sarcomas." 1 0 2 Are you one of the authors of this new 3 study? 4 One of the authors of these papers, yes. А 5 Yes. And I will mark it as Exhibit 7, a 0 poster presentation concerning the NAPP study. All 6 right? 7 8 (Blair Exhibit No. 7 was marked for identification.) 9 BY MR. MILLER: 10 11 0 And here is a copy, sir. Thanks. 12 And that's one of the reasons we had you sign a protective order is because I got this from 13 14 the files of Monsanto. Okay. 15 Α Then I have a question. 16 0 Sure. 17 MR. LASKER: For the record, I don't 18 think this document was marked "Confidential." It's 19 a public document. 20 MR. MILLER: This is a public document, 21 but my copy is marked "Confidential." I'm just 22 being --23 THE WITNESS: Yes, it's published in the 24 proceedings. 25 MR. MILLER: Yes, I understand.

Page 81 MR. LASKER: 1 I don't think these are 2 confidential documents. 3 MR. MILLER: Yeah, right, this is not a 4 confidential document. 5 MR. LASKER: It doesn't say "Confidential" on this. 6 MR. MILLER: All right, it's not a 7 confidential document. 8 BY MR. MILLER: 9 So let me ask you about Exhibit 7, and 10 0 11 just generally, let me ask you about the North American Pooled Project. Please tell me something 12 about this study that you're one of the authors of. 13 14 MR. LASKER: Objection. THE WITNESS: Pooling is assembling data 15 from different individual studies and putting it 16 17 together for analysis, which makes the analyses more 18 robust because there are larger numbers. BY MR. MILLER: 19 20 And are you still -- is this study still Q 21 ongoing? 2.2 А Yes. 23 And has it generated some results? 0 24 I think only this, although maybe there Α 25 is one other paper on another cancer. I sort of

Page 82 forget for sure now. But other things are ongoing. 1 Okay. Got it. 2 Q 3 Do you know John Acquavella? 4 Α I do. How do you know John Acquavella? 5 Q John is an epidemiologist that has 6 А studied farmers and pesticide exposures. 7 In the agriculture workers study, did --8 0 which you were an author of we just spoke briefly 9 10 about, right? 11 А Yes. 12 Previously. Did John Acquavella provide 0 some of the input on how to collect the data in that 13 14 study? 15 А No.



Confidential - Subject to Protective Order



Page 85 1 А Yes. 2 (Counsel conferring.) BY MR. MILLER: 3 4 Okay. I'm going to show you a 0 5 publication that you and others published in Environmental Health Perspectives in February of 6 7 2015, and just ask you a few questions about it, and I'm getting about to where I'm about at the end of 8 9 the line with my questions. You've been very patient with me. 10 11 Here is a copy for you, sir. 12 MR. MILLER: And I have a copy for 13 counsel. (Blair Exhibit No. 9 was marked for 14 identification.) 15 BY MR. MILLER: 16 17 All right. This is a publication "IARC 0 Monographs: 40 Years of Evaluating Carcinogenic 18 19 Hazards to Humans." 20 Do you remember that? 21 А Yes. And you're one of the authors? 22 Q 23 А Yes. 24 All right. I just put the sticker on the 0 25 wrong copy. Hang on.

Page 86 1 All right. A few questions on it, and 2 then we'll move on. 3 Basically, what you were looking at here 4 was to look historically at IARC's findings to see if they had gotten it right or wrong over the years. 5 Is that a fair assessment? 6 7 Α And to discuss the process that they go 8 through. 9 And what you concluded, and correct me if 0 I'm wrong, was -- was that IARC got it right most of 10 11 the time, or wrong? 12 That they get it right most of the time. Α 13 0 It says, for background: "Some critics 14 have claimed that IARC working groups, failures to 15 recognize study weaknesses and biases of working group members, have led to inappropriate 16 classification of a number of agents as carcinogenic 17 18 to humans." That was the background for which caused 19 you to want to research this subject, right? 20 21 Α Yes. And what did you do to investigate this 22 0 23 to see if in fact IARC had been getting it right more 24 often than not? 25 MR. LASKER: Objection to form,

Page 87 soliciting expert opinion. 1 2 BY MR. MILLER: 3 0 You can answer. 4 Well, we looked at the process that IARC А 5 followed, the historical examples of what they had done, and whether or not later changes were made to 6 7 the evaluations to indicate general agreement with what IARC had done or not. 8 9 And you concluded, "you" being this group 0 of scientists, concluded that these recent criticisms 10 11 are unconvincing, right? 12 MR. LASKER: Objection to form, beyond 13 the scope. 14 THE WITNESS: Yes. 15 BY MR. MILLER: 16 0 I'm not real good with numbers, but I'm 17 going to give it a try. One, two -- there's over 110 18 scientists that authored this paper. 19 Α Right. 20 So you're 40 years in -- in your field 0 21 now? 22 Α Yeah, right. And over that 40 years of studying this 23 0 issue, you have observed that farmers have an 24 25 increased incidence of this hematopoietic cancer,

Page 88 right? 1 2 Among others. А And non-Hodgkin lymphoma is a cancer of 3 0 4 the hematopoietic system, right? 5 Α Yes. 6 And you agree farmers have a good recall 0 of what pesticides they've used, right? 7 8 Δ Yes. 9 Even homeowners are aware of what they 0 10 spray on their products -- I mean on their gardens and their lawns? 11 12 Less so than farmers. А 13 0 Are they good, though, or no good at it, do you think? 14 15 А It depends. And exposure misclassification can occur 16 0 17 in a cohort study, can't it? 18 It can occur in all studies. А Yes, sir. Confounding is a problem but 19 0 20 it rarely occurs; is that fair? 21 MR. LASKER: Objection to form. 2.2 THE WITNESS: That's fair. 23 BY MR. MILLER: 24 Exposure miss -- exposure 0 25 misclassification most likely causes false negatives;

Page 89 1 is that fair? 2 Α Correct. 3 MR. LASKER: Objection to form, beyond 4 the scope, calls for expert opinion. 5 MR. MILLER: I've taken enough of your time. I may come back and ask some rebuttal 6 7 questions. I'm now going to yield the floor to the 8 attorneys for the Monsanto Corporation. THE WITNESS: Okay. 9 10 MR. MILLER: Thank you so much for your 11 time, Dr. Blair. 12 MR. LASKER: Go off the record. 13 THE VIDEOGRAPHER: The time is 14 10:52 a.m., And we're going off the record. 15 (Recess.) 16 THE VIDEOGRAPHER: The time is 10:57 17 a.m., and we're back on record. 18 CROSS-EXAMINATION BY MR. LASKER: 19 20 Good morning, Dr. Blair. My name is Eric 0 Lasker on behalf of Monsanto. I have some questions 21 for you this morning. 2.2 23 Α Okay. 24 Let's start off where you left off with 0 plaintiffs' counsel. You have been doing research 25

Page 90 regarding cancer in farmers for, what, 40 years now? 1 2 А Close. 3 And, in fact, you have publications on 0 4 cancer and hematopoietic cancers in farmers dating 5 back, from my research, at least to 1979? 6 А Yes. 7 0 And there have been epidemiological studies that have associated farming with 8 hematopoietic cancers and non-Hodgkin lymphoma dating 9 back to the 1960s, right? 10 11 Α Yes. And that was well before glyphosate was 12 0 on the market, correct? 13 14 Α Yes. 15 So it's fair to say that there is some --0 16 something going on with farmers that appears to be 17 associated with an increased risk of non-Hodgkin lymphoma that predated glyphosate being on the scene, 18 19 right? 20 А Yes. There is something going on with farmers 21 Ο and non-Hodgkin's that is associated with an 22 23 increased risk -- strike that. Strike that. 24 There is something going on with farmers 25 and their exposures that is leading to an increased

Page 91 risk of non-Hodgkin lymphoma that we know for a fact 1 can't be glyphosate, correct? 2 3 Yes. А 4 And when plaintiffs' counsel was asking 0 5 you about the issue of confounding, that is in epidemiology when there are other factors that may be 6 7 in play that cause an association between a disease 8 in a certain population aside from the one you're looking at, correct? 9 That is part of the definition of 10 Α 11 "confounding." Only part. 12 But for farmers, when we're studying 0 farmers today and we're looking at various 13 pesticides, and in particular, when we're looking at 14 15 glyphosate, we know that there are other factors out there that would be independent of glyphosate that 16 would increase risks for farmers of non-Hodgkin 17 lymphoma, correct? 18 Probably. When you say we know for a 19 А 20 fact --21 0 Well ---- is I think not true. 22 Α 23 Okay. But when you're studying 0 glyphosate in epidemiology, when you're focusing on 24 glyphosate in farmers, you want to make sure that you 25

Page 92 control -- that you can control for those other 1 possible confounders to be sure that you are actually 2 3 studying glyphosate, correct? 4 Α Yes. 5 0 Now, your research into farmers has included both case -- what's called case-control 6 7 studies and cohort studies, correct? 8 А Yes. 9 And you played a significant role -- I 0 think this was referred to briefly in your testimony 10 11 with questions from plaintiffs' counsel -- about the formation of the Agricultural Health Study, correct? 12 13 Α Correct. And the Agricultural Health Study is a 14 0 collaborative effort involving the National Cancer 15 Institute, the National Institute of Environmental 16 17 Health Sciences, and the United States Environmental 18 Protection Agency, correct? Those three, and also the National 19 А Institute of Occupational Safety and Health, and the 20 University of Iowa. 21 22 Q And the Agricultural Health Study is 23 what's called a cohort study, correct? 24 Α Yes. 25 And that is when you get a group of 0

Page 93 individuals, and in this case, farmers, correct? 1 2 А Yes. 3 And you --0 4 Α And their spouses. 5 Q And their spouses. And you find out various exposures 6 7 they've had, various facts about them before they have any -- the disease in question that you're going 8 to be studying, correct? 9 10 А Correct. 11 And then you follow them over time to 0 determine whether or not that disease develops --12 13 А Yes. -- or certain diseases develop? 14 0 15 And in this case you brought together -how many -- how many farmers and their wives did you 16 17 gather information on in your study? 18 About 80,000. А And for those 80,000 then, you obtained 19 0 20 information about all sorts of different exposures that they may have had, correct? 21 22 А Yes. 23 And that included obtaining information 0 24 regarding any exposures to glyphosate, correct? 25 А Yes.

Page 94 And at the time you gathered that 1 0 2 information, you were not -- you were looking at exposures, historical exposures going back in time, 3 4 correct? 5 Α Yes. And the Agricultural Health Study was 6 0 initiated and formed to address some of the 7 limitations in the earlier case-control studies that 8 9 had been conducted regarding risks of pesticides or other exposures in farmers, correct? 10 11 Α It -- it was initiated and formed to provide a different design to look at the same issue. 12 13 It was initiated, at least in part, to Ο address some of the limitations of the case-control 14 studies, correct? 15 16 Α Yes. 17 And, for example, one of the limitations 0 18 of the case-control studies was something called recall bias, correct? 19 20 It's a potential limitation. А 21 The Agricultural Health Study was 0 initiated in order to have a study that was examining 2.2 23 the possibility of exposures, for example, glyphosate 24 and non-Hodgkin lymphoma that did not have this problem with recall bias, correct? 25

Page 95 1 А Correct. 2 The issue of recall bias is that when you 0 are asking individuals who have a disease already 3 4 about their past exposures, the concern is that they 5 will recall more exposures than people who don't have the disease, correct? 6 7 А That's a concern. If you have recall bias, then you're 8 0 going to have an artificial increase in that odds 9 10 ratio, those numbers we were looking at previously, 11 that is due to the fact that the individual with cancer just recalls more exposures, not that he 12 13 actually had more exposures, right? Of course, it depends on the direction of 14 А the bias. It can be either direction. 15 16 But for recall bias, if a person with 0 17 cancer recalls more exposures than a person who 18 doesn't have cancer and hasn't been thinking about that --19 20 If they record more exposures, that would А be true. If they recalled less, it would be the 21 2.2 other direction. 23 Understood. And so the Agricultural 0 24 Health Study was designed to avoid that problem altogether, correct? 25

Page 96 1 А Correct. 2 The Agricultural Health Study was also 0 3 designed to try and deal with issues of 4 misclassification of exposures by going to farmers 5 who you -- you testified earlier have better recall and also periodic follow-up, correct? 6 7 Α Yes. 8 At the time of enrollment and -- and if 0 you don't have this recollection, I understand. 9 Ι will show you some studies and we can talk about it. 10 11 But at the time of enrollment, the 12 members of the AHS cohort had an average of about 15 years of experience mixing or applying pesticides, 13 14 correct? 15 Sounds about right. А 16 Q And you have been -- just to step back, 17 you've been researching the issues of potential 18 association between pesticides and cancer for nearly your entire professional career, correct? 19 20 Α Correct. 21 The effort to determine pesticides that 0 might be associated with cancer has been your life's 22 23 work, correct? 24 Well, one of them. Α 25 You certainly invested a lot of time into 0

Page 97 looking for potential expose -- associations between 1 2 pesticides and hematopoietic cancers, correct? 3 Α Yes. 4 When you heard that IARC was going to 0 look at this issue that you've been studying for 40 5 years of pesticides and cancer, you reached out to 6 them to ask them about what their -- what analyses 7 they were going to undertake, correct? 8 9 Let me strike that and ask again. When you learned that IARC was going to 10 11 be looking at pesticides and cancers, your life's work, you contacted IARC about that, correct? 12 Well, when IARC start -- that may be 13 А 14 true, but just let me explain a little. When IARC 15 decides they're going to do something, they send out information to people who might be able to provide 16 17 them with relevant papers and that sort of thing. So 18 if that happened, then I probably contacted them. Now, Dr. Blair, you provided counsel to 19 0 20 both sides with certain documents from your own files. 21 22 Α Yes. 23 Well, I'm going to ask you some questions 0 24 about some of those documents. I know we haven't 25 talked about them yet with plaintiffs' questioning.

Page 98 Let me mark as the next exhibit in line, 1 2 and we will make this --3 MR. LASKER: How have we been doing this? 4 Has it just been sequential? 5 MR. MILLER: I would continue with the 6 numbering. What is the next number? 7 8 MR. LASKER: It's 10. MR. MILLER: 10? That will continue. 9 (Blair Exhibit No. 10 was marked for 10 11 identification.) BY MR. LASKER: 12 And this is an e-mail, Dr. Blair, that we 13 0 obtained from your files, just in order to refresh 14 your recollection. This is dated March 19th, 2014, 15 and this is an e-mail from you to Kurt Straif, 16 17 correct? 18 Yeah. А 19 And who is Kurt Straif? 0 20 He's the head of the IARC Monograph А 21 program. 2.2 And seeing this e-mail, does this refresh 0 23 your recollection as to whether or not you reached 24 out to IARC after you found out that they were going to be conducting an analysis of pesticides and --25

Page 99 1 А Yeah, after the announcement about the 2 meeting had occurred. 3 Now, do you recall how IARC responded to 0 4 your e-mail? 5 А No. (Blair Exhibit No. 11 was marked for 6 identification.) 7 MR. LASKER: And counsel. 8 BY MR. LASKER: 9 And I'm going to show you a highlighted 10 0 11 document that I've highlighted to help you focus on parts of this. 12 13 (A discussion was held off the record.) BY MR. LASKER: 14 15 So, Dr. Blair, in response to your 0 inquiry, Kathryn Guyton sent you an e-mail back. 16 Who 17 is Kathryn Guyton? 18 She was the -- like the IARC coordinator А for that evaluation of pesticides that included 19 20 glyphosate. 21 And Kathryn Guyton asked whether you 0 would be interested in participating in the 22 23 Volume 112 meeting of IARC, correct? 24 Α Yeah. 25 And do you recall how you responded to 0

Page 100 that request? 1 2 I think initially I was saying, well, А maybe not. 3 4 Okay. Let's mark the next exhibit in 0 5 line. Well, strike that. 6 Do you recall having a concern about 7 serving on working group 112 because the working group would be looking at many of the studies that 8 you had been conducting that you had published as 9 part of your life's work? 10 11 Α Yep, that's one of them. 12 Your concern was that, given that this 0 13 was your life's work, it might be viewed as -- by 14 others as improper for you to be sitting on a 15 committee that was going to be evaluating whether or 16 not what you had been researching for 40 years 17 actually indicated an association of certain 18 pesticides and cancer, correct? 19 А Correct. 20 IARC continued, though, to solicit your 0 21 involvement in this working group despite that concern, correct? 22 23 Yes. Α 24 And in fact, Kathryn Guyton of IARC asked 0 25 that you chair the entire committee that was going to

Page 101 1 be looking at this issue, correct? 2 А Yes. When plaintiffs' counsel showed you the 3 0 4 part of that preamble that asks individuals on the 5 working group to disclose potential interests that might give rise to questions of bias, does that 6 disclosure form require individuals to disclose their 7 8 prior research activities and whatever interest they may have in the outcome of a monograph because of 9 those research activities? 10 11 Α I'm not sure. 12 Did you fill out a conflict of interest 0 13 form that listed as conflicts your life's work in trying to find associations between pesticides and 14 15 cancers? 16 А I -- actually, I don't recall. 17 Ο You don't recall doing that? I mean, I had to fill one out, but 18 А generally, the -- the conflicts aren't the research 19 20 you have done. The conflicts is hire for money, that 21 sort of thing. 22 So if there are individuals invited to be 0 23 members of IARC working groups who have personal 24 interests in the outcome of the IARC evaluation but do not have financial conflicts, that information 25

Page 102 1 does not have to be disclosed, correct? 2 I don't think so. А 3 Dr. Blair, the IARC working group that 0 4 considered glyphosate also review -- reviewed four 5 other pesticides, correct? 6 А Yes. 7 0 The other four pesticides were TCVP, parathion, malathion, and diazinon, correct? 8 9 Yes. А For each of these five pesticides, am I 10 0 11 correct that there were four different subgroups One for exposure, one for epidemiology, one 12 formed: 13 for animal toxicology and one for mechanism? 14 А Right. 15 And I think you stated that maybe three 0 months before the meeting, individuals on the working 16 17 group would be tasked to look at certain parts of the 18 science with respect to the various pesticides that were being reviewed, correct? 19 20 To look at the certain parts of? Α 21 Certain parts of the scientific 0 2.2 literature. 23 Yes, right. Α 24 The members of the working group would 0 25 not be looking at all the scientific literature on a

Page 103 pesticide before they went to the meeting, correct? 1 2 For example, you didn't look at anything outside of epidemiology, correct? 3 4 Up until shortly before the meeting when А 5 drafts, other drafts were distributed on it. 6 0 Okay. 7 But mainly you focused on your discipline Α and the working group you were in, yes. 8 9 Is it also fair to say that prior to that 0 week -- that one-week meeting, you would be focusing 10 11 on specific assignments that had been given to you to write certain parts of the Monograph? 12 That would be the main focus, not the 13 А 14 only focus. And the next focus is the subgroup 15 you're in, to look at that literature because that's 16 where your expertise lies. 17 Okay. And with respect to working group 0 112, the working group members split up the work that 18 they had with respect to all five of these pesticides 19 20 and all four different subgroup analyses, correct? 21 Α Yes. And I'd like to show you a document we 22 0 23 received from another IARC working group member, 24 Dr. Ross, and I think there was some testimony about 25 him earlier today. And this is going to be --

Page 104 MR. LASKER: Exhibit number again? 1 Marked this Defense Exhibit 11, is that the correct 2 3 number? 4 MR. MILLER: 12. 5 MR. LASKER: 12? (Blair Exhibit No. 12 was marked for 6 identification.) 7 8 MR. MILLER: Yeah, 11 was an e-mail from 9 Kathryn Guyton. And you have a copy of 12 --10 MR. LASKER: Yep. 11 BY MR. LASKER: 12 Actually, Dr. Blair, if you can just 0 trade -- oh, no, never mind. Got one. 13 14 Give this one -- you can actually have 15 this one so the court reporter can have the official exhibits. 16 17 And, Dr. Blair, I don't expect you to remember the various assignments that individuals on 18 the working group had, but if this is -- if you look 19 20 at the second page of this document, on the bottom it says "last update," and you can look at the one in 21 your hand, but "Last update, November 20, 2014." 22 So 23 this is about three-and-a-half months before that 24 working group meeting, the plenary session, the 25 one-week meeting we've talked about, correct?

Page 105 1 А Yes. 2 So that's about consistent with your 0 testimony earlier that it was about three months 3 4 beforehand that people started getting to work and 5 looking at some of the science, correct? 6 А Yes. 7 Ο And for working group 112, they had a lot of different eyes of science that they had to look 8 9 at, correct? They had -- what is it, one, two, three, four, five, six, seven, eight, nine, ten, 10 11 eleven, twelve, thirteen, fourteen, fifteen, sixteen -- seventeen different sections of science or 12 13 groups of science that they had to look at for malathion, correct? 14 15 А Yes. 16 0 And there was equally -- it looks like 17 about 15 or more bodies of scientific literature they 18 were looking at for parathion. Correct? 19 А Yes. 20 And there were 15 categories of science 0 for diazinon and also for glyphosate and for 21 tetrachlorvinphose (phonetic). Is that correct? 22 23 Phos. Α 24 0 Phos. And for each of these different 25

Page 106 pesticides, individual members of the working group 1 2 were assigned responsibility to look at the scientific literature in that area, correct, and then 3 4 to prepare the initial draft analysis that the 5 working group would look at during that one-week meeting, correct? 6 7 А Yes. And I've looked through this listing of 8 0 assignments, and correct me if I'm wrong, but you 9 were not given any assignment to write up any 10 11 individual portions of the working group's draft Monographs prior to the meeting; is that right? 12 No. Bottom of the second page, "Studies 13 А 14 of Cancer in Humans on Tetrachlorvinphos." 15 Okay. So your focus prior to the meeting 0 and prior to the one-week meeting was to review the 16 literature on tetrachlorvin -- tetrachlorvinphos? 17 18 Tetrachlorvinphos, yes. А And prepare a report that would then form 19 0 20 the basis of the discussion of the epidemiology 21 subgroup on tetrachlorvinphos at that meeting, 22 correct? 23 Yes. Α 24 And that was the focus of the research 0 25 you were doing or the study you were doing prior to

Page 107 that meeting, correct? 1 2 Tetrachlorvinphos was in those studies, А 3 that's right. 4 And for each of the individual 0 5 pesticides, and, for example, with respect to glyphosate, there was particular individuals who were 6 7 the people who during those -- that three-month 8 period prior to the meeting were looking at the literature with respect to glyphosate. So, for 9 example, with epidemiology, that was Dr. Forrest --10 11 Forastiere, correct? 12 Forastiere. А 13 0 Forastiere. And for animal toxicology, 14 that was Dr. Jameson, correct? 15 А Yes. Those would been the individuals -- those 16 Ο 17 would have been the individuals who within that 18 three-month period were -- prepared an analysis on either the epidemiology of glyphosate or on animal 19 20 studies and glyphosate that would then be presented 21 to that working group during that one-week meeting, 2.2 correct? 23 Preparing a document and the tables, yes. Α 24 You mentioned previously that those 0 25 documents then were distributed to the working group

Page 108 members shortly before the meeting; is that correct? 1 2 Sometime before the meeting, shortly. А Ι 3 must admit I don't quite remember the time frame, 4 but of --5 Do you remember -- do you remember how 0 many days before the working group meeting --6 7 Α No. -- you obtained copies of any of the --8 0 9 That I don't. It's because there were --А there's websites where they're on, and you can go to 10 11 the website. The ones you -- people pay most attention to, of course, is the working group you're 12 in, but the documents are fed into a website that is 13 14 available to group members. 15 So there's no process to actually 0 16 physically send to working group members any analyses 17 of these pesticides or glyphosate before the working 18 group meeting --19 I don't think that was the case. I think А 20 you used the website. 21 So for individual members of the working 0 group, they either did or did not look at -- go to 22 23 the website to find out something before the meeting 24 began, correct? 25 I assume so, yeah. А

Page 109 Some of the working group members may 1 0 have just shown up at the meeting and seen these 2 analyses for the first time when they -- when the 3 4 working group plenary session -- or when the working 5 group meeting began, correct? 6 I have no way of knowing. Α 7 Ο Well, for you personally, would I be correct in my understanding that you did not look at 8 9 any analyses for glyphosate, for example, for anything other than epidemiology before you got to 10 11 that meeting? 12 No, I don't think that's correct. Α Т don't remember how many of all the things I scanned, 13 but I did at least look at a lot of -- whether I 14 looked at every single one, I don't know, but I 15 looked at a lot of them because I knew you were going 16 17 to have to evaluate things. 18 Do you recall how many days that was 0 before the meeting began that you looked at those? 19 20 Α No. 21 And you do not know what was reviewed by Ο other working group members before that one-week 22 23 meeting began, correct? 24 No, other than each draft was assigned a Α 25 secondary reviewer, and so every draft had a

Page 110 secondary reviewer who looked at it before the 1 2 meeting. 3 Okay. So it would -- there would be at 0 4 least two people of the working group, but you're not 5 sure how many others who would have looked at drafts of analyses before that one-week meeting began? 6 7 Α True. The bulk of the work then of doing the 8 0 analysis for the working group of all the data took 9 place during that one-week session, correct? 10 11 А Well, that -- I mean it's a little hard to answer because a lot of work goes into reviewing 12 13 all the papers by the people who did -- wrote the draft and so forth, but the bulk -- now I don't know, 14 this is adding up minutes. 15 16 Q Right. 17 А I don't know. So putting aside sections for which an 18 0 individual was the principal author or maybe the 19 20 secondary author, the bulk of the work then for the working group in analyzing the scientific literature 21 22 would take place during that one-week session, 23 correct? 24 Well, a lot of it would. The bulk -- I'm Α 25 just quibbling with the bulk because I don't have any

Page 111 information to tell you about that other than those 1 2 documents are available. 3 So you don't know one way or the other 0 4 whether --5 I don't know one way or other. So I А can't answer your comment where the bulk of it was --6 7 So it's possible that working group 0 members would be looking at the science for the first 8 9 time at the beginning of that one-week meeting or it's possible not, you just can't say one way or the 10 11 other; is that fair? 12 I can't say one way or the other. Α So let's talk about that one-week period 13 0 14 then. During that one week, the working group needed to research -- specifically with Volume 112, the 15 working group needed to reach classifications under 16 17 the IARC scheme of cancer rating for five different 18 pesticides, correct? 19 Α Correct. 20 So is this a -- is this -- are you 0 21 working through weekends, or is it a five-day workweek, or how long was this? 2.2 23 You work however much time you have Α 24 available while you're there. It often means nights and weekends. 25

Page 112 So for the one-week session for each of 1 0 the five pesticides, you had maybe a day or a little 2 bit more of a day of time to be able to reach a 3 4 determination, correct? Doing the division, that is correct. 5 Α But you understand that it isn't done -- things are done 6 7 first all things on one day and all things on the 8 next. Right. 9 Q They repeat it and come back to it. 10 А 11 0 Understood. And if I understood correctly, during the first week of the week the 12 13 working group splits up into those subgroups, 14 correct? 15 Yes. А So you have subgroup meetings for the 16 Ο 17 first part of the week, and then you meet together as 18 a plenary group, the entire group about midway? 19 There's -- there are plenary sessions Α every day. Always plenary sessions. In the early 20 21 part, they are more instructive rather than 22 evaluative. 23 When does the working group as a whole 0 24 first have an evaluative meeting to reach an 25 assessment?

Page 113 I would be guessing at what day that 1 А actually comes on. 2 Sometime in --3 0 4 А I mean it's not the first day. 5 The evaluative process of determining 0 whether or not the science in particular categories 6 point one way or the other, first is conducted by the 7 subgroup that has responsibility for that area, 8 9 correct? 10 Α Correct. 11 So, for example, when you broke into the 0 epidemiology subgroup, you would be then looking at 12 the analyses that were prepared by the individual 13 assigned for each of five different pesticides, 14 15 correct? 16 А In some serial order. 17 0 Yes, obviously. 18 You would then listen to the presentations of the individual working group member 19 20 who had been assigned to prepare the analysis for that pesticide, correct? 21 22 А Prepare the document for that pesticide. 23 And over the next maybe two or three 0 24 days, the subgroup would go through each of those 25 analyses and reach their conclusion based upon the

Page 114 subgroup expertise as to how they are classified as 1 science with respect to each of those pesticides, 2 3 correct? 4 Would go through the documents of the А 5 review of the papers to come to that conclusion. Ι just object to your use of "analyses." 6 7 0 Okay. I'm sorry. 8 Some of the times it's just putting Α 9 things in a table. That's hardly an analysis. It's an assembly of the data. 10 11 0 Fair clarification. So let me go back 12 then. The -- the work that was being done 13 14 during that three-month period before the meeting, 15 the responsibility was to assemble the data and put 16 into tables. It was not to come up with an 17 evaluation during that prior period, correct? 18 Right. А So the evaluation process doesn't begin 19 0 20 until the start of that one-week period, correct? 21 Α Correct. So -- and then during that one-week 22 0 23 period for Monograph 112, which is the monograph for 24 glyphosate, the working group was then doing the 25 analysis for five different pesticides, correct?

Page 115 1 А What analysis was done and evaluation of 2 five different pesticides. So the analysis and evaluation that led 3 0 4 to the classification of glyphosate was -- and I recognize it was split over the week -- but was a 5 total combined time of roughly a day plus doing the 6 7 math, correct? Understanding it's just doing the math, 8 Α 9 and I don't actually remember how many -- how much -how many hours it took, and it varies by how easy it 10 11 is to come to a decision. 12 So you would have maybe a day or two of 0 13 analysis and evaluation that went into the IARC working group's classification of glyphosate, 14 15 correct? 16 А Roughly correct. 17 0 So --But spread over the five days. 18 А 19 0 Right. 20 So it -- you know, it's important that Α it's not just done this day and then it's done. 21 22 Q Right. 23 It's done, you look at it, you think А 24 about it, you come back to it, you look at it and 25 think about it, you come back to it.

Page 116 1 Q Right. 2 That's a different process than just you Α 3 qot this day. 4 Understood. And that would be the same 0 5 process for the other subgroups. So, for example, IARC's -- the IARC working group analysis of the 6 7 science with respect to animal toxicology of 8 glyphosate would have been conducted with 9 different -- over different days for a total amount of time, but maybe a day plus for glyphosate, 10 11 correct? 12 In the same procedure of looking at it, Α evaluating, reconsidering, coming back a day later 13 and so forth. 14 15 The analysis of glyphosate science with 0 respect to mechanism of toxicity and the like, that 16 would have been a combined total time of 17 18 approximately a day or a little bit more than a day for the IARC working group, correct? 19 20 Again, in the same procedure that people Α go through, just doing the math. I don't actually 21 know how much time they spent. 22 23 Well, it's obviously something less than 0 24 a week's worth of time, some portion, one-fifth or a little bit more of the time --25

Page 117 1 Α Yes. 2 -- they spent on glyphosate. Q So that's a lot of work in a short period 3 4 of time. 5 А Except the documents are already there. So -- but for the analysis, it's a lot of 6 0 7 work in a short period of time. The analysis of the --8 No. Again, you keep saying "analysis." 9 Α 10 Q Okay. 11 А It's not an analysis. It's a document with tables that have been prepared that the people 12 look at. 13 14 I understand. My -- my mistake. 0 Let me 15 clarify. 16 The evaluation analysis only takes place 17 during that one-week period, correct? 18 А Yes. And for the working group for that 19 0 20 one-week period where you actually do the evaluation and the analysis of five different pesticides with 21 four different categories of science, that's a lot of 22 23 work in a week. 24 It is a lot of work. А 25 For glyphosate -- well, strike that. 0

Page 118 When you have the first plenary session, 1 2 which is evaluative -- I think that's the term you used -- well, strike that. 3 4 At the end of that process where the 5 subgroup is doing its evaluations of the literature in its -- in its discipline, does it then provide a 6 7 presentation to the plenary of what the subgroup has determined is its conclusion with respect to that --8 the strength of that science for that pesticide? 9 10 Α Yes. 11 So the epidemiology subgroup would give 0 its presentation to the full plenary session on the 12 epidemiologic evidence for each of the different 13 14 pesticides, correct? 15 Α Yes. Not all at one time. Again, as 16 they come along. 17 0 Right. Understood. For glyphosate, the full working group 18 ultimately determined that the epidemiology on 19 20 glyphosate and cancer was limited, right? 21 Α For the full working group? 22 Q Yes. 23 Well, for the full working group, it's Α 24 listed as probable. 25 I'm sorry. I'm limiting it just to the 0

Page 119 1 epidemiology, not for the -- not for the full 2 analysis. 3 А Yes. 4 0 But the full working group does --5 А Does look at each one of them, yes. THE REPORTER: You're talking at the same 6 7 time. It's? 8 THE WITNESS: It was limited. BY MR. LASKER: 9 So for the full --10 0 11 А That was a recommendation of the subgroup, and the working plenary group agreed. 12 13 0 So just so I'm clear, the IARC working 14 group, both the subgroup and the full working group, determined that the evidence of glyphosate with 15 respect to non-Hodgkin lymphoma was limited, correct? 16 17 For epidemiology, yes. Α 18 The term "limited" as used by IARC, and 0 as you understood it when you were making that 19 20 finding, is that epidemiology -- epidemiology studies have found an association between glyphosate and 21 cancer, but that chance, bias and confounding could 22 23 not be excluded as explanations for the finding, 24 correct? 25 Α Correct.

Page 120 1 0 Now, you had previously in your previous answer talked about the separate evaluation that IARC 2 came to as far as overall the 2A classification, 3 4 correct? So epidemiology is a part of that, right? 5 Α Yes. But the 2A classification for glyphosate 6 0 7 was based, at least in part, on a separate determination regarding the animal studies, correct? 8 9 А Yes. The 2A classification for glyphosate is 10 0 11 based upon the determination that the animal studies provided strong evidence of carcinogenicity in 12 animals for glyphosate, correct? 13 Yes, that's as I recall it. Because now 14 А 15 you're going to the subgroup --16 Q Right. 17 -- that I didn't sit in on, you know, and Α I just have to remember what they said. Yes, I think 18 19 that's right. 20 When the animal subgroup did its initial 0 21 assessment of glyphosate and presented their conclusions to the plenary session, it had not 22 23 classified the animal studies of glyphosate as 24 providing strong evidence of cancer in animals, had 25 it?

	Page 121
1	A I don't remember.
2	Q Do you recall whether or not in fact the
3	animal toxicology subgroup had determined that the
4	animal studies provided limited to inadequate
5	evidence that glyphosate could cause cancer in
6	animals?
7	A I I don't recall.
8	Q Well, Dr. Blair, let me let me show
9	you another document that's been provided to us, and
10	I will represent in from Dr. Blair Matthew
11	Blair, and Dr. Blair was another member of the
12	working group 112, correct?
13	A I think so.
14	Q You testified about him earlier. He did
15	the work for Mississippi State, correct?
16	A No.
17	Q I think you said he's an expert in
18	animal
19	A You said Matthew Blair?
20	Q I'm sorry.
21	A Ross.
22	Q Matthew Ross. I understand. My
23	apologies.
24	A Yes.
25	Q This is a document you received from

Page 122 Dr. Ross, and Dr. Ross was a member of working group 1 112, correct? 2 3 Α Yes. 4 You had mentioned that Dr. -- Dr. Ross 0 5 was an expert in cancer -- animal cancer bioassays, 6 right? 7 А Yes. MR. LASKER: And this is 13? 8 9 (Blair Exhibit No. 13 was marked for identification.) 10 11 BY MR. LASKER: O And I would like to ask you --12 MR. MILLER: May I have a copy, please, 13 Counsel? 14 15 MR. LASKER: Yes. If I can. BY MR. LASKER: 16 17 If I could ask you -- and this is --0 18 these are --MR. MILLER: I want to object first. 19 20 Lack of foundation. 21 MR. LASKER: Understood. 2.2 BY MR. LASKER: 23 And if I could ask you just to take some 0 24 time to look through, and we will take time and -- to 25 read -- for you to read through this, these notes.

Page 123 1 And why don't we do that first so you can just familiarize yourself with the notes and -- and 2 3 what they appear to set forth. 4 (Perusing document.) А And just for the record, these notes at 5 0 the top of the first page state: "March 6, 2015, 6 7 Plenary General Remarks." And this date would be 8 about halfway through that working group one-week meeting, correct? 9 10 Α Yeah. Yes. 11 And the process that appears to be 0 reflected in these notes of presentations to the 12 13 plenary session by different groups for different 14 substances would be consistent with the process that you told us about a little while ago, right? 15 16 Α Yes. 17 So what would happen is the plenary group 0 qot together, and the subgroup -- people in the 18 individual subgroups for the individual pesticides 19 20 would then give presentations to the full working 21 group, correct? 22 Α Report where they are in the process, 23 what they were thinking, yes. And so these notes would reflect about 24 Ο 25 midway through the working group one-week meeting,

Page 124 1 correct? If that time frame fits midway through, 2 А 3 I --4 And if I could direct you to the last Q 5 page of this document and -- actually, let me take you first to the second page of the document, 6 7 because there's -- there's these different groups 8 identified, Group 1, Group 2, and then Group 3. 9 So -- and Group 4. Am I correct in my understanding that 10 11 from that Group 1 would be the exposure assessment, Group 2 would be epidemiology, Group 3 would be 12 animal studies -- I'm sorry -- and then Group 4 then 13 14 would be mechanistic data, correct? 15 Α Correct. 16 Q And then the final page of this document, 17 there is the presentation of each of these subgroups 18 as of March 6th, 2015, with respect to glyphosate, Right here (indicating), glyphosate? 19 correct? 20 The last page? А Is it the last page? I believe it's the 21 0 last page of the document. The very bottom of the 22 23 last page, do you see Glyphosate Group 1, Glyphosate 24 Group 2, Glyphosate Group 3, and Group 4? 25 Here is the last page of mine. Α

Page 125 1 Q Yeah, right here (indicating). Glyphosate, glyphosate, right there (indicating). 2 3 Α Okay. 4 MR. MILLER: Again, I object to the 5 entire line of questions for lack of foundation for the document. 6 BY MR. LASKER: 7 8 So with respect to glyphosate as 0 9 reflected in these notes, there is a presentation by the -- there is a presentations by the exposure 10 11 group, by the epidemiology group, by the animal cancer -- animal bioassay group, and the mechanistic 12 13 group, Groups 1 through 4, correct? 14 А Yes. 15 And Group 2 is your group, the 0 epidemiology group, correct? 16 17 А Yes. And the notes here state: "Glyphosate, 18 0 negative non-Hodgkin lymphoma. Case-control 19 glyphosate, " arrow, "non-Hodgkin lymphoma. AHS, 20 21 negative data." 22 Is this consistent with your recollection 23 of the epidemiology working group's presentation of 24 the data on glyphosate and non-Hodgkin lymphoma? 25 Α Yeah, roughly so. The case -- there were

Page 126 case-control studies were positive and AHS was 1 2 negative, yeah. For Group 3, for the subgroup that was 3 0 4 responsible for looking at the animal data for 5 glyphosate and cancer, the determination was that that evidence was limited to inadequate, correct? 6 7 А I -- that is what it says. I actually don't remember. 8 9 And so you -- sitting here today, can you 0 exclude the possibility that the animal toxicology 10 11 subgroup of IARC determined that the animal data associating glyphosate with cancer was limited to 12 inadequate? 13 14 А No. 15 Do you recall what happened from the Ο time of this initial plenary session in March -- on 16 17 March 6, 2015, through to the end of the working 18 group that led to the change of the evaluation of the 19 animal data from limited or inadequate to strong? 20 MR. MILLER: Object to the form of the 21 question. 22 Well, only in a sense that THE WITNESS: 23 from sort of preliminary discussion where things are, 24 then the subgroups go back and -- and look and 25 evaluate and discuss, and that's what happened. Ι

Page 127 was not in the subgroup, so I have no idea what the 1 discussion was. 2 BY MR. LASKER: 3 4 So sometime after this initial -- this 0 5 plenary session on March 6, 2015, something happened over the next few days that led the subgroup to 6 change its evaluation of the animal data with respect 7 8 to glyphosate. Is that fair to say? 9 You know, I'm not even sure I can say Α that, because what this says is "limited to 10 inadequate." So if note-taking is messy, it could be 11 12 limited or inadequate. Now it's a choice. So they 13 haven't chosen. I have no idea. I really don't remember what went on at that time, other than this 14 15 is saying they're exactly unsure where to put it. And I was not privy to discussions of that group at 16 that time. 17 So... 18 You are aware that the ultimate 0 determination that appears in the final monograph is 19 20 that the animal data was strong. Correct? 21 А Yeah. And in fact, if the animal -- if the 22 0 ultimate determination that the animal data was 23 24 either limited or inadequate, the full working group would not have reached the determination that 25

Page 128 glyphosate was a probable carcinogen, correct? 1 2 MR. MILLER: Object to the form of the 3 question. 4 THE WITNESS: Probably not. BY MR. LASKER: 5 6 0 In fact, with that analysis and that evaluation of the animal data and the conclusion of 7 8 your subgroup that the epidemiology data was limited, the highest classification that IARC working group 9 could have come to is that glyphosate is a 10 11 possible --12 Α That's correct. -- carcinogen, right? 13 0 And in fact, with inadequate animal data, 14 the IARC working group may have concluded that the 15 size of the whole was inadequate to reach 16 17 determination, and it would be a Group 3 substance, 18 correct? 19 They could have concluded that, yes. А 20 And you discussed earlier that pursuant 0 to the preamble for IARC, IARC only considers 21 scientific literature that is peer-reviewed or 22 23 made-publicly-available regulatory documents; is that 24 correct? 25 Not just regulatory. It's peer reviewed Α

٦

	Page 129
1	or publicly available is the key thing.
2	Q Understood. Prior to Monograph 112
3	the Monograph 112 working group meeting, you were
4	aware of unpublished epidemiological data regarding
5	glyphosate and hematopoietic cancers, correct?
6	A Well, I'm hesitating because it means
7	were we working on the pooled analysis at that time,
8	which I think was probably true.
9	Q Okay. And, in fact, we have some
10	documents on that that I will show you about that.
11	So we you had some testimony earlier
12	in question response to questions from Mr. Miller
13	about the North American Pooled Project, correct?
14	A Yes.
15	Q That is a study that is pooling data that
16	has been previously used for the Canadian McDuffie
17	McDuffie study and the U.S. studies in that 2003
18	case-control study in the United States, correct?
19	A It's three different case-control studies
20	in the United States.
21	Q Right. Yeah. So all of those studies
22	were combined for the North American Pooled Project
23	in this pooled analysis, correct?
24	A Yes.
25	Q And that was De Roos 2003 was the

Page 130 1 Α De Roos was the pooling of the American, 2 the U.S. studies, and they were then pooled with the Canadian studies. 3 4 So let me mark as Exhibit 13 -- 14. I'm 0 as good as Mr. Miller at this. 5 6 MR. MILLER: It's a high compliment. 7 MR. LASKER: I have to count the double 8 digits. You were on the single digits. So I don't 9 know. It's a little harder when you have to take off 10 your shoe. 11 (Blair Exhibit No. 14 was marked for 12 identification.) BY MR. LASKER: 13 And this is a series of e-mails that 14 0 15 we -- that you provided to us from your files. 16 And if -- am I correct that these are 17 e-mails discussing some of the analyses that were 18 being conducted for the North American Pooled Project 19 in October of 2014? It looks like it, yeah. 20 Α So this would have been prior to the IARC 21 0 working group meeting, which obviously was in March 22 23 of 2015. 24 Α Right. 25 In these e-mails, Dr. Pahwa --0 Correct.

Page 131 1 who is Dr. Pahwa? 2 He's a scientist in Canada. А Is that a he or a she? 3 0 4 А A she. 5 And she is an epidemiologist like 0 6 yourself? 7 А Yes. And Dr. Pahwa and you are discussing the 8 0 epidemial -- epidemiologic analysis that was being 9 discussed as part of the North American Pooled 10 11 Project in these e-mails, correct? 12 Α Correct. 13 0 And in her October 23rd e-mail to you and 14 others, I guess these -- am I correct these other 15 individuals are other epidemiologists who are part of the North American Pooled Project study? 16 17 Α Correct. 18 In this October 23rd e-mail, Dr. Pahwa 0 provides a summary of a meeting you guys had on 19 20 October 20 in which you discussed in part the possibility of getting some -- I will focus this 21 because it's getting out of focus. 22 23 Dr. Pahwa is recounting a discussion that 24 you had on October 20 about the possibility of 25 getting some NAPP data on glyphosate published in

Page 132 time for consideration by the Monograph 112 working 1 group, correct? 2 3 А Yes. 4 And during this meeting, you explained 0 5 your role on the Monograph 112 working group and the deadline for getting data published for consideration 6 7 by the working group in its evaluation of glyphosate, 8 correct? Well, is it in here somewhere? 9 А 10 0 Yes. 11 Α You're saying --I'm sorry. It's the final bullet on the 12 0 13 first page, and it's highlighted on the document, but it starts: "Aaron will be" -- the final bullet. 14 15 Okay. Closing date. All right. Yes. Α "Aaron will be on the IARC" --16 Q 17 Α Yeah. -- "Monograph 112 working group on 18 0 March 3rd to 10 to help evaluate malathion, 19 20 parathion" --21 Yeah, okay. А -- "diazinon, glyphosate," et cetera. 22 Ο 23 "The closing date for data is February 3rd. Manisha 24 has agreed to lead an analysis of glyphosate and NHL, 25 MM and HL risks. She will submit her proposal to the

Page 133 NAPP executive committee by October 24th. 1 Once approved, a progress check will be done in a month to 2 determine if it's feasible to meet the February 3rd 3 4 deadline. NHL is the priority cancer site." 5 You see that? 6 А Yeah. 7 Ο And in your e-mail back to Manisha, you state: "Let me know if I can help in trying to meet 8 the IARC manuscript deadline." Correct? 9 10 Α Yeah. So you were -- not only were you the 11 0 chair of the working group, but in the months leading 12 up to the working group, you were involved in 13 investigating some data that might inform the 14 decision of the working group but only if it was 15 published, correct? 16 17 А Yes. Now, let me mark the next document of 18 0 19 mine. (Blair Exhibit No. 15 as marked for 20 identification.) 21 2.2 BY MR. LASKER: 23 And can you -- am I correct these are 0 24 some further e-mails between you and other 25 individuals, investigators for the North American

Page 134 1 Pooled Project, presenting some analysis of the data with respect to glyphosate and cancer risks, correct? 2 3 Well, I can clearly read the names, so Α 4 it's people in the North American Pooled Project. 5 Yes, okay. Finally, I see glyphosate, so it appears б to be so, yes. 7 0 And there are a series of communications 8 reflected in this document between you and other NAPP investigators about, say, for certain analyses of 9 glyphosate that could be published in time for the 10 11 IARC working group deliberations, correct? 12 I take your word for it. I --А Well, there is data on this -- there's 13 0 14 data on this document with respect --15 I'm not disagreeing. I just mean you Α 16 handed this to me, and these are e-mails of years 17 ago, and you're saying this is correct. I'm just 18 saying if it's in the document, I agree. Okay. Well, just to be clear, this is an 19 0 20 e-mail that was sent to you -- and these e-mails were sent to you in October of 2014, roughly four, 21 four-and-a-half months before the IARC working group 22 meeting, correct? 23 24 Α Correct. 25 And these e-mails contain analyses of the 0

Page 135 North American Pooled Project data with respect to 1 glyphosate, and in this case multiple myeloma, 2 3 correct? 4 Well, at least -- yes. А 5 And if you could, because this is the way 0 e-mails are, they always work this way when you print б 7 them out, they don't go in chronological order so it's hard to read them. 8 9 But if I could ask you to turn to the very last page, which is the first e-mail in this 10 11 chain on October 27, 2014, from Dr. Pahwa, it starts: "Hi, John, Shelly and Laura." Do you see that? 12 13 А Yeah. Now, in this -- on October 27 -- it's not 14 0 15 focusing, so let me just read it, what the e-mail 16 states. Dr. Pahwa is discussing -- states: "I 17 have prepared a research proposal for assessing 18 glyphosate exposure and NHL risk in the NAPP. While 19 we had discussed looking at glyphosate exposure and 20 the risks of non-Hodgkin lymphoma, multiple myeloma 21 and Hodgkin lymphoma in the NAPP, I thought to start 22 23 off with non-Hodgkin lymphoma since it has been 24 identified as a priority cancer type in general and 25 has the largest sample size compared to the other

Page 136 1 cancer types." 2 Correct? 3 You say this is the last page of this Α 4 document you handed me? 5 Yes, the last page -- Dr. Pahwa is 0 sending around a proposal for assessing glyphosate б exposure in non-Hodgkin's lymphoma risk, correct? 7 All right, here it is. You -- I just 8 А couldn't see this "I have prepared," but it's in a 9 couple of words. Okay. 10 11 0 Right. 12 All right. А 13 0 So Dr. Pahwa, on October 27th, 2014, she 14 sends around a proposal for assessing glyphosate exposure and non-Hodgkin lymphoma in the NAPP data, 15 16 correct? 17 Α Yes. 18 Now, in response to her e-mail, and again 0 we have to go backwards in time, but Dr. Harris -- so 19 20 it's on the bottom of the second to the last page, the e-mail that responds to Dr. Pahwa. In response, 21 Dr. Harris, another NAPP investigator, suggests 22 23 extending the analysis to include other cancers, 24 correct? 25 Α Okay. Yes.

Page 137 1 0 And then in response to Dr. Harris's e-mail, another NAPP investigator, Dr. Freeman, notes 2 that there may already have been an investigation of 3 4 the NAPP data to determine whether there was an association between glyphosate and multiple myeloma, 5 6 correct? 7 А So tell me your interpretation of this 8 sentence again. 9 That Dr. Beane-Freeman in the e-mail was 0 asking whether or not -- hey, haven't we already 10 11 looked at the NAPP data on glyphosate to determine if there is an association with multiple myeloma, 12 13 correct? That's her question. Yes. Yes. 14 А 15 And then Dr. Pahwa comes back and says, 0 16 You're right, we've already done this, but I'm not sure what we found. Correct? 17 18 А Yes. And then Dr. Freeman in her e-mail, which 19 0 is on the middle of this page, on October 28th, 2014, 20 at 10:54, suggests that the group of NAPP investors, 21 including yourself, have, quote: A strategic 22 23 decision about whether to include multiple myeloma in 24 the paper that was being considered for publication 25 in time for the IARC Monograph review of glyphosate,

Page 138 1 correct? 2 А Yes. 3 We're not going to read that, but 0 4 Dr. Freeman raises two factors for consideration: 5 How far along the analysis is of glyphosate and multiple myeloma from the NAPP data; and whether 6 7 there was, quote, any hint of an association, end 8 quote. Correct? 9 Α Yes. And she states that the answers to those 10 Ο 11 questions and probably others might affect how we think about the question, correct? 12 13 А Yes. So the NAPP investigators, including 14 0 15 yourself, wanted to find out first whether there was, quote, any hint of an association between glyphosate 16 17 and multiple myeloma before deciding whether to make 18 that data available for use in the IARC review, 19 correct? 20 Whether to complete the analysis. А 21 In response to Dr. Freeman's e-mail, 0 Dr. Harris took a look at the analysis that had been 22 23 conducted from the North American Pooled Project data 24 regarding glyphosate and multiple myeloma, correct? Where -- where is this? So I see --25 Α

Page 139 1 0 The first -- the first page now, the final e-mail, it's from Dr. Harris. 2 3 А Okay. 4 And she is going through --Q 5 А Okay. -- and saying, Yes, we've done this 6 0 7 analysis, and she presents the data from the North American Pooled Project on glyphosate and multiple 8 myeloma, correct? 9 10 А Okay. 11 0 Correct? 12 А Yes. 13 0 Dr. Harris reports back to the group that the North American Pooled Project data did not show 14 an elevated risk for multiple myeloma associated with 15 glyphosate, correct? 16 17 Α Yes. 18 The adjusted odds ratio for multiple 0 myeloma for ever and never use of glyphosate was 1.23 19 20 with confidence intervals of 0.86 to 1.76, correct? 21 Α Yes. That's what epidemiologists refer to as a 22 0 23 null finding, correct? 24 No, that's not what they refer to as a Α 25 null finding.

Page 140 1 0 Not the --2 That's what they refer to as an excess Α that isn't statistically significant. 3 4 A nonstatistically significant finding, 0 5 correct? Nonstatistically significant excess. 6 Α 7 0 Okay. So there was no statistically 8 significant association between glyphosate exposure 9 and multiple myeloma in the NAPP data, correct? 10 Α Correct. 11 0 Dr. Harris also reports results with proxy respondents excluded, correct? The last three 12 columns in her table? 13 14 А Yes. 15 A proxy is a next of kin or a spouse, not 0 16 the actual individual who had the potential exposure, 17 correct? 18 А Correct. And generally speaking, self-reported 19 0 data of the individual who had the exposure is 20 21 considered more reliable than proxy reported exposure data, correct? 2.2 23 Correct. Α 24 0 When proxy respondents were excluded, the 25 NAP data -- NAPP data showed that the odds ratio for

Page 141 ever/never use of glyphosate and multiple myeloma was 1 0.97 with confidence intervals of 0.63 to 1.48, 2 3 correct? 4 А Right. 5 So using the most reliable exposure data, 0 there was no suggestion whatsoever of any increased 6 7 risk of multiple myeloma with glyphosate exposure, 8 correct? 9 А Correct. So that was a null finding, correct? 10 0 11 А Yes. Now, Dr. Harris notes that they could 12 0 13 have a draft of this paper, including this glyphosate analysis, available for review in the next few weeks 14 15 and that a paper could be submitted for publication 16 early in the new year or before, correct? 17 And that's the very beginning of her e-mail, the second paragraph, the last sentence: 18 " I expect you will have a draft to review in the next 19 few weeks, and the paper could be submitted" --20 Well, if you're reading it, I don't find 21 Α it, but okay, fine. 22 23 Well, no, I want you to be able to see Ο In the very top of the e-mail, the first line 24 it. 25 "Hi, everyone. Thanks all for weighing in on is:

Page 142 1 this." Correct? 2 А Yeah. 3 And then the second paragraph, the last Ο 4 sentence, starting at the end of line 2: "I expect 5 we will have a draft to review in the next few weeks and a paper could be submitted early in the new year 6 or before." Correct? 7 8 Okay. Yes. А 9 And you were copied on obviously this 0 e-mail that sets forth the NAPP data for glyphosate 10 11 and multiple myeloma, correct? 12 А Correct. 13 But despite the fact that you had this 0 data and it was in a form that could be submitted for 14 review and submitted for publication in time for the 15 IARC Monograph, this data was not in fact published 16 17 in time for the IARC Monograph 112 review, was it? 18 I think not. А In fact, the data was not published until 19 0 20 June of 2016, some twenty months later and well after the IARC working group had conducted its review of 21 glyphosate, correct? 22 23 And I don't think it was submitted to --Α 24 it can be submitted to IARC if it's accepted for publication, but I don't think this was. 25 So I think

Page 143 your answer -- your comments are correct. 1 2 Now, the June 2000 --Q And I just want to make the point that it 3 Α 4 doesn't have to be published, it has to be accepted, 5 which means it's available from the journal. Good clarification. So if you had -- you 6 0 7 and the other NAPP investigators had submitted this 8 data, it could have been considered by the IARC working group even if it hadn't been published yet? 9 10 Α If it had been accepted by the journal 11 and up on the journal's website, which happens to -actually, one of the papers I got is the website 12 13 version. It is the same thing as the published one. 14 But you quys didn't -- you quys didn't do 0 15 that. You didn't get this data in a position that the IARC working group could consider it, correct? 16 17 А Correct. And -- but you were obviously aware of 18 0 this data during the IARC working group 19 deliberations, right? 20 21 Α Yes. Did you mention the NAPP findings of no 22 0 23 association between glyphosate and multiple myeloma 24 to any of your fellow working group members during 25 the Monograph 112 deliberations?

Page 144 1 А I don't think so. But I don't recall for sure. It wasn't published. 2 Just to be clear, it wasn't published 3 0 4 because you guys decided not to publish it, correct? 5 Because we didn't go through the process А to get everything ready to send it off for б 7 publication. It's still not a sure thing, you understand. You make it sound like you decide, then 8 9 it's done for sure. No, that's not the case. You work on it, you look at it, you revise, you send it 10 11 to the journal to get reviews back from authors of --12 the reviewers at the journal and so forth, and all that goes into the decision of whether you can make 13 it, and we didn't do that. That is correct. 14 Dr. Harris in October of 2014 is 15 0 16 suggesting, Hey, let's get this -- let's submit this 17 to a journal and get it published so the IARC working 18 group can consider it, but you didn't do that, 19 correct? 20 Did not do that. А 21 Now, Dr. Pahwa had also discussed in 0 these e-mails that she was looking at the North 22 23 American Pooled Project data with respect to 24 glyphosate and non-Hodgkin's lymphoma, correct? 25 А Right.

Page 145 1 0 And the NAPP investigators did not publish any findings with respect to glyphosate and 2 non-Hodgkin's lymphoma prior to the monograph one --3 4 IARC 112 meeting in March 2015, correct? 5 А I think that's correct, yeah. Now, you have presented -- the NAPP 6 0 7 investigators have presented data about glyphosate and non-Hodgkin's lymphoma at various scientific 8 meetings, correct? 9 At least two, I think. 10 А 11 0 Okay. Let me ask you about the first of those. What I believe is the first, and correct me 12 13 if I'm wrong. (Blair Exhibit No. 16 was marked for 14 15 identification.) 16 MR. MILLER: 16? 17 MR. LASKER: 16. 18 BY MR. LASKER: And, Dr. Blair, this is a presentation 19 0 that the North American Pooled project investigators, 20 including yourself, made with respect to what the 21 NAPP data showed for glyphosate and non-Hodgkin 22 23 lymphoma, correct? 24 Yeah. Yes. Α 25 And this was presented on June 2015, 0

Page 146 which was after the IARC -- a few months after the 1 2 IARC Monograph 112 meeting, correct? 3 Right. Α 4 Now, if I can direct you to the first 0 data table in this log deck, and it's a few pages in, 5 and specifically -- so it would be this table right 6 7 here (indicating). Okay. We will put it up on the 8 screen. 9 MR. LASKER: Help me focus this. Zoom 10 out, actually. (Counsel conferring.) 11 BY MR. LASKER: 12 13 0 So the -- this table presents data on 14 what the North American Pooled Project had found with 15 respect to glyphosate use and non-Hodgkin lymphoma risks, correct? 16 17 Α Yes. And the first -- the overall odds ratio 18 0 for ever/never use of glyphosate and non-Hodgkin 19 20 lymphoma in the North American Pooled Project is 1.22 with confidence intervals of 0.91 to 1.63, correct? 21 22 А Correct. 23 So this is basically the same finding 0 24 that the NAPP had made with respect to multiple myeloma back in October of 2014, almost exact same 25

	Page 147
1	odds ratios, not statistically significant, correct?
2	A The odds ratio that are similar, right?
3	Q Yes.
4	A Is that your point?
5	Q Yes.
6	A Yes.
7	Q And not statistically significant,
8	correct?
9	A Yes.
10	Q And just like with the multiple myeloma
11	analysis we looked at before, we also have an
12	analysis that breaks out proxies and looks only at
13	the most reliable exposure data, and I think that is
14	the table that looks like this (indicating). I
15	apologize, there's not there are no page numbers
16	here.
17	A Okay.
18	Q But in this analysis, proxy by
19	self-respondents, just as with multiple myeloma
20	finding, when you looked at the NAPP data and you
21	looked at the most the more reliable
22	self-respondent only data, you have an odds ratio for
23	non-Hodgkin lymphoma and glyphosate in the North
24	American Pooled Project of 1.04, with a confidence
25	interval of 0.75 to 1.45, correct?

Page 148 Correct. 1 А 2 So, again, this is a null finding from 0 the North American Pooled Project with respect to 3 4 whether or not glyphosate is associated with non-Hodgkin lymphoma, correct? 5 6 А Yes. 7 0 Did you mention these North American Pooled Project findings of no association between 8 9 glyphosate and non-Hodgkin lymphoma to any of your fellow working group members during the Monograph 112 10 11 deliberations? 12 А I don't think so. And I want to say, actually I don't know whether these were available or 13 14 not. So you -- I mean whether I even knew about 15 them, because the analysis of multiple myeloma was going on, but I don't know whether this one was done 16 17 or not. If it was, I'm sure you're going to show me, 18 but I don't know whether this one was done or not. 19 Well, you certainly knew that you had the 0 20 ability to look at that. You were --21 Well, that's a different thing than Α knowing what it is. We can look at a lot of things. 22 23 So in October of 2014, though, you and 0 24 Dr. Pahwa and the others were talking about, Hey, 25 let's look at the data from our North American Pooled

Page 149 Project with respect to glyphosate and non-Hodgkin 1 lymphoma, correct? 2 3 А Yes. 4 Is it your testimony that you in fact, 0 5 though, then didn't look at that data? 6 I -- there were a bunch of things going А 7 on, and they were already analyzing, and I just don't 8 remember the sequence that got to it. You make it sound like as if you can decide to look at it, and 9 just it's over and done. These things take months 10 11 and months and months. And so if you haven't looked at anything at all, the odds aren't good that you can 12 complete it beforehand, before some date. 13 And I think that was part of the thinking about non-Hodgkin 14 lymphoma, that we couldn't get it ready in time. 15 You haven't published your findings with 16 0 17 respect to glyphosate and non-Hodgkin lymphoma to 18 this day, have you? 19 Α No. It's now three years later, correct? 20 0 Scientific research takes time. 21 Α The -- and because of the fact that you 22 0 23 had not published these results, including this 24 finding of -- a null finding in the North American 25 Pooled Project for glyphosate and non-Hodgkin

Page 150 lymphoma, that information was not available to IARC. 1 2 Correct? 3 Α No. 4 It was not available, correct? 0 5 А No. 6 0 I'm going to restate that. It is correct that IARC did not have this 7 information, right? Yes, IARC didn't have it? 8 9 IARC did not have it. Α IARC didn't have it. 10 0 11 А No. And the various regulatory agencies, 12 0 13 including the EPA and regulatory agencies around the world, also have not had this information that the --14 that you've been aware of with respect to non-Hodgkin 15 16 lymphoma? 17 А Yeah, except -- so, okay, I see you're pushing this hard now. So what if we look at 18 frequency of days per year of use? 19 20 0 Okay. So now when you look at the people who 21 Α used it more, they do have an excess of non-Hodgkin's 22 23 lymphoma among the self-respondents. 24 That -- now, that's interesting you 0 25 picked that one out. Why did you not look at

Page 151 1 duration or lifetime days? 2 There's a lot --Α 3 There's a lot of analyses. You picked 0 4 that one. 5 There are a lot of them. You look at a А lot of different things and you have to try to 6 evaluate the whole thing. I picked out one and you 7 8 picked out one. 9 Okay. But you didn't present any of the 0 data so that the IARC working group could look --10 11 Α Because it wasn't -- I don't think it was available at the IARC working group time. If it --12 13 0 But it was available to you. 14 I'm not sure it was available to me. Α Ιf 15 you have information to show it's available, well, tell me, but I don't it was available. I remember 16 17 this coming after the IARC working group stuff. 18 We just looked at October 28th, 2014 0 e-mails where you or the NAPP investigators were 19 20 discussing --What to do. They didn't -- I don't 21 Α remember it saying we had done it and this 22 23 information was available. That's the issue. 24 Now, so that I understand, the NAPP 0 25 analysis was based upon data that was already

Page 152 available to the IARC working group because it was 1 2 pooling --3 А Yes. 4 -- the McDuffie case report and the 0 5 De Roos 2003 report. 6 А Correct. 7 0 Okay. Now, during the IARC Monograph --8 during the IARC Monograph 112 deliberations, you were also -- strike that. 9 During the IARC Monograph 112 10 11 deliberations, you were also aware of unpublished data on glyphosate and non-Hodgkin lymphoma from the 12 13 Agricultural Health Study, correct? You know, I -- I don't remember. 14 А 15 Okay. Well, we will go through this, but 0 let me first refresh and let the jury understand 16 17 because during Mr. Miller's questioning you didn't 18 have the opportunity to talk about the findings from the Agricultural Health Study that has been published 19 20 on glyphosate and non-Hodgkin lymphoma. So let me provide for you, and we will 21 mark this as Defense Exhibit 16 -- 17. 17. 22 Sorry. 23 (Blair Exhibit No. 17 was marked for 24 identification.) 25 MR. MILLER: Thank you. Exhibit 17.

Page 153 1 MR. LASKER: Exhibit 17. 2 MR. MILLER: We have a rule in the law, 3 Doctor, it's called hungry break. 4 MR. LASKER: Oh, you want to take a 5 break? 6 MR. MILLER: Whatever. It's not up to 7 me. It's up to you, Doctor. You're the witness. So 8 you can keep going or you can take a break. It's up 9 to you. THE WITNESS: It would be nice to take a 10 11 break. It's sort of a physiological position. So is 12 that --13 MR. LASKER: Okay. That is -- we can 14 take a break whenever you want. I just don't know if 15 you mean now or later. Whenever you want to, just 16 let me know. 17 THE WITNESS: I have no clue. 18 MR. LASKER: You have no clue whether you want to take a break? 19 20 THE WITNESS: No. I mean --21 MR. LASKER: Well, we should have -- we 22 should definitely have a lunch break. If you want to 23 take it now, it's up to you. 24 THE WITNESS: Well, you're on a topic 25 What I'm trying to find out is, are you going now.

Page 154 to go on this for a while and then switch to 1 2 something else? I would prefer to get this done. 3 MR. LASKER: Okay. 4 THE WITNESS: But I don't know that. 5 MR. LASKER: Okay. Well, why --THE WITNESS: Only you know that. 6 MR. LASKER: Okay. Well, why don't we 7 get this done, and then we will switch to something 8 9 else. 10 THE WITNESS: Okay. 11 MR. LASKER: Okay. 12 BY MR. LASKER: 13 So, with respect to the De Roos 2005 0 14 paper, this is a paper that you were -- a study that you were co-author on, correct? 15 16 А Yes. 17 And this is the cohort study we have been 0 discussing before and the analysis of cancer 18 incidence among glyphosate-exposed pesticide 19 applicators, correct? 20 21 Α Yeah. Yes. 22 0 And if you turn to page 49, the first page actually, on the "Materials and Methods" 23 24 section, the De Roos 2005 paper was reporting out the 25 findings from the AHS cohort based upon exposure data

Page 155 gathered between 1993 and 1997, and incidence of 1 cancers identified as of December 31st, 2001, 2 3 correct? 4 Well, the '93 to '97 is correct. I guess А 5 the other is. 6 If you read down a little bit further 0 along that same section, you will see --7 8 А Yes. 9 0 -- cancers. 10 А Okay. Yes. Okay. 11 And if you go to page 51, Table 2, based 0 on this data, De Roos 2005 identified 92 cases of 12 13 non-Hodgkin lymphoma in farmers and the cohorts who 14 had been -- who had reported exposure to glyphosate, 15 correct? 16 А Yes. 17 And De Roos calculated and adjusted risk 0 18 ratio for ever/never use of glyphosate and non-Hodgkin lymphoma of 1.1 with a confidence 19 20 interval of 0.7 to 1.9, correct? 21 Α Correct. Which is showing no statistically 22 0 23 significant association, correct? 24 Α Yes. 25 And De Roos 2005 also presents data on 0

Page 156 non-Hodgkin lymphoma and glyphosate in association 1 with the duration and intensity of exposure to 2 3 glyphosate, correct? 4 Yes. Α 5 That data was presented on page 52, 0 Table 3? 6 7 А Yes. 8 And provides an analysis of 61 cases of 0 non-Hodgkin lymphoma in farmers who had been exposed 9 to glyphosate, correct? Towards the bottom of that 10 11 chart, the non-Hodgkin lymphoma. 12 Α Yes. Yes. Yes. And for both -- let me do this so it's 13 0 14 not in the -- actually, it's better to put it there. Which I found it in the table. Now you 15 Α 16 don't need to. 17 For both cumulative exposure days --Ο well, first of all, let me see if I understand this. 18 19 What is cumulative exposure days in the 20 AHS evaluation? The number of days per year they say they 21 Α applied a chemical multiplied by the number of years 22 23 they said they used it. 24 And what is the intensity of exposure? 0 25 It's those two factors weighted also by Α

Page 157 how they use protective equipment and things such as 1 2 that that would influence exposure. So in the De Roos 2005 paper for both 3 0 4 cumulative exposure days, which is this data here (indicating), and for intensity weighted exposure 5 dates, which is this data here (indicating), the 6 7 relative risk for non-Hodgkin lymphoma was below 1.0 8 for higher exposures to glyphosate, correct? 9 А Correct. 10 0 So farmers who had either more days of 11 exposure to glyphosate or had more intense exposure to glyphosate had a high -- had a lower --12 13 Α Lower. -- lower incidence of non-Hodqkin 14 0 15 lymphoma than farmers who had not used glyphosate, 16 correct? 17 А That was not statistically significant. So this would be a negative association. 18 0 It wouldn't be a null finding, but it would not be 19 20 statistically significant, correct? 21 Α Correct. 22 Ο Okay. And are you aware of some of the 23 discussions that have taken place following the IARC 24 classification of glyphosate about this AHS study and its strengths or weaknesses? 25

Page 158 I mean I'm involved in the study, so if Α 1 the answer is are there -- am I involved in 2 discussions about it, well, yes. 3 4 Okay. Well, let me show you --Q 5 Α But why don't you ask what you're 6 interested in. Let me show you specifically -- let me 7 0 show you specifically a publication by Dr. Portier. 8 I think you mentioned him earlier. 9 You know Dr. Portier, correct? 10 11 А I do. (Blair Exhibit No. 18 was marked for 12 identification.) 13 BY MR. LASKER: 14 15 And this is Defense Exhibit 18. 0 16 А You have two things there. Did you --17 Oh, that has highlighting. Thank you. 0 Actually, you have three things there. 18 А MR. MILLER: Three things. 19 20 BY MR. LASKER: 21 Okay. And in this publication, 0 Dr. Portier is -- well, first of all, it's entitled 22 23 "Differences in carcinogenic evaluation of glyphosate 24 between the IARC -- between the International Agency 25 for Research on Cancer and the European Food Safety

Page 159 Authority, " correct? 1 2 А Yes. 3 And in this publication, a variety of Ο 4 individuals are trying to address their views about 5 the differences between what IARC concluded with respect to glyphosate and cancer and what the 6 7 European Food Safety Authority concluded, correct? 8 А Yes. 9 And if we turn to the second page of this 0 commentary, Dr. Portier is talking specifically 10 11 about -- at the bottom of the first page and then turning over to the second page -- the Agricultural 12 13 Health Study we were just looking at, the 2005 publication, correct? 14 15 Okay. Yes. Α 16 0 And at page 2, on the top of that left 17 column, Dr. Portier writes: "Despite potential 18 advantages of cohort versus case-control studies, the AHS only had 92 NHL cases in the unadjusted analysis 19 20 as compared to 650 cases in the case-control studies." Correct? 21 22 Α Yes. 23 So he is pointing to the fact that 0 24 there's only 92 NHLs found as of 2005? 25 А Yes.

Page 160 He also talks about the fact that the 1 0 2 median follow-up time in AHS was 6.7 years, which is unlikely to be long enough to account for cancer 3 4 latency, correct? 5 Α Yes. Now, in fact, the 6.7 years of follow-up 6 0 to which Dr. Portier is referring to is not the 7 8 amount of time between exposure and cancer, is it? 9 А No. In fact, as we discussed earlier, at the 10 0 11 time of entry into the Agricultural Health Study, the subject applicators, the farmers, had an average of 12 13 about 15 years of pesticide use already, correct? 14 Correct. А 15 And glyphosates had been on the market 0 since 1974 or about that time. I think Mr. Miller 16 17 just read something about that in his questioning. 18 Right? 19 А Yeah. 20 So on average, by the time the data 0 21 collected for the 2005 De Roos study was analyzed, the farmers would have had -- more than 20 years had 22 23 passed from the time of their first exposure to their 24 cancer potentially, correct? 25 Α More than twenty years' exposure to what?

Page 161 1 To glyphosate. Q 2 Some may have. Right? А 3 Q Correct. 4 Some may have. А 5 Certainly more than 6.7 years. That's 0 6 not the correct year to be looking at for how much 7 exposure they had had, correct? 8 That's the person -- their follow-up А time. 9 10 So that was the time from the 0 11 questionnaire to follow-up, not exposure to follow-up? 12 13 А Correct. 14 So Dr. Portier's comment here in this 0 15 publication is inaccurate, correct? There is 16 something wrong with it? 17 Α Tn --18 MR. MILLER: Object to the form of the question, but it says "in addition to median 19 20 follow-up time." 21 MR. LASKER: You can object. You can't testify. That's what the witness does. 22 23 THE WITNESS: Well, I -- I'm debating 24 whether to answer your question or give you an 25 epidemiology primer. I think I will just -- the

Page 162 length of time of follow-up has to be from the time 1 you've followed people. 2 BY MR. LASKER: 3 4 Right. Q So if a person was exposed to anything 20 5 Α years before you started the study and died 19 years 6 7 after -- before you started the study, they wouldn't be in it. 8 9 Understood. 0 So there is that element in it, but it's 10 Α 11 correct that 6.7 is not the total amount of time that 12 people would have -- some of the people would have 13 been exposed in this study. Well, the -- the median we talked about 14 Ο 15 before for these farmers was that if they had 15 16 years of pesticide use prior to -- at the time of 17 their questionnaire, correct? 18 15 years of pesticide use. Α And you had data also on glyphosates, 19 0 20 correct? 21 But, again, it's a matter of how many Α 22 people started using it and when they started using 23 it. 24 I'm just saying your characterization is 25 not fully descriptive. It goes on in the cohort

Page 163 study. There are staggered times --1 2 Understood. 0 3 -- going on and so forth. People have Α 4 different amounts, but it could be -- some of them 5 clearly have it more than 6.7 years. 6 And we're not -- to be clear, we're not Ο 7 talking about my characterization of the study. 8 We're talking about Dr. Portier's characterization of 9 the study. MR. MILLER: Well, I object and move to 10 11 strike that. 12 BY MR. LASKER: 13 0 And just so it's clear --MR. MILLER: I just object and move to 14 15 strike. Dr. Portier's characterization is follow-up, 16 not exposure. You're interchanging those two terms 17 intentionally to mislead, and I object. 18 BY MR. LASKER: 19 Just to be clear, the period of 6.7 0 20 years, which Dr. Portier says is unlikely to account for the cancer latency, is not the period of time 21 from exposure to cancer that was assessed in the 2.2 23 non -- in the AHS study, correct? 24 Α That's correct. He says it's the median 25 follow-up time.

Page 164 1 0 Right. So cancer latency, what's important is date of exposure to date of cancer, not 2 date of questionnaire to date of cancer, correct? 3 4 Yes, but he says follow-up time, not Α 5 latency. 6 No, he mentions latency right there. 0 7 That's what he talks about. He says, "Unlikely to be 8 long enough to account for cancer latency, " correct? 9 But he says it's a median follow-up time. А 10 0 Correct. 11 Α Yeah. But just we're clear, the median 12 0 13 follow-up time doesn't tell you anything about the period of exposure to cancer. That's relating for --14 to latency, correct? 15 16 Α Yes. 17 Okay. Now, in fact, the AHS has 0 18 conducted additional analyses of glyphosate following the 2005 paper -- published study with far larger --19 20 a far larger number of incidence of NHL cases and 21 longer follow-up, correct? There is a paper on that? 22 А 23 AHS has conducted analyses of 0 24 qlyphosate --25 А Oh, okay. Okay.

Page 165 -- following the 2005 publication with a 1 0 2 far larger number of NHL cases and a longer follow-up, correct? 3 4 I think that's underway, yes. Α 5 0 Let me mark as next exhibit in line, and I will do this as Exhibit A and B. So 19-A and 19-B. 6 (Blair Exhibit Nos. 19-A and 19-B 7 were marked for identification.) 8 BY MR. LASKER: 9 10 And let me represent that there is a 0 11 printing date on this that is when this document was printed, somebody -- or maybe for public -- for 12 production, but there is also a date on the document 13 of when it was prepared. So we will have two dates 14 15 on the document. 16 And this is yours. 17 Α Oh, yes. I'm sorry. I was thinking you were talking about an analysis of just glyphosate 18 people, but there is a -- this paper has been 19 20 published actually for non-Hodgkin's lymphoma. Okay. Well, we will talk about that. 21 0 22 Α Yeah. 23 We will talk about what data was 0 24 published and what data was not published. 25 But this is 19-B. And here you are.

Page 166 So I marked two versions of -- well, 1 first of all, if you could just identify for the 2 record what I've handed you as Exhibit 19-A and 19-B. 3 4 Well, they look like documents, probably Α 5 drafts that were prepared for the study of lymphoma and pesticide use in the Agricultural Health Study. 6 7 0 And these are drafts dated February 6, 2013, and March 15, 2013, correct? 8 9 Well, mine says --А Well, there's a print --10 0 11 -- December 5th, 2016, and this one is Α November 30th, 2016. 12 13 0 And just -- that's why I want to clarify when we talk about -- that's when it was printed out 14 15 by somebody, that's a Word -- something the Word 16 program does, but if you look at the actual -- in the 17 text --18 Α Oh, okay. Okay. Yes. Yes. So these are drafts prepared in February 19 0 2013 and March of 2013, correct? 20 21 Α Yes. 22 0 And if you look at the February '13 --23 February 2013 -- strike that. 24 If you look at the February 2013 draft, 25 there is -- in fact, starting on the very first page,

Page 167 a comment on the draft by an AEB, and that would be 1 2 you, correct? Aaron Blair. 3 On the first page? А 4 Well, if you look on the right, you will 0 5 see these little comment bubbles. And if you look throughout the document, you will see these comment 6 7 bubbles. 8 А Yes. Yes. 9 And these -- this is your comment --0 10 these are your comments on the document, correct? Yeah. Correct. 11 Α And if you look at the March 2013 draft, 12 0 which is the next document, it also has various 13 14 comments by you on the publication -- on the draft publication, correct? 15 16 А Yes. 17 Okay. Now, let's -- so it's fair to say 0 that as of March 2013, you had reviewed at least two 18 versions of this draft publication, correct? 19 20 Α Yes. Well, let's focus on the March 2013 21 0 draft. And if I could turn you first to page 6 in 22 23 the discussion of the study population. 24 We're at 2000 -- oh, March '13. Okay. Α Yes, got it. 25

Page 168 1 0 So I turn you to page 6. 2 А Six? Yes. And this has a discussion of the 3 0 4 study population about halfway through, correct? 5 Α Yes. 6 And now we're looking at all -- I'm 0 7 sorry, if you look at page 7, all incidence of primary non-Hodgkin lymphoma in the AHS cohort from 8 enrollment through December 31st, 2008, correct? 9 At 10 the very top. 11 Α Yes. So this study includes an additional 12 0 seven years of follow-up, an additional seven years 13 14 of NHL cases beyond those that were reported and published in the De Roos 2005 paper, correct? 15 16 Α Yes. And if you look at page 9 of this 2013 17 0 18 draft paper, in the second paragraph on that page, it talks about the fact that this study also includes 19 20 additional exposure data from a follow-up questionnaire. 21 22 So you have five years of additional exposure data that was not available for the 2005 23 24 study that was published, correct? 25 А Correct.

Page 169 1 0 Then the 2013 paper -- or 2013 study, I'm sorry, that includes a series of tables in the back 2 that reports on the findings of various analyses of 3 4 different exposures and the risks of non-Hodgkin 5 lymphoma, correct? There's a whole bunch of tables б back here. 7 А Okay. Data tables? 8 0 Yeah. 9 А So how are these data tables prepared? 10 Q 11 А I don't understand your question. 12 Okay, let me strike that. 0 This is the data that was available to 13 14 the Agricultural Health Study and was to be presented in this publication, correct? 15 16 Α Yes. 17 0 And this is -- these tables are showing 18 the relative risks of non-Hodgkin lymphoma in farmers with various exposures based upon the additional data 19 20 that had been generated in the AHS study, correct? 21 Α Correct. 22 0 Now, I've looked through these tables, 23 and the 2013 study does not appear to contain data on 24 ever/never use. But I would like to have you turn to 25 page 34.

Page 170 1 And on page -- on page 34 of the 2 document, we have the AHS updated data on glyphosate and non-Hodgkin lymphoma, correct? 3 4 Α Yes. And we have -- this is the data for both 5 0 duration and intensity-weighted duration of exposure 6 7 to glyphosate, correct? 8 Well, I think that's the case. I have to А 9 look at the -- not duration but total days of exposure and intensity-weighted days of exposure. 10 11 0 Okay. Well, isn't total days of exposure the duration of exposure? 12 13 Not in normal epidemiologic parlance. А 14 0 Okay. 15 Α Duration is often measured in years, and that can be different than the total number of days. 16 17 But in the 2005 De Roos paper, De Roos 0 18 was -- 2005 De Roos paper, duration was number of 19 days and --20 А Yes. And this is the same. It's the 21 same. 22 It's the same analysis --Q 23 Same analysis. А 24 -- as the 2005 exposure -- 2005 0 25 publication, except in this analysis we have a

Page 171 1 category also of no exposure, correct? 2 А Yes. 3 And the De Roos 2005 analysis that we 0 4 looked at was based upon -- the exposure analysis was based upon 61 cases of non-Hodgkin lymphoma in 5 6 farmers who had reported exposure to glyphosate, 7 correct? That sounds right to me. 8 А 9 The 2013 analysis includes data on 250 0 10 NHL cases among farmers who had reported exposure to 11 glyphosate, correct? Just add up the three rows of exposure, about 250? 12 13 А About. I was looking, and say, Well, it's not going to add to 250, but it's about 250. 14 I'm not quibbling. 15 16 0 I think it actually is, but it's about 250. That's fine. 17 18 And so this 2013 cohort study has results for glyphosate and non-Hodgkin lymphoma -- I'm sorry. 19 20 Strike that. This 2013 cohort study with results for 21 glyphosate and non-Hodgkin lymphoma is more than four 22 23 times larger than the De Roos 2005 study, correct? 24 Α Yes. 25 It's gone from 61 -- or 62 to 250 cases. 0

Page 172 1 А Yes. 2 And the confidence intervals for the 0 3 various analyses of NHL based upon the levels of 4 glyphosate exposure, because it's a larger study, are 5 much tighter than the confidence intervals were for De Roos 2005, correct? 6 7 Α Correct. 8 Because this study now has more power, 0 9 correct? 10 Α Correct. 11 0 So this 2013 cohort study finds no association -- no evidence of association between 12 13 exposure to glyphosate and non-Hodgkin lymphoma, 14 correct? 15 Correct. А 16 0 And based upon the data that's set forth 17 here, if you look at individuals who had no exposure 18 to glyphosate, which is that first row, and you look at the three categories of individuals who did have 19 exposure to glyphosate, if we were to do an 20 ever/never analysis of glyphosate and non-Hodgkin 21 lymphoma, the -- the relative risk here would be 22 23 something below 1.0, correct? About 0.9? 24 That's a reasonable guess, I think, yes. Α 25 So that means that the incidence of 0

Page 173 non-Hodgkin lymphoma in farmers exposed to glyphosate 1 2 in the 2013 cohort study was lower than the incidence of non-Hodgkin lymphoma in farmers who were not 3 4 exposed to glyphosate, correct? 5 But not statistically significant. Α So it's a negative association, but 6 0 7 statistically --Not statistically significant. 8 А Not a null result but a negative 9 0 10 association. 11 Α Correct. And the applicators in the highest levels 12 0 of exposure to glyphosate, both by lifetime days and 13 intensity-weighted lifetime days, had the exact same 14 15 incidence of non-Hodgkin lymphoma as applicators with 16 no exposure to glyphosate whatsoever, correct? 17 А Correct. So for the highest -- for each of these 18 0 measures of exposure, for the relative risk for 19 non-Hodgkin lymphoma at the highest level of exposure 20 to glyphosate as compared to not exposed was a 21 completely null result, correct? 22 23 А Yes. 24 The median lifetime use in days for the 0 25 highest exposure group now is 172 days, correct?

Page 174 Where do I see that? 1 А 2 Right here (indicating). The median days Q 3 in the highest exposure group, 173 days. Ι 4 apologize. 5 So the highest -- the highest exposure group for duration, we're looking at farmers with an б 7 average of 173 days of exposure to glyphosate, 8 correct? 9 I must be on the wrong table then. Α If you look at the first column --10 Q 11 Α Well, it's just not the ones I had. Maybe I've got the --12 13 Q Are you on page 34? 14 Page 34. Α 15 If you --Q The March 15th document. 16 А 17 0 Yep. 18 Right? Glyphosate --Α We have none, low, medium. Right here 19 0 20 (indicating). You have the numbers in the brackets, Those numbers in the brackets are the median 21 right? 22 days of exposure, correct? Right here (indicating). 23 Oh, 173. I'm sorry. I was hearing Α 24 something else. It was there. I thought it's not 25 the same number. Yeah, okay. Yes.

Page 175 So the median lifetime days of glyphosate 1 0 2 exposure in this high exposure group where there was no finding of any increased risk of non-Hodgkin 3 4 lymphoma whatsoever was 173 days, correct? 5 Α Well, again, now I'm quibbling, because we've got two categories --6 7 0 We have three. One is cumulative days, and the other is 8 Α 9 the intensity-weighted one. And so I think you're right that the judgment is this is the days, but that 10 11 finding applies all across that row, and that can't 12 be. 13 0 Okay. You know, but I think you're right, I 14 Α 15 think this is cumulative days, yes. 16 Q Got it. Okay. That's not your fault. That's --17 А 18 And -- yes. 0 19 -- the paper's fault. Α 20 And because of the fact that we now have 0 21 longer follow-up, the exposure levels at each of 22 these three categories of low, medium and high 23 exposure to glyphosate also are much higher than the 24 exposure levels in the corresponding analysis in the 25 2005 published paper, correct?

Page 176 1 Α The cumulative exposure is higher. 2 Now, these findings for glyphosate have 0 never been published, have they? 3 4 They haven't been published. Α No. 5 0 These findings, the AHS updated findings for glyphosate and non-Hodgkin lymphoma were not 6 considered by IARC in its review of glyphosate, 7 8 correct? 9 Α No. These findings also have not been 10 Ο 11 available to any of the regulatory agencies that have been conducting reviews of glyphosate and cancer, 12 13 correct? 14 Correct. А 15 Now, this obviously is data that you had 0 in your possession and were aware of at the time of 16 17 the IARC working group meeting, which is two years 18 after you reviewed this paper, correct? 19 Say again. Α 20 Well, you reviewed this data in 0 March 2013, correct? 21 22 А Yes. 23 And then in March 2015, you were the 0 24 chair of the IARC working group that was considering 25 the question of --

Page 177 1 А Yes. 2 -- what the epidemiological data shows Q 3 with respect to --4 Yeah, right. Α 5 -- glyphosate and non-Hodgkin --0 6 А Right. 7 0 So you obviously knew about --8 THE REPORTER: Excuse me. I need you to 9 finish that question, please. BY MR. LASKER: 10 11 I'll say it again. So in -- let me 0 12 rephrase. 13 At the time that you were the chair of 14 the IARC working group and a member of the 15 epidemiology subgroup that was looking at the evidence of whether or not glyphosate was associated 16 17 with non-Hodgkin lymphoma, you were aware of this 18 updated data of a study four times larger than the published 2005 paper with respect to glyphosate and 19 20 non-Hodgkin lymphoma, correct? 21 That there were analyses of such data, Α but no published studies. 22 23 Correct. But you were aware of what the 0 24 data showed, correct? 25 А But no published studies. Yes.

Page 178 1 0 Right. And did you alert any of your 2 fellow working group members or any of the other members of the subgroup on epidemiology at IARC about 3 4 the fact that this much larger AHS cohort study with 5 larger follow -- a larger time of follow-up and higher levels of exposure had been conducted? 6 7 Α No. Now, the IARC working group also cited to 8 0 a meta-analysis that IARC had prepared of the 9 epidemiological studies regarding glyphosate and 10 11 non-Hodgkin lymphoma. And Mr. Miller asked you about that earlier today. Correct? 12 13 Α Yes. Well, let me show you a copy of that 14 0 15 meta-analysis, if I might. 16 (Blair Exhibit No. 20 was marked for identification.) 17 18 BY MR. LASKER: This is Defense Exhibit 20. 19 0 20 And also let me just -- we have -- do you 21 have the monograph working group which was a plaintiffs' exhibit? Oh, you have that. Okay. 22 23 This was marked previously as a plaintiffs' exhibit, I just don't remember what 24 25 number it was, but this is the monograph.

Page 179 1 MR. LASKER: Do you remember what number this is, Mr. Miller? 2 3 MR. MILLER: This should be 20. 4 MR. LASKER: Four. Plaintiffs' 4? No, this is Plaintiffs' 4. It's the same -- you guys 5 6 marked this. 7 MR. MILLER: Oh, I'm sorry. MR. LASKER: I'm talking about the --8 9 MR. MILLER: Well, we need to be more precise. Okay. 20 was the last exhibit you handed 10 11 me. Now you're asking me what the original monograph 12 was? MR. LASKER: I believe it's Plaintiffs' 13 Exhibit 4. 14 15 MR. MILLER: Four? Okay. Very well. On 16 we go. BY MR. LASKER: 17 18 I'm just going to hand you a copy of the 0 monograph again. It's the same document. Mr. Miller 19 20 can confirm. 21 But with respect to the meta-analysis that IARC conducted, that is mentioned on page 30 22 23 of the monograph. So if I could just turn you to 24 page 30 of the monograph. 25 And do you see there is the discussion of

Page 180 a meta-analysis? 1 2 А Yes. 3 And the meta-analysis is identified as 0 4 Schinasi and Leon. That is the publication, the paper I just handed to you, which we marked as 5 exhibit -- Defense Exhibit 20, correct? 6 7 А Correct. 8 And it discusses the meta-analysis that 0 was done by Schinasi and Leon, and then an adjustment 9 that the working group made to that monograph -- I'm 10 11 sorry, to that meta-analysis so as to use fully adjusted estimates of the risks with non-Hodgkin's 12 13 lymphoma and glyphosate, correct? 14 Α Yes. 15 And the IARC working group's conclusion 0 16 was that the meta risk ratio of all the epidemiology 17 was 1.3, which had a confidence interval of 1.03 to 18 1.65. So it just made barely that level of statistically significance, correct? 19 20 Α Correct. 21 Now, the meta-analysis was based in part Ο on the 2005 AHS publication, correct? 22 23 Correct. Α 24 It was not based upon the data we've now 0 25 just looked at of the 2013 AHS data, correct?

Page 181 1 Α Right. 2 So if we look at Defense Exhibit 20, 0 which is the Schinasi paper, and if you look at 3 4 page 4505, this sets forth the various studies that IARC looked at with respect to glyphosate and 5 non-Hodgkin lymphoma and the risk ratios from those 6 studies, correct? 7 8 А Correct. 9 And the meta-analysis is a process of 0 weighing these findings from these studies, correct? 10 11 Α Right. And the way that the meta-analysis works 12 0 is it gives a different weight to different studies 13 based upon the power of the study, which is reflected 14 in the size of those confidence intervals, correct? 15 16 Α Correct. 17 So the IARC meta-analysis weighing of the 0 18 2005 AHS study, which is listed here, is based upon the 71 cases of non-Hodgkin lymphoma that were 19 20 available as of the time of that 2005 publication, 21 correct? 22 А Correct. 23 Now, as we've already discussed, the 2013 0 24 data finds for a much larger number of NHL cases --25 provides findings for a much larger number of NHL

Page 182 cases, we had like some four times, like 250 cases --1 2 Right. Α 3 -- in that data, correct? 0 4 Α Right. 5 And the confidence intervals, because 0 it's a much larger study, were much tighter in that 6 7 2013 data than the -- than the data we have here, 8 correct? 9 Α Correct. 10 Ο And we already talked about the fact that 11 the relative risk from the 2013 data of ever/never use was below 1.0, something like 0.9, so it was 12 slightly below the 1.1 relative risk for the De Roos 13 2005 paper, correct? 14 15 Α Correct. 16 0 So if the 2013 data, which you were aware 17 of, had been available for IARC in its meta-analysis, 18 the AHS data would have had significantly more weight in the meta-analysis than is reflected here --19 20 А Yes. -- and the relative risk data would have 21 0 2.2 been lower than the 2005 study that's incorporated 23 here, correct? 24 The relative risk for the AHS study would Α 25 have been lower.

Page 183 Right. 1 Q 2 Was lower. Yeah. А Yes, it would have been. 3 0 4 А Yeah. So it's fair to say, given that IARC --5 0 your meta-analysis was just barely statistically 6 significant at 1.03 in the lower bound, if IARC had 7 had the data from the 2013 study, much more -- a much 8 larger study, much greater weight, lower relative 9 risk -- that would have driven the meta-relative risk 10 11 downward, correct? 12 А Correct. And the meta-relative risk with that 2013 13 0 data from the AHS study that you were aware of would 14 have not have been statistically significant, would 15 16 it? 17 Α I don't know, but probably not. Probably not. 18 0 Now, during the Monograph 112 working 19 20 group meeting, IARC provided the working group with this meta-analysis data, correct? 21 22 Α Yes. 23 Did you mention to anyone at the meeting 0 24 the likely impact that the more recent data from AHS 25 would have in decreasing the meta -- meta-relative

Page 184 risk for glyphosate and non-Hodgkin lymphoma? 1 2 А No. 3 Now, the Schinasi meta-analysis also 0 4 includes data from a case-control study, a pooled 5 analysis in the U.S., the De Roos 2003 paper, and it includes relative risk from the McDuffie paper from 6 7 Canada, correct? Those are also on this chart? 8 А Yes. 9 And Schinasi, IARC used an odds ratio of 0 10 2.1 for the Canadian -- I'm sorry, for the U.S. 11 case-control data, correct? It's on the charts here, the De Roos 2003 with an odds ratio --12 13 А You are --We're still -- we're still on the 14 0 15 Schinasi paper. Same --16 А Oh, okay. Oh, okay. 17 So the De Roos 2003 is listed here. 0 That's the U.S. case-control data, and that's an odds 18 ratio of 2.1, correct? 19 20 Α Yes. 21 MR. MILLER: What page are we on? MR. LASKER: We're on page 4505. 22 23 MR. MILLER: 4505. 24 BY MR. LASKER: 25 And McDuffie, that's the Canadian 0

Page 185 case-control study, and that's 1.2, correct? 1 2 Α Correct. And now if -- there's a little bit 3 0 4 different weighting of those two studies because 5 McDuffie is a little bit larger, but if you were to sort of take those two studies in aggregate as 6 considered by the meta-analysis, that works out to --7 for those two studies an odds ratio of about 1.6 for 8 purposes of meta-analysis if you combine those two 9 studies, correct? 2.1, 1.2, it's going to be around 10 11 that -- that area, right? 12 Α Probably. I don't know. Sometimes you 13 can't just put them together. Roughly -- but roughly, roughly 1.6 or 14 Ο 15 so, correct? 16 Α Probably. 17 Okay. Now, the NAP data -- NAPP data 0 that we were discussing earlier, that's actually a 18 pooled analysis of the data from McDuffie 2001 and 19 20 De Roos 2003, correct? 21 Α Yes. And the way that this meta-analysis works 22 0 is IARC takes the most recent and most comprehensive 23 24 pooled analysis and doesn't consider the earlier studies, correct? 25

Page 186 1 So, for example, Kantor 1992 is not in here because it was pooled into De Roos 2003, 2 3 correct? 4 А They do -- unless the individual papers 5 have information that isn't in the pooled analyses, which is often the case. 6 7 0 But with respect to this analysis, for example, De Roos 2003, they don't include Cantor --8 the Cantor study. They include the most recent 9 pooled data, correct? 10 11 Α In this table. 12 0 Yes. 13 Α Yes. 14 And in this meta-analysis. 0 15 Α And in this meta-analysis. So if we were then to use -- if the NAPP 16 Q 17 data had been available to IARC, the data we were 18 looking at previously, you recall that the NAPP odds ratio, even including proxy respondents for 19 20 ever/never use, for glyphosate and non-Hodgkin's lymphoma was 1.22, correct? We looked at that 21 previously. 22 23 Sounds right. А 24 Okay. So if the NAPP data, again that 0 25 you were aware of at the time, had been available to

Page 187 IARC and had been put into this analysis and replaced 1 McDuffie 2001 and De Roos 2003, the odds ratio number 2 for the U.S. and Canadian case-control studies would 3 4 drop from probably somewhere around 1.6 to 1.2 or so, 5 correct? I -- you know, I'm not comfortable making 6 Α 7 pronouncements about your combining of data from different studies without me seeing the data. 8 9 Okay. Well, just so we're clear, the 0 10 NAPP data is your data. We looked at it earlier. 11 А It's not in front of me. I'm not comfortable --12 13 0 Okay. Well, then ---- with combining --14 А 15 -- let's go -- that's a good point. 0 16 A -- different things without seeing that. 17 Let's go back to that. That's a very 0 good point. 18 So if we could refer -- okay. Look back 19 20 to Defense Exhibit --21 MS. SHIMADA: 16. 2.2 BY MR. LASKER: 23 -- 16. So it should be on that -- on the Ο 24 pile, probably in reverse order. 25 MR. MILLER: Well, while we look at that,

Page 188 1 we're calling a break. It's 1 o'clock. We've been 2 qoing --3 MR. LASKER: We're in the middle -- when 4 we finish this line of questioning, we will take a 5 break. 6 MR. MILLER: We said that a half an hour 7 ago. MR. LASKER: When I finish this line of 8 9 questioning. I'm almost done. We'll be fine. I've 10 got maybe five or ten more questions at most. 11 THE WITNESS: Is this the one you're --12 BY MR. LASKER: 13 0 That's the one. 14 А Okay. 15 So this is the one that we looked at 0 16 previously, and the first data table we looked at was 17 the -- this table right here, right? This is the 18 ever/never use. That's it. 19 So the ever/never use of this pooled 20 analysis that's pooling the data from McDuffie and 21 from De Roos 2003, the data that you had was 1.22 as the odds ratio, correct? 2.2 23 Correct. Α 24 So that is a lower odds ratio than was 0 25 used for purposes of the IARC meta-analysis because

Page 189 that meta-analysis was combining a 2.1 and a 1.2, 1 2 correct? 3 Α Yes. 4 So if that NAPP data had been available 0 5 to IARC for its meta-analysis, that also would have lowered the meta-relative risk for glyphosate and 6 7 non-Hodgkin lymphoma even further, correct? 8 А Probably. 9 MR. LASKER: We can take a break now. THE VIDEOGRAPHER: The time is 12:56 p.m. 10 11 We're off the record. 12 (Lunch Recess.) 13 THE VIDEOGRAPHER: The time is 1:47 p.m., 14 on March 20th, 2017. And we are on the record with 15 video 3. 16 MR. MILLER: I just wanted to make a 17 short statement regards time management. Plaintiffs 18 went about an hour and 30 something. I think the --19 THE VIDEOGRAPHER: 1:34. 20 MR. MILLER: 1:34. So far defendants 21 have gone --2.2 THE VIDEOGRAPHER: Two hours. 23 MR. MILLER: -- two hours. 24 Counsel for Dr. Blair has been kind 25 enough to say a total of eight hours, and that's time

Page 190 on record I wanted to clear up and we want our equal 1 time on the record. So we think you would have two 2 hours left then. 3 4 MR. LASKER: I don't have any problem with that. 5 6 MR. MILLER: Okay, great. Hopefully you 7 will be done before then, and certainly I'm not going to go on just to hear myself talk either, believe me. 8 Just -- all right, let's go. 9 BY MR. LASKER: 10 11 0 Okay, back on the record. Dr. Blair, I would like to continue our 12 discussion of the 2013 AHS data on glyphosate and --13 14 or actually on pesticides and lymphoma risk or non-Hodgkin lymphoma risks, and particularly the 15 16 glyphosate data. 17 If I could ask you to turn to page 84 of that document, Supplemental Table 7. And you had 18 testified earlier this morning about the fact that 19 the definition of non-Hodgkin lymphoma has changed 20 over time. Do you recall that? 21 22 А Yes. 23 And in this 2013 study, the AHS data is 0 24 actually presented with two different definitions of 25 non-Hodgkin lymphoma, and Supplemental Table 7 is

Page 191 data that uses what is referred to as the old NHL 1 2 definition. 3 Do you see that? 4 А Yes. 5 0 Okay. And do you recall how the definition changed from the old definition to the 6 7 definition that's being used today? 8 MR. MILLER: Excuse me, Counsel. Page number? 9 MR. LASKER: 84. 10 THE WITNESS: Lymphoma -- non-Hodgkin 11 lymphoma now includes multiple myeloma and chronic 12 lymphocytic leukemia. 13 BY MR. LASKER: 14 15 Okay. So this data table, Supplemental 0 16 Table 7 is defining non-Hodgkin lymphoma as not 17 including multiple myeloma or CLL; is that correct? 18 Correct. А Okay. So let's look at the data for 19 0 glyphosate under the old definition, and that's on 20 21 page 91. 22 And on the middle of the page, again we 23 have glyphosate data, both the duration and intensity 24 of use, correct? 25 А Yes.

Page 192 1 0 And again, we have data on no exposure and then low, medium and high exposure groups, 2 3 correct? 4 А Correct. 5 Now, the total number of -- of farmers 0 with non-Hodgkin lymphoma in this analysis is 72 plus 6 7 51 plus 60, that's about 183 farmers, correct? 8 А Correct. 9 So with using this data from the 2013 Ο 10 study, the study is about three times larger than the 11 published data from the 2005 study, correct? 12 Α Okay. And the findings as far as the relative 13 0 14 risks are concerned are pretty close to what the findings were with the new definition, correct? 15 16 А Correct. 17 0 As far as non-Hodgkin lymphoma risks? 18 А Yes. So as we look at no exposures versus 19 0 different levels of exposure, the ever/never risk 20 ratio is again something like 0.9 or so, correct? 21 22 А Probably. 23 Okay. And the same discussion we had 0 24 previously about how use of this updated data in the 25 IARC meta-analysis would lower the meta-relative

Page 193 risk, that same answer would apply for this data as 1 well, correct? 2 3 А Yes. 4 Now, I would like to take you to another 0 part of the analysis in the 2013 -- in the 2013 AHS 5 study with respect to different NHL subtypes. 6 7 Now, let me -- let's turn first to page 7 8 of the -- of the paper because they discuss the 9 different subtypes there. And there are five different groups of subtypes discussed under tumor 10 11 characteristics. 12 Do you see that? 13 А Yes. So the -- this is looking at different 14 0 15 types of non-Hodgkin lymphoma putting them into categories, correct? 16 17 Α Correct. And then there is a separate analysis 18 0 conducted in this 2013 paper looking at the relative 19 20 risks for the studied herbicides for each of the different NHL subtype categories, correct? 21 22 А Correct. And that data -- that analysis starts on 23 0 24 page 69. And specifically on page 69, we have data 25 on glyphosate. Let's look first so we can get the

Page 194 categories correct -- on page 66 at the beginning of 1 the table, so we can understand what is what. 2 So page 66 has the different categories 3 4 of non-Hodgkin lymphoma on those columns on the top, 5 right? 6 А Correct. 7 0 Okay. And then if you just keep your finger on that page just so you can remind yourself 8 9 which categories are which, page 69 is where they have the findings for glyphosate, and I would like to 10 11 ask you about the glyphosate finding with respect to -- on these different types of non-Hodgkin 12 13 lymphoma. So if you look at page 69, the AHS 14 15 analysis in the first subtype grouping, which is chronic B-cell lymph -- lymphocytic lymphoma, small 16 17 B-cell lymphocytic lymphomas, and mantle cell 18 lymphomas, the 2013 AHS data analysis does not find any association between glyphosate and that NHL 19 20 subtype, correct? 21 Α Correct. And if we look at -- in fact, for that 22 0 23 subgroup -- oh, strike that. 24 If you look at the large B-cell 25 lymphoma --

Page 195 1 MR. MILLER: I'm sorry. What page are we 2 on? 3 MR. LASKER: We're on page 69. 4 MR. MILLER: Thank you. 5 BY MR. LASKER: 6 -- the second column is large B-cell 0 7 lymphoma, correct? Diffuse large B-cell, yeah. 8 А 9 And the 2013 AHS data actually finds a 0 statistically significant negative association 10 11 between increased glyphosate exposure and -- and diffuse large B-cell lymphoma, correct? 12 13 А For days per year, yes. Yeah. So, in other words, as a farmer 14 0 15 has more days of exposure of glyphosate in this study population, the instance of large B-cell lymphoma 16 17 actually decreases, correct? 18 А Correct. And that's a statistically significant 19 0 20 finding, correct? 21 А Trend test. Yes. The 2013 AHS data also looks at 22 0 23 follicular B-cell lymphomas, correct? 24 Α Yes. 25 And the 2013 AHS analysis does not find 0

Page 196 1 any association between glyphosate exposure and 2 follicular B-cell lymphomas, correct? 3 Deficits that aren't statistically Α 4 significant. 5 And when you say "deficits," what 0 actually they found in this study, again, is as the 6 7 level of -- as a farmer had more days of exposure to 8 glyphosate, the incidence of follicular B-cell 9 lymphomas went down, correct? 10 Α No. It means that at any level of 11 exposure, the level, the relative risk was less than 12 1.0. 13 Correct. Correct. Correct. 0 14 It was 0.7 or 0.6. It does not go down. Α 15 So what with the 2013 AHS data reveals is 0 16 that any level of exposure to glyphosate resulted in 17 a lower incidence of follicular B-cell lymphomas, 18 correct? Lower -- lower incidence or lower 19 Α 20 relative risk that isn't statistically significant. 21 And with respect to the category for --0 Other B-cell. 22 Α 23 -- other B-cell type lymphomas, again we 0 24 see that with any level of exposure to qlyphosate, the incidence of B-cell type lymphomas, the relative 25

Page 197 1 risk goes down, correct? 2 It's lower. А 3 And if you look at the point estimate for 0 4 relative risk, both for the other B-cell type 5 lymphomas and the follicular B-cell lymphomas at the highest level of exposure, the relative risk is 30 to 6 40 percent lower for farmers with the highest level 7 8 of glyphosate exposure compared to farmers with no 9 exposure, correct? 10 А Correct. 11 0 Did you inform anyone at the IARC working group that the AHS -- that the Agricultural Health 12 13 Study had conducted additional analyses of glyphosate for various NHL subtypes? 14 15 No, because it wasn't published. А 16 0 Now, let me ask you to turn to page 78 of 17 this paper. And here we have a table that's looking 18 at potential individual and joint effects of pesticide combinations and NHL risk, correct? 19 20 Yes. А 21 So now we're looking to see, well, what 0 if you put two different types of pesticides 22 23 together, what is that -- what is reflected in the 24 data for that, correct? 25 А Correct.

Page 198 1 0 So let's turn to page 80 and 81. And here we have the data for glyphosate with -- in 2 combination with other types of -- with other --3 4 three other pesticides. 5 Do you see that? 6 Α Yes. 7 0 So glyphosate and atrazine, glyphosate 8 and 2,4-D, and glyphosate and chlordane, correct? 9 Yes. А And the analysis, when you look at it 10 0 11 this way for glyphosate only, and the atrazine -glyphosate and atrazine analysis, glyphosate only is 12 13 0.96; for glyphosate only with the glyphosate and 2,4-D, it's 1.1; for glyphosate only and glyphosate 14 and chlordane is 0.9. 15 So in the glyphosate-only portions of 16 17 this, again we're not showing any increased risk of 18 non-Hodgkin lymphoma, correct? 19 А Correct. 20 MR. MILLER: Object to the form of the 21 question. 22 BY MR. LASKER: 23 And with respect to combinations, if you Ο look at farmers exposed to glyphosate and atrazine 24 25 together, there is no increased risk -- statistically

Page 199 significant increased risk of non-Hodgkin lymphoma, 1 2 correct? 3 Say again. А 4 For farmers who are exposed to both 0 glyphosate and atrazine, there is no statistically 5 significant increased risk of non-Hodgkin lymphoma, 6 7 correct? 8 Δ Correct. For farmers exposed to both glyphosate 9 0 and 2,4-D, there is no statistically significant 10 11 increased risk of non-Hodgkin lymphoma, correct? 12 А Correct. 13 For farmers exposed to glyphosate and 0 chlordane, there is no statistically significant 14 15 increased risk of non-Hodgkin lymphoma, correct? 16 А Yes. And this is also information that the 17 Q IARC working group did not have at the time it made 18 its analysis of glyphosate, correct? 19 20 А Correct. 21 Now, I want to show you another document 0 that was from your production to us, and this is an 22 23 e-mail between you and some of the other Agricultural 24 Health Study investigators in February 2014. First of all, who is Dr. Alavanha 25

Page 200 (phonetic)? 1 2 Alavanja. А 3 Alavanja. 0 4 He was an investigator at the National А 5 Cancer Institute and was involved in the Agricultural Health Study. 6 7 Is he an epidemiologist as well --0 8 А Yes. 9 -- as yourself? Q Okay. Let's mark this as Defense Exhibit 10 11 21. (Blair Exhibit No. 21 was marked for 12 identification.) 13 BY MR. LASKER: 14 Well, first of all, do you recall when it 15 0 was that the glyphosate data was removed from this 16 17 AHS study that we've been talking about? 18 Not exactly, but it went through many А iterations after we decided to remove it because 19 20 there really wasn't -- you couldn't put it all into 21 one paper. 22 Let's look at an e-mail dated February 0 23 28, 2014, and this is an e-mail from Dr. Alavanja to 24 other members of the AHS, including yourself, 25 correct?

Page 201 1 Α This is the one you just handed me? 2 0 Yes. 3 А Yes. 4 Dr. Alavanja, he was the lead author, 0 5 wasn't he -- was he not, on the 2013 paper that we 6 were just looking at? 7 А The document, yes. Right. In his February 14, 2014 e-mail, 8 0 Dr. Alavanja is discussing the AHS team's efforts to 9 get its updated NHL analysis published, correct? 10 11 Α Yes, I quess so. And I take it from your former answer, 12 0 you're not -- you don't recall now whether or not the 13 14 glyphosate data was still in the paper at this point in time or not, correct? 15 16 Α No, it was not because it had been 17 submitted to a journal, and we never submitted to a 18 journal with that data in it. 19 Okay. So in this e-mail Dr. Alavanja is 0 discussing the fact that the International Journal of 20 Cancer had decided not to publish what was at that 21 22 point the updated manuscript for non-Hodgkin lymphoma 23 and other pesticides, correct? 24 Yes. Insecticides. Α 25 Insecticides. And Dr. Alavanja 0

Page 202 attributes the journal's decision not to publish the 1 AHS paper on NHL and insecticides on the fact that 2 3 the paper did not present conclusive evidence 4 associating NHL with any of the pesticides examined, 5 correct? 6 А That's what it says. 7 0 So Dr. Alavanja is referring to the fact 8 that journals are sometimes less willing to publish epidemiologic studies if they don't find positive 9 associations, correct? 10 11 Α Yes. This problem is sometimes referred to as 12 0 publication bias, correct? 13 14 Α Yes. 15 It's more difficult to get negative 0 findings published, correct? 16 17 А Correct. And as a result, sometimes negative 18 0 findings and epidemiological studies are not 19 published, correct? 20 21 Yes. Right. А And Dr. Alavanja notes in the second 22 0 23 paragraph of his e-mail -- and let's see, if it's working its way -- I was going to read it: "At the 24 25 current time" -- and this is the second paragraph

Page 203 starting at the very beginning: "At the current time 1 IARC is making plans for a new monograph on 2 pesticides." 3 4 And so, again, we're talking about the 5 monograph that ultimately became Monograph 112 where you were the chair prior, correct? 6 7 Α Well, it preceded that monograph 8 certainly. 9 Right. So when he is talking about IARC 0 10 is making plans for a new monograph on pesticides, he 11 is referring to the monograph that was the one that you ultimately worked on, correct? 12 13 А Yes. Right. And Dr. Alavanja states: "Concerning 14 0 IARC's timetable for selecting candidates for the 15 16 monograph, it would be irresponsible if we didn't 17 seek publication of our NHL manuscript in time to 18 influence IARC's decision." Do you see that? 19 20 А Yeah. 21 And you would agree that the AHS provides 0 important data regarding potential associations 22 23 between pesticides and cancer, correct? 24 Α Yes. 25 You would agree that the AHS data and the 0

Page 204 most updated AHS data should be considered by IARC, 1 2 correct? 3 А Yes. 4 You would agree that it would be --0 5 А Well, wait, wait. If it's been 6 published. 7 0 And you would agree with Dr. Alavanja that it would be irresponsible for the AHS --8 9 Agricultural Health Study investigators not to publish the updated findings on pesticides and NHL in 10 11 time to influence IARC's decision, correct? 12 I don't agree with that. And the Α No. reason is because the timetable about when you have 13 to have it published is arbitrary. And doing 14 15 analyses and writing papers is not wedded to a timetable. And what is irresponsible is to rush 16 17 something out that's not fully analyzed or thought 18 out. 19 Let me ask you --Q 20 That's irresponsible. А 21 I'm sorry. Let me ask you then about the 0 e-mails you were talking about previously with 22 23 respect to the North American Pooled Project, and we 24 can go back to those if you want. But as I remember, 25 Dr. Pahwa was discussing the possibility of doing

Page 205 some analyses of NHL and multiple myeloma and 1 glyphosate in time to get those published for the 2 IARC analysis, right? 3 4 Α Yeah. 5 And at that time you offered Dr. Pahwa 0 whatever help she needed to see if you could get that 6 7 data published, and this is before you saw what the data was, correct? 8 I don't remember about that. Maybe. 9 Α 10 I -- I just don't remember about that. 11 0 So --I mean about whether I had seen the --12 Α There's --13 any data or not. I mean tables come out. none of this is listed in -- glistened down in your 14 15 mind about where things are. 16 0 Well, if we can go back to Exhibit 14, 17 and that should be in your pile there, but I can give you another copy if you want if that would be easier. 18 Dr. Blair. 19 20 Α Yeah. So -- so this, just to refresh our jury's 21 Ο 22 recollection, was prior to Dr. Pahwa going back and 23 finding out what the data showed from NAPP for 24 glyphosate and NHL or MM and -- or HL, Hodgkin 25 lymphoma. You were offering Dr. Pahwa whatever help

Page 206 you could to try to get the data published in time 1 for the IARC monograph meeting, correct? 2 3 Α Yeah. 4 But then after we -- after you determined 0 5 and found out what the data showed with respect to glyphosate and these cancers, the data wasn't 6 7 published, correct? 8 The paper wasn't finished, and you have Α to finish things in the analysis and the writing 9 before you can publish it. 10 11 Okay. So let's go back then to what the 0 IARC analysis was and what the working group did. 12 13 So the IARC working group then in its 14 analysis of the epidemiology was relying upon -- was 15 not relying upon the most up-to-date AHS data, 16 correct? 17 It was relying upon the most up-to-date А published data, and that's always the standard at 18 19 TARC. 20 I understand. But just so the record is 0 21 clear, IARC was not relying upon the most updated analysis that you were aware of from the AHS data 22 23 with respect to glyphosate and non-Hodgkin lymphoma, 24 correct? 25 Now you present it as if the analyses Α

Page 207 1 were completed. Analyses were done, manuscripts were 2 in description, but the work wasn't finished, which means it's incomplete, and that you don't want to be 3 4 reporting on. And we didn't. So -- understood. 5 0 6 And because of the fact that you had not 7 completed the manuscript that was in at least manuscript form in March of 2013 in time for it to be 8 a publication by March 2015, IARC didn't have that 9 information? 10 11 Α That's correct. 12 Now, going back to this issue of Ο 13 publication bias, did the Agricultural Health Study 14 decide not to include data regarding glyphosate and non-Hodgkin lymphoma in its updated publication 15 because the data did not show a positive association? 16 17 Α No. It decided to do pesticides first because we proceeded -- insecticides first, we sort 18 of proceeded down that line early on and didn't think 19 20 we had time to switch and do the other when IARC 21 become clear that that's what they were going to look 22 at. Now, you and other AHS investigators are 23 0 24 certainly aware, and we looked at some of this 25 discussion previously, that questions have arisen

Page 208 about IARC's -- I won't say questions -- have arisen 1 about IARC's classification of glyphosate, correct? 2 3 MR. MILLER: Objection to form. 4 Questions by whom, Monsanto? 5 BY MR. LASKER: 6 Well, let me put it this way: You're 0 7 aware that Christopher Portier, we looked at one of his publications, has been defending the IARC 8 classification of glyphosate by relying on the old 9 data from the Agricultural Health Study to try and 10 11 minimize the importance of that study, correct? Well, I guess as he reported about what 12 Α 13 IARC did, it was the -- there's no new published data from AHS to look at. 14 15 And --0 16 А Is that what you're saying? 17 0 Well, Dr. Portier, though, as we looked at previously, in defending the IARC classification, 18 has included arguments that the AHS data -- the AHS 19 study in 2005 was of smaller numbers and limited 20 follow-up. Remember we looked at that? 21 22 Α Yes. 23 Okay. Nearly four years have passed now 0 24 since you and the other AHS investigators looked at 25 the updated and more robust AHS data and found no

Page 209 association between glyphosate and non-Hodgkin 1 lymphoma, correct? 2 3 MR. MILLER: Object to the form of the 4 question. 5 BY MR. LASKER: 6 Ο You can answer. 7 MR. MILLER: You can answer. 8 BY MR. LASKER: 9 I will repeat the question. 0 10 А Yes. 11 0 Nearly four years have passed now since you and other AHS investigators looked at the updated 12 data and saw that it did not show any association 13 14 between glyphosate and non-Hodgkin lymphoma, correct? 15 MR. MILLER: And I object to the form of 16 the question because you intentionally leave out that it's not statistical. 17 18 THE WITNESS: Yes, we -- we've looked at some data like that, but we haven't looked at a 19 20 finished product. BY MR. LASKER: 21 22 Q Now, the updated AHS data would directly 23 answer the questions Dr. Portier raised about the 24 size of the study and about the length of follow-up 25 time, correct?

Page 210 1 Α Yes. 2 But you and the other AHS investigators 0 have, as of today's date in March 2017, not yet 3 4 published this updated AHS data on glyphosate, 5 correct? 6 А Correct. 7 0 In fact, the AHS has actively sought to prevent Monsanto from learning about this updated AHS 8 data, hasn't it? 9 I -- I -- I don't know about that. 10 Α 11 0 Well, let me ask you -- let me show you another e-mail from your document production to us. 12 13 (Blair Exhibit No. 22 was marked for identification.) 14 15 BY MR. LASKER: 16 This is Defense Exhibit 22. 0 And this is an e-mail in which 17 Mr. Sandler is responding to your e-mail to him 18 attaching a copy of a subpoena we sent to you in this 19 20 litigation, correct? 21 Α Yes. 22 Q Mr. Sandler notes --23 А It's a woman. 24 0 I'm sorry? It's a woman. 25 А

Page 211 Oh, Ms. Sandler. Dr. Sandler? 1 0 2 Dr. Sandler. А 3 Dr. Sandler. Thank you. 0 4 Dr. Sandler notes that our subpoena to 5 you, and Dr. Sandler -- just so I understand, Dr. Sandler is with NIEHS? 6 7 А Correct. The National Institute of Health? 8 0 Environmental Health Sciences. 9 А And Dr. Sandler notes in her e-mail back 10 0 that our subpoena to you was seeking the same AHS 11 papers and requests for data that Monsanto had 12 13 separately sought from the AHS investigators affiliated with the National Institutes of Health 14 15 through a FOIA request, correct? 16 MR. MILLER: Object to the form of the 17 question. Intentionally misrepresenting the 18 document. Read the document, Counsel. 19 BY MR. LASKER: 20 Dr. Blair? 0 21 Apparently that's it. Α And Dr. Sandler states, quote: We were 22 0 23 hoping to make the Freedom of Information Act go away 24 by offering data through a data sharing agreement. 25 Do you see that?

Page 212 1 А I do. 2 But -- and then Dr. Sandler says: "It's 0 3 probably time to seek protection from NA -- NIH 4 lawyers." Correct? 5 А Yes. 6 So the AHS investigators at the National 0 7 Institutes of Health were seeking protection from National Institutes of Health lawyers to prevent 8 9 Monsanto from getting access to the updated AHS data showing no association between glyphosate and 10 11 non-Hodgkin lymphoma. 12 MR. MILLER: Object to the form of the 13 question. THE WITNESS: Maybe they did. I'm 14 just -- I see the e-mail. It's the only thing I know 15 16 about it. BY MR. LASKER: 17 18 Okay. But you received this e-mail, 0 It's from your document production. 19 correct? 20 Yes. But I'm saying I see this e-mail А and that's the only thing I know about this. 21 22 You would agree that it's not appropriate 0 23 for the National Institutes of Health to be seeking 24 protection from its lawyers to prevent Monsanto from 25 learning that the updated AHS data showed no

Page 213 1 association between glyphosate and non-Hodgkin lymphoma, don't you? 2 MR. MILLER: Objection. Calls for a 3 4 legal conclusion. We already had one subpoena 5 quashed. 6 THE WITNESS: I quess I don't see -- give 7 me your question again, because I don't see it here. 8 They're asking for data. That's the raw data. BY MR. LASKER: 9 So do you believe -- well, strike that. 10 0 11 You would agree that it's not appropriate for the National Institutes of Health to turn to its 12 13 lawyers to protect it from Monsanto's efforts to 14 obtain updated Agricultural Health Study data with respect to glyphosate and non-Hodgkin lymphoma, don't 15 16 you? 17 MR. MILLER: Objection to the question. It calls for a legal conclusion, when you've already 18 19 lost before the court. 20 THE WITNESS: I don't think I can provide -- I mean there is a Freedom of Information 21 22 Act that government employees follow, so I --23 BY MR. LASKER: 24 0 Let me --25 -- I don't think I have any expertise in А

Page 214 this. 1 2 Do you think it's appropriate for the 0 National Institutes of Health to try and use legal 3 4 means to avoid providing Monsanto with updated 5 Agricultural Health Study data? MR. MILLER: Object to the question. 6 7 Requires a legal conclusion and on a motion to quash you've already lost, Counselor. And that's the third 8 9 time you've asked the witness the same question. You're clearly harassing the witness. 10 11 BY MR. LASKER: 12 Do you think it's appropriate for the 0 National Institutes of Health to use its lawyers to 13 prevent Monsanto from getting updated AHS data that 14 shows no association between glyphosate and 15 16 non-Hodgkin lymphoma? 17 MR. MILLER: Objection to the question. 18 Calls for a legal conclusion on a motion to quash you 19 have already lost and will lose when you try again. 20 You are harassing the witness. That is the fourth time you have asked the same question. You have only 21 a certain amount of time left. 22 23 Ask it again and there will be a fifth 24 objection. 25 MR. LASKER: Okay. So you are objecting

Page 215 to us finding out why the NIH has not given us the 1 update from the Agricultural Health Study showing no 2 association between glyphosate and cancer --3 4 MR. MILLER: I'm referring to the 5 National Institute of Health and their attorneys to find out what their legal rights might be, Counselor. 6 7 BY MR. LASKER: And, Dr. Blair, perhaps counsel may try 8 0 to prevent you from answering this question one more 9 time, but I will ask you one more time. 10 11 MR. GREENE: Objection. I don't know if Dr. Blair --12 13 MR. LASKER: He can answer that -- if that's his answer, that's fine. I just want an 14 15 answer from him. MR. GREENE: It's his position --16 17 MR. LASKER: That's his -- if he has that answer, that's fine. I need to hear an answer from 18 19 him, though. He's the witness. 20 MR. MILLER: What's the question, Counselor? 21 2.2 BY MR. LASKER: 23 Dr. Blair, do you think it's appropriate 0 for the National Institutes of Health to use their 24 25 lawyers to prevent Monsanto from getting updated

Page 216 Agricultural Health Study data showing no association 1 2 between glyphosate and non-Hodgkin lymphoma? 3 MR. MILLER: And I object to the 4 question. This calls for a legal conclusion on the 5 harassing subpoenas that have been sent out by Monsanto and have been quashed by this court as 6 7 recently as two weeks ago. You have now asked the 8 witness the same question six times. Ask it of the 9 National Institutes of Health attorneys. Ask it of Judge Chhabria, see if Judge Chhabria will give it to 10 11 you. 12 BY MR. LASKER: 13 Dr. Blair, do you have an answer to my 0 14 question? 15 MR. MILLER: You don't have to answer 16 that. 17 MR. LASKER: He's not your witness. MR. MILLER: He's not my witness, but --18 19 BY MR. LASKER: 20 Dr. Blair, do you have an answer to my 0 21 question? 22 А No. 23 All right. Dr. Blair, you have had the 0 24 opportunity to discuss the IARC classification with 25 various interested parties over the past three years,

Page 217 1 correct? 2 In general, yes. Right. А 3 I would like to ask you about some of 0 4 those communications. (Blair Exhibit No. 23 was marked for 5 6 identification.) BY MR. LASKER: 7 Marked as Exhibit 23. And this is an 8 0 e-mail string from March 23rd to March 25th of 2015 9 between you and a number of members of the IARC 10 11 staff, including Kurt Straif, Dana Loomis and Kate Guyton, correct? 12 Yeah. 13 А 14 And in the beginning of this e-mail 0 15 chain, which again is at the end of the physical 16 documents, or actually it's the third page in, you 17 are advising IARC about a number of press interviews 18 that you had conducted in the wake of the IARC classification of glyphosate, correct? 19 20 Α Yes. 21 And you state here that the reporters 0 questioned you about why the IARC evaluation of 22 glyphosate was different than those done earlier 23 24 elsewhere, correct? 25 А Yes.

Page 218 1 0 You stated -- I'm sorry, you state that your answer to the question was that, quote: 2 New information becomes available over time. Right? 3 4 Α Yes. 5 0 In discussing this new information, did you inform any of these reporters about the updated 6 Agricultural Health Study data finding no association 7 8 between glyphosate and non-Hodgkin lymphoma based 9 upon a study that was three to four times larger than the 2005 AHS paper? 10 11 MR. MILLER: Objection to the form of the 12 question. THE WITNESS: No, because we're talking 13 14 about papers that are published. 15 BY MR. LASKER: 16 Q Is there any rule that reporters impose 17 like IARC imposes that prevents you from informing 18 them about scientific data if it's not published? 19 There is when talking about the IARC Α 20 data, which is based on published studies. 21 Well, did the reporters -- here you're 0 saying new information becomes available over time. 22 23 Did you tell those reporters, Listen, I'm only going 24 to talk to you about the published data and not the 25 unpublished data that I'm aware of?

Page 219 1 А No, I certainly didn't do that. 2 You've also had a --0 Let me add to that, though. Yes, I 3 Α 4 didn't do that, but it's only prudent and appropriate 5 to talk about studies that are finished before you start talking to the press about them. 6 7 0 And --8 Because things change. А 9 And it's your decision with the AHS, as 0 an AHS investigator, to determine and decide when 10 11 you're going to try and submit things for them to be published, correct? 12 13 А Absolutely. You've also had a number of discussions 14 0 15 with a reporter named Carey Gillam, correct? 16 А Yes, I think so. 17 Did you ever tell Carey Gillam about the 0 updated AHS data showing no association between 18 glyphosate and non-Hodgkin lymphoma? 19 20 Α No. 21 Now, Ms. Gillam reached out to you in 0 September of 2016, and let me show you the document 22 23 because I don't know if you will remember this. And let's this -- we will mark this as 24 25 Exhibit 24.

Page 220 (Blair Exhibit No. 24 was marked for 1 identification.) 2 BY MR. LASKER: 3 4 And this is an e-mail exchange between 0 5 you and Carey Gillam, correct? 6 Α Yes. 7 0 And in this e-mail she is reaching out to you in September 2016 after a phone call she had with 8 Chris Portier, correct? 9 10 Α Yes. 11 0 And again, we've discussed the fact that 12 Chris Portier has been critical of the published 2005 AHS study because of what he viewed as limited 13 numbers and limited use of follow-up, correct? 14 15 А Yes. 16 0 Did the issue of the AHS study come up 17 during this conversation with Ms. Gillam? 18 The issue of the AHS study? А Yes. And Dr. Portier's criticisms of 19 0 20 that study. I -- I don't recall. 21 А Do you recall if Ms. Gillam was following 22 0 23 up on Chris Portier's observations about the 2005 AHS 24 study? 25 Well, she had talked to him, but I --Α

Page 221 nothing do I remember specific what was in the 1 2 conversation she had with him. 3 But you do know that you did not tell her 0 4 about the updated AHS data we've been discussing, 5 correct? 6 А Correct. 7 0 You also contacted -- you were also 8 contacted by someone named Marie-Monique Robin, 9 correct? Well, let me show you --10 11 А Is there a document here somewhere? 12 There will be. It's the next one in Ο line. Just wait a second. 13 14 Doesn't ring a bell. А MR. LASKER: This will be Defense 15 Exhibit 25. 16 (Blair Exhibit No. 25 was marked for 17 18 identification.) MR. MILLER: Thank you. 25. 19 20 MR. LASKER: 25. BY MR. LASKER: 21 And so this is an e-mail in August of 22 0 23 2016 from Marie-Monique Robin to you, correct? 24 А Yes. 25 And in her e-mail to you, Ms. Robin 0

Page 222 explains that she is the author of a number of books 1 2 that have been sharply critical of Monsanto and glyphosate, including, quote, Our Daily Poison, 3 4 correct? 5 А I assume that is in there somewhere, but --6 7 It's right at the beginning of her e-mail 0 to you. "I am the author of documentaries and books, 8 9 The World According to Monsanto, Our Daily Poison --10 А Okay. Yes. 11 Q -- Crops of the Future, Good Old Growth. 12 А Yes. And she also in that e-mail in the next 13 0 14 paragraph accuses Monsanto of crimes against the 15 environment and the ecosystem because of its sales of 16 glyphosate, correct? 17 Well, I don't see exactly the words you Α just read, but --18 19 Well, she talks about submitting --0 20 and about halfway through, she talks about making recommendations to the International Criminal Court 21 22 in The Hague to recognize the crime of ecocide. 23 Do you see that? 24 Α Okay. 25 So she is suggesting that Monsanto should 0

Page 223 be tried in the International Court -- Criminal Court 1 2 in The Hague, correct? 3 I -- I quess. I mean this is not А 4 something I -- I mean this sounds legal that I -- I 5 can guess what the words say, but I have no idea what 6 that means. 7 0 And Ms. Robin was referred to you by Kathryn Guyton of IARC, correct? That's what her 8 9 subject line says. 10 Α Yes. Do you know why IARC suggested that 11 0 Ms. Robin speak with you about glyphosate and her 12 views about the International Criminal Court? 13 14 Α No. 15 0 Do you believe --Other than I assume it's because I was on 16 А 17 the IARC panel. 18 Do you believe that the sale of 0 glyphosate amounts to a violation of international 19 criminal law? 20 21 Α I --2.2 MR. MILLER: Calls for a legal 23 conclusion. 24 THE WITNESS: Yeah, I --25 BY MR. LASKER:

Page 224 You don't have an opinion one way or the 1 Q other on that? 2 3 Α No. 4 Did you --0 5 MR. LASKER: Whoever is on the phone, if б they could moot -- mute their line, please. MR. MILLER: Is anyone on the phone? 7 8 MS. WAGSTAFF: Yeah, Aimee Wagstaff. Ι 9 will put it back on mute. 10 MR. MILLER: Thank you. Thank you, 11 Ms. Wagstaff. BY MR. LASKER: 12 13 Did you tell Ms. Robin about the updated 0 14 Agricultural Health Study data that showed no 15 association between glyphosate and non-Hodgkin 16 lymphoma? 17 А No. 18 0 Okay. You were also contacted on 19 March 6th --20 A I did not tell her about the incompleted 21 AHS study --22 0 Understood. 23 -- that purports to show no -- yes. Α Let's use those words from now on. 24 And again, as an investigator for the 25 Q

Page 225 AHS, it was your determination whether to submit that 1 2 data for publication or not, correct? Yes. Not mine; authors. 3 А 4 0 You were one of --5 I'm just one of the authors. Α -- the authors. Okay. 6 0 7 (Blair Exhibit No. 26 was marked for identification.) 8 THE WITNESS: Are we done with the one we 9 just looked at? 10 11 MR. LASKER: Yes, we are. 12 BY MR. LASKER: So Exhibit 26, now you have an inquiry 13 0 from Mr. A Martin from Bloomberg News, correct? 14 15 Andrew Martin? 16 Α Yes. 17 And in his e-mail to you on March 24th, 0 2016, he states, quote: I wonder if you would be 18 willing to talk about the pesticide -- pesticide 19 industry's response to the IARC report on glyphosate, 20 21 in particular criticism that was specific to you. 22 Do you see that? 23 Yes. Α 24 And you in response to this reach out to 0 25 IARC asked them what -- what this might be about,

Page 226 correct? You reach out to Kathryn Guyton and Kurt 1 Straif of IARC. 2 You have to go backwards. It's the first 3 4 page that has your response. 5 Well, I certainly referred him to IARC. Α I --6 7 Well, you reach out to IARC and say, any Q idea of what criticisms he is referring to --8 9 Okay, yes. I see it. Α -- or any advice. 10 Q 11 Yes. Right. А So you asked IARC for advice as to how to 12 0 13 respond to Andrew Martin from Bloomberg News. 14 The -- actually, the decision was always А 15 who was going to talk to whom. IARC people talk to 16 some, I talk to other people, and it was just a 17 decision of who was going to talk to him. 18 So IARC in their response to you state 0 that Mr. Martin might be talking about two potential 19 20 criticisms, correct? There are two potential issues that come to mind? 21 This is the top? 22 А 23 The top e-mail. 0 24 А Yes. 25 And the first potential criticism that 0

Page 227 IARC identifies is the issue of the negative AHS 1 study outweighing the positive studies on non-Hodgkin 2 lymphoma, correct? 3 4 Okay. Yes. А 5 And the second potential criticism is 0 about experts reviewing their own work --6 7 Α Yes. 8 -- which is the issue that you had raised 0 at the very beginning of this process, correct? 9 10 А Yes. 11 0 And Mr. Straif of IARC refers you to some IARC Q&A in response to those criticisms regarding 12 13 IARC's treatment of the Agricultural Health Study, 14 correct? 15 "We have posted additional material on 16 our website responding to some criticisms." Do you 17 see that? 18 This is still in the top? А 19 Yeah, the top e-mail, the third 0 paragraph: After the latest invitation to the 20 21 European Parliament, we have posted additional materials on our website" --22 23 Okay. Okay. Yes. All right. Α 24 -- "responding to some criticisms 0 25 including the AHS issue." Correct?

Page 228 Okay. Yes. 1 А 2 So let's take a look at that IARC Q&A Q 3 document. 4 (Blair Exhibit No. 27 was marked for 5 identification.) BY MR. LASKER: 6 Exhibit 27. And this is from the IARC 7 0 website dated March 1st, 2016. So this is a few 8 weeks before the e-mail exchange we just looked at, 9 10 correct? 11 Α Yes. So this is the Q&A on glyphosate that 12 0 13 IARC refers you to with respect to the criticisms of 14 the AHS study, correct? 15 Α Yes. Now, with respect to the Agricultural 16 Q 17 Health Study, if you can go to page 2, there is in 18 the middle of the page in bold a discussion of the Agricultural Health Study and the criticisms of 19 20 IARC's dealing with that study and then IARC's 21 response. Correct? 22 А Yes. 23 And IARC in its Q&A states: 0 "The 24 Agricultural Health Study has been described as the 25 most powerful study, but this is not correct. The

Page 229 AHS data on cancer and pesticides use in more than 1 50,000 farmers and pesticide applicators in two 2 states in the U.S., the weakness of the study is that 3 4 people were followed up for a short period of time, 5 which means fewer cases of cancer would have had time to appear." Correct? 6 7 А Yes. 8 But as of this date, you were aware and 0 9 had been for three years that there was more AHS data that had a longer follow-up and some four times more 10 11 cases of NHL than had been discussed in the 2005 12 published paper, correct? 13 Α Yes. For analyses that had not been 14 completed. 15 Did you write back to Kurt Straif at IARC 0 16 and point out that there is actually more updated data available from the AHS and that this criticism 17 18 was no longer valid? 19 No, because IARC works on papers that Α 20 have been published. And the IARC O&A also refers in that 21 Ο 22 last -- second paragraph, last paragraph in response 23 to the questions about the Agricultural Health Study 24 that the IARC working group had done an analysis --25 statistical analysis of the results of all of the

Page 230 available studies on glyphosate and non-Hodgkin 1 lymphoma, which includes the AHS and all the 2 case-control studies, and that's referring to the 3 4 meta-analysis, correct? 5 Α Yes. And the Q&A states that the data from all 6 0 7 the studies combined showed a statistically 8 significant association between non-Hodgkin lymphoma 9 and exposure to glyphosate, correct? 10 Α Correct. 11 0 And did you write back to Kurt Straif and point out that there was updated both from the 12 13 Agricultural Health Study and through the NAPP that, if included, would result in that meta-analysis not 14 showing a statistically significant increased risk of 15 non-Hodgkin lymphoma? 16 17 Α No, because those studies hadn't been published and weren't finished. 18 19 Now, you have also had conversations 0 since the IARC glyphosate monograph with scientists 20 at EPA, correct? 21 22 А Yeah, I guess. I --23 MR. LASKER: Let's mark this as 24 Exhibit 28. (Blair Exhibit No. 28 was marked for 25

Page 231 identification.) 1 2 BY MR. LASKER: Now, Dr. Blair, does EPA have any rule 3 0 4 that states that it will not look at data unless it's been published, to your knowledge? 5 6 Not to my knowledge. А 7 0 Okay. So this is an e-mail chain from May 2016 between you and a scientist at EPA named 8 9 Natasha Henry. Did you in fact meet with EPA about 10 glyphosate on or about May 2016? 11 А I'm trying to remember whether we met or just talked. I actually don't remember. 12 Okay. Do you recall if you've had more 13 0 14 than one conversation with EPA about glyphosate? 15 I had two conversations with this person. А 16 But two for sure. 17 Okay. And did you tell Dr. Henry or 0 anyone else at EPA about the updated AHS findings of 18 no association between glyphosate exposure and AH --19 and non-Hodgkin lymphoma that are set forth in that 20 2013 study we just looked at? 21 No, because the studies weren't finished 22 Α 23 and weren't published. 24 But we just talked about the fact that 0 25 EPA does not limit its anal- -- analysis to published

Page 232 1 data, correct? 2 But it makes a difference to scientists А 3 to not release things before you're finished with it. 4 And that was the case here. 5 Did EPA ask you any questions about the 0 6 AHS? 7 А I don't remember. 8 And you are aware that EPA has -- is in 0 the process of -- of conducting its analysis and has 9 issued some findings with respect to glyphosate and 10 11 cancer, including non-Hodgkin lymphoma, correct? 12 I've seen it in the press. А EPA, in reaching that determination, has 13 0 not had the benefit that you have of having seen the 14 15 updated Agricultural Health Study data showing no 16 association between glyphosate and non-Hodgkin 17 lymphoma, correct? 18 А Correct. Now, you've also been contacted by 19 0 20 plaintiffs' attorneys in this litigation, correct? 21 Α Yes. 22 0 Let me mark as the next exhibit in line, 23 Exhibit 29. 24 (Blair Exhibit No. 29 was marked for 25 identification.)

Page 233 1 MR. MILLER: 28. I could be wrong. 2 MR. LASKER: This is 29. THE WITNESS: This is 29. 3 4 MR. MILLER: Okay, 29 it is. 5 BY MR. LASKER: 6 0 And this is an e-mail exchange between 7 you and Kathryn Forgie, who is sitting at the end of 8 this table, at the Andrus Wagstaff law form -- law 9 firm, correct? 10 Α Yes. 11 And did you in fact meet with Ms. Forgie 0 or any other plaintiffs' attorneys in December 2015? 12 13 Α Well, I must admit I don't remember, but this sounds like I did. So I must have. 14 Well, let me ask you --15 0 I know I talked to her. 16 Α 17 Separate from this document, you've 0 had -- you've had a conversation with plaintiffs' 18 counsel. 19 20 Absolutely. Yes. А How many conversations have you had with 21 0 plaintiffs' counsel in this litigation prior to 22 23 today? 24 Well, it -- I'm not sure I can give a Α 25 precise answer, but not many.

Page 234 1 0 A half dozen? 2 I don't think it was that many, but I А don't know for sure. 3 4 Three or four? 0 5 Α That would be my guess, three or four. And what -- what did you and plaintiffs' 6 0 7 counsel discuss during these conversations? Well, as I recall, they were asking about 8 Α what went on at IARC and I think whether or not I 9 would provide advice regarding this. And I said no. 10 11 0 Did they ask you any questions about your own scientific research including the Agricultural 12 Health Study? 13 I don't remember. 14 Δ Do you recall if you shared with 15 0 plaintiffs' attorneys any information about either 16 17 the North American Pooled Project or the Agricultural 18 Health Study analyses that were still going forward? 19 T doubt it. Α 20 You said you had three or four 0 conversations with plaintiffs' counsel. 21 No, I said I guessed. 22 Α 23 So the first conversation, was the issue 0 24 of whether or not you would serve as an expert witness raised? 25

Page 235 1 А Well, I'm not sure whether it was the first conversation or which one. I --2 So there were a series of conversations 3 0 4 in which you guys were discussing the possibility, 5 three to four conversations; is that fair? 6 There was more than one. I don't Α 7 actually know what the number was. But adding the numbers, it's more than one. That's all I know for 8 9 sure. 10 0 Do you recall how long these conversation 11 lasted? 12 А Not long. 13 0 Let me show you an e-mail from May of 14 2016. And this is an e-mail exchange between you and 15 a Dr. Weisenburger. Do you who Dr. Weisenburger is? 16 А I do. 17 O Who is Dr. Weisenburger? He is a cancer researcher. 18 А MR. MILLER: May I have a copy, please. 19 Exhibit 30? Maybe it is behind there. 20 21 MR. LASKER: I'm sorry. I did that. 22 Just -- sorry. 23 MR. MILLER: Sure. Okay. Exhibit 30. 24 (Blair Exhibit 30 was marked for 25 identification.)

Page 236 1 BY MR. LASKER: 2 Okay. So this is an e-mail that was Q forwarded to you from Dr. Weisenburger. Again, I'm 3 4 sorry, I missed it. Who was Dr. Weisenburger? 5 Α Pardon? 6 Who is Dr. Weisenburger? 0 7 Α He's a pathologist who does epidemiologic studies like I do. 8 And he -- he actually is one of the other 9 0 investigators with you on the North American Pooled 10 11 Project? He is. 12 Α And so he also would be aware and would 13 0 14 have been aware of this analysis of the NAPP data that we looked at earlier before the IARC 15 16 monograph --17 Well, probably, but there's a lot of А 18 co-authors in that study and they get informed at different times, depending on where you are in the 19 20 analysis, and I don't remember about this one. Eventually he would be informed if he wasn't then. 21 22 And so Dr. Weisenburger here --0 23 Dr. Weisenburger, these e-mails reflect, is serving 24 as an expert witness for plaintiffs' counsel, 25 correct?

Page 237 1 А I think so. You have had conversations --2 Q 3 Yes. А 4 -- with him where he's told you that, 0 5 correct? 6 А Yes. 7 0 And in this e-mail he is passing on to you, he is letting you know that plaintiffs' counsel 8 have contacted him about discussing his first case, 9 10 correct? 11 Α Yes. What did Dr. Weisenburger tell you about 12 0 his meetings with plaintiffs' counsel regarding this 13 14 litigation? 15 MR. MILLER: Objection. 16 THE WITNESS: I -- I -- I don't remember. 17 BY MR. LASKER: 18 Do you recall having conversations with 0 him about the NAPP data and how and when that might 19 20 be published? I'm sure we had conversations about that. 21 Α Well --22 Q 23 I don't remember details, but I'm sure we А 24 had conversations. Okay. You had mentioned earlier with 25 0

Page 238 respect to the NAPP that there has been a number 1 of -- more than one presentation of that data to 2 date, correct? 3 4 Well, two for sure. Maybe more than Α 5 that. 6 And during that process, the NAPP 0 7 investigators, you and Dr. Ferguson and other --8 Dr. Weisenburger, I'm sorry, and others have been 9 looking at the data in different ways, correct, and reporting it in different ways? Is that fair to say? 10 11 Α We've been looking at the analyses that have been done trying to make judgments about what it 12 13 says. Is that what you mean? 14 Well, in your presentation of the data, 0 15 the data you're presenting had been changing over time, correct? 16 17 I don't actually know whether that's true Α 18 or not. 19 Okay. Well, let me show you an e-mail 0 20 exchange between NAPP investigators -- actually, before we get to that, let's just refer back to 21 Exhibit 29, which is the e-mail exchange between you 22 and Ms. Forgie, plaintiffs' counsel. 23 24 And if you look at the first e-mail in 25 that chain, it's dated -- again, it's the last page,

Page 239 so the second to the last page or the last page of 1 the document. It's from Ms. Forgie to you, and it 2 states: "Dear Dr. Blair" -- and this is dated on 3 4 August 20, 2015, correct? Go to the last page. 5 So Ms. Forgie sent you this e-mail, plaintiffs' counsel, on August 20, 2015, correct? б 7 А August 20. I thought you said August 15. 8 August 20. 9 And in this e-mail, plaintiffs' counsel 0 indicates that they have spoken to you twice with 10 11 regard to pesticide exposure and cancer, and she notes that she is an attorney with Aimee Wagstaff, 12 13 correct? 14 Okay. Yes. А 15 Okay. So I just want to put that in 0 time. 16 17 If we can go back now to what has been marked as Exhibit 31. This is now an e-mail exchange 18 on August 26, 2015, correct? I'm sorry. 19 20 I don't have 31. Α (Blair Exhibit No. 31 was marked for 21 22 identification.) 23 MR. LASKER: I'm sorry, I need to give 24 you one here. Let me finish this process. 25 MR. MILLER: 31?

Page 240 1 MR. LASKER: 31. 2 MR. MILLER: 31. BY MR. LASKER: 3 4 So this is -- this e-mail is about a week 0 5 after your e-mail exchange with plaintiffs' counsel, 6 correct? 7 А Yes. Yes. August 20 -- 26th. So if we can now look at the earliest 8 0 e-mail in this string, Exhibit 31, so, again, you got 9 to go back to the end and read forward, Dr. Pahwa is 10 11 advising you and other NAPP investigators that she was going to be presenting findings about glyphosate 12 use and NHL risk at the International Society for 13 Environmental Epidemiology in August -- on 14 August 31st, 2015, correct? 15 16 Α Yes. 17 And she states in her e-mail, the very 0 last line, that she is sharing her slide deck for 18 that presentation with you all in advance, quote, 19 20 given the sensitivity of the topic, correct? 21 Α Yes. And in your e-mail response, which is --22 0 23 starts on the bottom of the first page of this 24 document and then continues through the second page, 25 you state that Dr. Pahwa will need to be prepared for

Page 241 questions after the presentation and that the -- the 1 question is going to be, Do these data indicate that 2 3 the IARC evaluation was wrong? 4 Do you see that? 5 А It's on the first page? It's on the second page. 6 0 7 А Yes. And you also suggest alerting IARC in 8 0 advance of the meeting, correct? 9 10 А Yes. 11 0 Now, you do not suggest alerting Monsanto to the NAPP data, do you? 12 13 Α No. 14 And if you look at page -- the first page 0 of this e-mail chain, in fact, you were concerned 15 that Monsanto might be, quote, scanning programs of 16 17 meetings like ISEE and might find out about the NAPP 18 findings, correct? Well, if you're presenting at a meeting, 19 Α you can't be concerned about them finding it because, 20 21 aqain --22 Q Doctor --23 А -- it's at the meeting. Dr. Blair, do you see --24 0 25 MR. MILLER: Don't. Stop. Let him -- I

Page 242 1 object. 2 Doctor, if you want to finish the answer, 3 go right ahead. 4 MR. LASKER: I'm sorry. MR. MILLER: He doesn't have the right to 5 6 interrupt you. 7 BY MR. LASKER: 8 I'm sorry, did you have more to say? 0 Ι 9 thought you were finished. It's -- if you're presenting at a 10 А 11 meeting, you would assume people might be able to get something, and you just want to be prepared to deal 12 13 with questions that might come. It's known that this is pretty topical. 14 15 You state in your e-mail that, quote: 0 Ι 16 just suspect Monsanto has someone scanning programs 17 of meetings like ISEE and would want to get press if 18 they can. Correct? 19 А Yes. Yes. 20 And you were worried about that 0 21 possibility, correct? 22 А Worried about the person presenting not 23 being prepared to address questions that are relevant 24 to them. And for that reason, you decided -- you 25 0

Page 243 told Dr. Pahwa that she should alert IARC in advance, 1 2 correct? 3 Because it would affect what IARC gets, А 4 yeah. 5 Now, let me show you another e-mail that 0 branches off in this e-mail chain of Exhibit 31, 6 7 Exhibit 32. (Blair Exhibit No. 32 was marked for 8 9 identification.) 10 MR. MILLER: 32. 11 MR. LASKER: 32. MR. MILLER: Gotcha. 12 BY MR. LASKER: 13 And this e-mail chain sort of branches 14 0 15 off from the earlier e-mail chain, and the second e-mail in this chain starting from -- again, we've 16 17 got to go to the back, so we have to read this 18 backwards, I apologize -- but the second to the last page, there is an e-mail that was sent by you at 19 20 4:11 p.m. on August 26, 2015. 21 Do you see that? 22 Α Yeah. 23 So that e-mail was sent -- and, I'm Ο sorry, to make you do this, if you go back to 24 25 Exhibit 31 -- this e-mail was sent roughly nine hours

Page 244 after you -- after you had raised the issue of the 1 2 questions that Dr. Pahwa might receive about her presentation, correct? 3 4 Okay. Α 5 0 And as set forth in this e-mail now at 4:11 p.m., and Dr. Pahwa's responding e-mail at 4:22, 6 7 Dr. Pahwa had revised her slide presentation in response to comments she had received from you and 8 9 from the other NAPP investigators, correct? 10 А Yes. 11 0 She also states that the abstract of the 12 NAPP findings for glyphosate and non-Hodgkin 13 lymphoma, quote: Does not appear on the ISEE website 14 or in the conference program. Correct? 15 Α Yes. 16 0 So she addressed your concern about the 17 possibility that Monsanto might learn about these 18 NAPP findings. Correct? 19 Α Yes. 20 Dr. Pahwa agrees with you that it would 0 21 be best for her not to deal with any potential press 22 at the COP conference about her NAPP findings, 23 correct? 24 Α Yes. 25 She states, though, that she will prepare 0

Page 245 some talking points, and that she will share them 1 with you and the rest of the group prior to the 2 conference, correct? 3 4 Α Yes. In response, you again suggest that the 5 0 abstract and the slide deck should be shared with 6 7 IARC prior to the ISEE conference, correct? 8 Α Yes. 9 So even though you now were sure that 0 10 Monsanto was unlikely to learn about the NAPP 11 findings, you still wanted IARC to be prepared in the event that the findings somehow got out to the 12 13 press --14 А Yes. 15 0 -- correct? 16 Α Yes. 17 And then you prepared some talking points 0 for Dr. Pahwa in case she was questioned about the 18 NAPP findings and how they relate to the IARC 19 20 evaluation, correct? Which -- where are you reading --21 А 22 0 The first page now, the last e-mail: "I 23 think we also should provide some suggested talking 24 points in case" --25 Α Okay, yes. First page, yes.

Page 246 1 0 So you prepared some talking points for Dr. Pahwa just in case --2 3 Yes. А 4 0 -- she was asked about IARC? 5 А Yes. 6 0 Now, Dr. Pahwa gave a subsequent 7 presentation about the NAPP findings in connection with IARC's 50th anniversary conference in June 2016, 8 9 correct? 10 Α Yes. 11 0 Let me show you an e-mail chain with respect to that presentation. And this is going to 12 13 be 33. (Blair Exhibit No. 33 was marked for 14 identification.) 15 16 BY MR. LASKER: And this is the e-mail chain between 17 0 various of the NAPP investigators, including 18 Dr. Cantor, correct? 19 20 Α Yes. 21 And you are on there as well. 0 22 Α From Dr. Cantor, yes. 23 Who is Dr. Cantor? 0 24 He is a retired epidemiologist from the А National Cancer Institute. 25

Page 247 And Dr. Cantor actually was lead author 1 0 on one of the first studies on -- that reported data 2 3 on glyphosate and non-Hodgkin lymphoma, correct? 4 Α Correct. And in his original case-control study, 5 0 he did not find any association between glyphosate 6 and non-Hodgkin lymphoma, correct? 7 That's what I remember. 8 Α 9 But that data has now been pooled into 0 10 the NAPP, correct? 11 А Yes. Now, in this e-mail chain, there is a 12 0 discussion of five abstracts that the NAPP was 13 14 preparing for the IARC conference, correct? 15 Α Yes. And one of these abstracts addressed the 16 0 17 NAPP findings that were going to be reported with 18 respect to glyphosate and non-Hodgkin lymphoma, 19 correct? 20 Α Yes. And Dr. Cantor in his e-mail talks 21 0 specifically about that abstract with respect to 22 23 glyphosate, correct? 24 Α Yes. And in his e-mail about the NAPP 25 0

Page 248 findings, Dr. Cantor states that the findings with 1 respect to glyphosate and NHL, quote, are less than 2 convincing given that control for other pesticides 3 4 resulted in attenuated OR, which aren't in the 5 abstract. Correct? 6 А Yes. So we discussed earlier the NAPP data in 7 Ο June 2015 which showed no association between 8 glyphosate and non-Hodgkin lymphoma when adjusted for 9 other pesticides. You recall that, correct? 10 11 Α Yes. 12 And Dr. Cantor is explaining in his 0 e-mail now in January 2016 that the NAPP data still 13 did not show any statistically significant 14 15 association between glyphosate and non-Hodgkin lymphoma when the data was controlled for other 16 17 pesticides, correct? 18 А Correct. But in presenting the NAPP data for the 19 0 20 IARC meeting, the abstract only reports odds ratios without controlling for other pesticide exposures, 21 2.2 correct? 23 I don't remember. Α Well, Dr. Cantor is expressing that 24 0 25 concern in this e-mail, correct, that the data on --

Page 249 the control data is not reported in the abstract? 1 2 Well, he suggests the last sentence be Α 3 removed. 4 He states that: "Results in the second 0 5 abstract glyphosate -- about glyphosate are less than convincing given that control for other pesticides 6 resulted in attenuated OR which aren't in the 7 8 abstract." 9 So this concern is that the presentation of the NAPP data was not making clear that when the 10 11 data was controlled for other exposures, there was no 12 association between glyphosate and non-Hodgkin lymphoma? 13 I understand all that. I don't -- but 14 Δ 15 then he suggests it should be removed from the -- and 16 so I'm not clear whether he is suggesting remove it 17 from the abstract for this meeting or from some later 18 publication. I'm not clear about that. 19 But his concern was that we were 0 20 presenting -- the NAPP was presenting data without presenting the data on controlled --21 22 А Clear ---- exposures with glyphosate and other 23 0 24 pesticides? 25 Α Yes.

Page 250 1 0 Okay. So let's turn to the slide deck 2 that the NAPP presented at that IARC conference. (Blair Exhibit No. 34 was marked for 3 4 identification.) MR. MILLER: And this is Exhibit 34. 5 BY MR. LASKER: 6 7 0 So you could take a chance to look through it. This document Exhibit 34 is the 8 9 presentation that was made -- strike that. Hold on a second. I'm not sure I have the right one. 10 I don't 11 know if this is the right one. This is June 2016 -yeah, no, I'm sorry, this is right. Okay. 12 13 So this is the presentation that was made in June 2016 as part of the IARC @ 50 Conference, 14 15 correct? 16 А I think so, yes. And unlike the June 2015 data that we --17 0 18 that we talked about earlier which presented only the controlled odds ratios accounting for other pesticide 19 exposures, this June 16 presentation also presents 20 21 odds ratios not controlled for those exposures, correct? So it's presenting the uncontrolled data. 22 23 (Perusing document.) Α 24 Do see the reports that -- both for 0 25 uncontrolled and for controlled for the pesticide

Page 251 1 exposures, have both those data in there? 2 And if you look at the tables -- on the bottom of those tables, they have ORA and ORB. 3 So ORA is the unadjusted numbers and ORB is the adjusted 4 5 numbers. Do you see that? 6 А Yes. 7 0 And so by presenting the unadjusted data, NAPP was able to present data that it could report as 8 9 being statistically significant with respect to glyphosate and non-Hodgkin lymphoma, correct? 10 11 А Where on this table it says it's adjusted 12 for --13 Yes. Q -- 2,4-D, diazinon and malathion. 14 А 15 Right, that's ORB, correct? 0 There's ORA and there's ORB, and you 16 17 present, unlike in June 2015 when you controlled for 18 other exposures and just presented the controlled data, in this presentation you've now added in a 19 presentation of the uncontrolled odds ratios, 20 21 correct? 22 Α Oh, yes. If that's your point, yes. Ι thought you were saying it was only presenting ORA. 23 24 Well, it presents both. 25 It presents both. And by presenting the 0

Page 252 uncontrolled data, you therefore were able to present 1 NAPP data to IARC that had a numerical number that 2 3 was statistically significant, correct, with respect 4 to glyphosate? 5 А That is the case, yes. 6 And unlike the June 2015 data we looked 0 7 at, the June 2016 presentation does not provide any odds ratios that exclude proxy respondents and relied 8 solely on the more reliable self-reported data, 9 10 correct? 11 А Suggested for use of proxy respondents. It does not -- it does not present data 12 0 13 solely for self-respondent data, though, correct? 14 It's suggested for use of proxy -- proxy А 15 respondents. 16 Q I understand. My question is, it does 17 not present data solely from self-reported --18 А That ---- correct? 19 0 20 That adjustment does literally the same Α 21 thing. Well, we know from the June 2015 data 22 Q 23 that when self-responded only data from the NAPP is 24 used, the result is virtually null, with odds ratio 25 of 1.04 for glyphosate and non-Hodgkin lymphoma,

Page 253 1 correct? 2 А Yes. 3 But that information is no longer in the 0 4 presentation in 2016; that's been -- correct? 5 Α It's adjusted for proxy respondents. 6 That data point, 1.04, showing a null 0 7 result from the most reliable exposure data for 8 glyphosate and non-Hodgkin lymphoma is no longer in 9 the presentation. MR. MILLER: Objection. Asked and 10 11 answered. He said it's been adjusted. 12 MR. LASKER: Okay. Now we have two 13 witnesses, but I will ask the question --14 MR. MILLER: No, you don't have two 15 witnesses. 16 THE WITNESS: Just say it again. 17 MR. MILLER: You have one lawyer who is harassing one witness. He said it had been adjusted. 18 19 BY MR. LASKER: 20 Dr. Blair --Ο 21 Say it again. А -- the data with the 1.04 odds ratio that 22 0 23 was in the presentation in June 2015 that showed a 24 complete null result of ever versus never use for 25 glyphosate and non-Hodgkin lymphoma, is that 1.04

Page 254 data point in this presentation? 1 2 MR. MILLER: Objection. Asked and 3 answered. 4 Go ahead, Doctor. 5 THE WITNESS: I don't actually know whether it is, but there are a lot of data points 6 7 that are less than 1.0. 8 You know, so is the one you're mentioning in there, I -- I would have to pour through this. 9 You may be right, but I'm saying there are a lot of 10 11 others in here that are less than 1.0. 12 BY MR. LASKER: 13 It's fair to say, Dr. Blair, that the 0 NAPP has presented different data, and presented 14 different data now in June 2016 for this IARC meeting 15 16 than it had presented in June 2015, correct? 17 Α Yes. And that's because analyses move along and you do different things. 18 19 Okay. And this presentation in June 2016 0 was made -- and one of the authors, by the way, or 20 one of the listed authors on this June 2016 21 22 presentation is Dr. Weisenburger, correct? 23 Yes. Α 24 And Dr. Weisenburger as of this time we 0 25 know was already serving as an expert witness for

Page 255 plaintiffs, correct? 1 2 Probably, yeah. А 3 Let's mark as the next exhibit in line an 0 4 e-mail you received from Dr. Weisenburger on August -- in August 2016. 5 6 (Blair Exhibit No. 35 was marked for identification.) 7 8 BY MR. LASKER: And this is Exhibit 35. 9 Q MR. MILLER: 35. 10 11 MR. LASKER: 35. 12 MR. MILLER: Got it. BY MR. LASKER: 13 14 And again, so the record is clear, at the 0 15 time Dr. Weisenburger wrote this e-mail to you in August 2016, he was serving as an expert witness for 16 17 plaintiffs in this litigation, correct? 18 I -- I don't know that, but you must have Α 19 the dates. 20 Well, we can go back to this. He had 0 21 sent you an e-mail in -- in May 2016. I think that was Exhibit 30 if you want to refer back. 22 23 No, that's --Α 24 May 2016. 0 25 I'm just saying you asked me point blank Α

Page 256 1 all these dates --2 Q Okay. -- and immediately I do it, you start 3 Α 4 fumbling through the paper. Just say, No, we got an 5 e-mail, and got it, and then we will move on. Okay? 6 Well, I was trying to find the e-mail to 0 7 help refresh your recollection. 8 No, you weren't. А Dr. Blair -- Dr. Blair, in May of 2016, 9 0 you had an e-mail that made it clear to you that 10 11 Dr. Weisenburger was serving as an expert for plaintiffs in this litigation, correct? 12 13 Α Yes. 14 Okay. So in August of -- let me get my 0 15 dates correct -- in August of 2016, you certainly were aware of the fact that Dr. Weisenburger was 16 17 serving as an expert witness for the plaintiffs in 18 this litigation, correct? 19 Α Yes. 20 And in his e-mail to you, he is pressing 0 for publication of the NAPP data as it had been most 21 22 recently presented at the IARC meeting, correct? 23 Α Yes. 24 Dr. Weisenburger says, quote: 0 It is 25 important to get our U.S.-Canadian paper on this

Page 257 1 submitted soon as to be considered by the European authorities in their review of glyphosate. Correct? 2 3 Yes. To be --А 4 MR. MILLER: You read the quote wrong. 5 MR. LASKER: I'm sorry. I will read it 6 again. 7 THE WITNESS: Yeah. 8 BY MR. LASKER: 9 I will read it again. The earlier 0 10 e-mail, and that's --11 Α Yes. Okay. I'm sorry. No, it's okay, it's down in the bottom. 12 13 Only just "European authorities" was not in the line 14 you were reading and I was trying to follow. To be fair --15 0 16 А But it's down below. It's okay. 17 To be fair, the e-mails below are between 0 18 Christopher Portier and Dr. Weisenburger, correct? 19 Yes. Yes. А 20 And Christopher Portier is also an expert 0 witness for plaintiffs, correct? 21 22 Α I don't -- maybe I know that. But I 23 don't know. 24 I will represent to you that he has 0 25 because he's subpoenaed already for plaintiffs in

Page 258 1 this litigation. 2 Α Okay. So the first e-mail is between Chris 3 0 4 Portier and Dennis Weisenburger, two plaintiffs' 5 experts in the litigation, talking about the EU's review of glyphosate, correct? 6 7 Α Yes. 8 And then Dr. Weisenburger turns to you 0 9 and sends an e-mail saying, quote: It seems important to get our U.S.-Canadian paper on this 10 11 submitted soon so it can be considered in this 12 review. Correct? 13 А Correct. And he is talking about the NAPP paper 14 0 15 that was now being --Α 16 I -- I assume so. I'm sure that's the 17 case, yeah. 18 So -- and again, as one of the 0 investigators on the NAPP, you and Dr. Weisenburger 19 20 have the ability to publish data or not publish data 21 as you -- as you choose, correct? 22 No. Dr. Weisenburger and I and the many Α 23 other authors on the paper make the decision when 24 papers are ready for submission for publication. 25 So you certainly have the ability to try Q

Page 259 and get data published at --1 2 Absolutely. А 3 -- whatever time when you decide to do 0 4 so. 5 Absolutely. Α And prior to the IARC working group 6 0 7 meeting, you had data from the North American Pooled 8 Project, you had data from the Agricultural Health Study, and you decided, for whatever reason, that 9 that data was not going to be published at that time, 10 11 and therefore was not considered by IARC, correct? 12 Again, you foul up the process. Α No. What we decided was the work that we were doing on 13 14 these different studies were not yet -- were not yet 15 ready to submit to journals. Even after you decide to submit them to journals for review, you don't 16 17 decide when it gets published. 18 You submit --0 But first you have to decide is it ready 19 А 20 for submission; that the -- all the authors are satisfied with the analysis and interpretation, and 21 22 that's the process these papers are in. You submitted AHS data for pesticides in 23 Ο 24 2014, correct? 25 I -- again, I don't know what you're А

Page 260 1 referring to AHS data on. Many AHS data on 2 pesticides are submitted. 3 Okay. There's an updated data -- updated 0 4 study on the Agricultural Health Study data on 5 non-Hodgkin lymphoma and pesticides, and you decided to submit that data in 2014, and in fact, that study 6 7 was published in 2014, correct? 8 А Yes. All right. And you decided not to submit 9 Ο data that had been included in a draft with that same 10 11 pesticide data for publication, correct? 12 А Yes. 13 And you to this day have not submitted 0 that data for publication, correct? 14 15 Α Correct. 16 0 But in this exchange in August 2016, we 17 have two plaintiffs' counsel discussing how they can 18 get certain data published so that it could be considered, correct? 19 20 MR. MILLER: Object to the form of the 21 question. 2.2 BY MR. LASKER: 23 That is Chris Portier and Dennis 0 24 Weisenburger trying to figure out, now that the NAPP 25 data has been reviewed and altered from August of --

Page 261 from 2015 to 2016, they're now talking about how can 1 we get this published, aren't they? 2 MR. MILLER: Object to the form of the 3 4 question. 5 THE WITNESS: Well, that's not the words I would use to describe what they're trying to do, 6 7 but that is okay. 8 MR. LASKER: Let's take a brief break. Ι 9 may be done. THE VIDEOGRAPHER: Okay. The time is 10 11 3:10 p.m. We're going off the record. 12 (Recess.) 13 THE VIDEOGRAPHER: The time is 3:16 p.m., 14 and we're back on the record. 15 BY MR. LASKER: 16 Q Dr. Blair, I need you to turn to another 17 issue briefly. What is the Ramazzini Institute? 18 It's not an institute. It's an Α association, a professional association. 19 20 Have you ever done work for the Ramazzini 0 association? 21 2.2 А No. 23 Have you ever collaborated with the 0 24 Ramazzini association with respect to any scientific 25 research that you can recall?

Page 262 Not that I -- I don't think so. 1 Α I -- I'm 2 a member of it. I don't think I've ever done 3 anything with them. 4 So you're -- you're a member. Does that 0 5 mean you've gone to meetings? 6 I've been to one meeting. А 7 0 Okay. Have you had any discussions with anyone at Ramazzini regarding glyphosate? 8 9 I don't remember it, but I quess it's А possible. 10 11 MR. LASKER: Thank you, Doctor. I have no further questions. 12 13 I do have to -- just before I forget, there was one document that -- and we can do this 14 15 after you are done, but I am remembering now, so I 16 want to do it. There was one document that you used 17 in your direct examination that was an e-mail that's 18 confidential and under the protective order. So just that document, and it was really like maybe two or 19 20 three questions about that document, we will designate as "Confidential" under the protective 21 2.2 order. 23 MR. MILLER: That is fair. Okay. 24 MR. LASKER: And that's that. 25 MR. MILLER: Great. Let's switch seats

Page 263 1 and keep this moving. 2 THE VIDEOGRAPHER: The time is 3:18 p.m. 3 We're going off the record. 4 (Recess.) THE VIDEOGRAPHER: The time is 3:22 p.m., 5 6 March 20th, 2017, and we are on the record with video 4. 7 8 REDIRECT EXAMINATION BY MR. MILLER: 9 Good afternoon, Dr. Blair. 10 0 11 Α Afternoon. Again, I'm Michael Miller, and I started 12 0 out today asking questions, and I'm going to follow 13 14 up in response to the questions from Monsanto's 15 attorneys, okay? 16 А Okay. 17 Okay. Now, you and I never met each Ο before today, have we? 18 19 I don't think so. А 20 No. I'm about your age. I'm not sure --0 21 yeah, our memories are what they are. But we've never met each other, right? 22 23 Right. Α 24 Okay. And we've never talked on the 0 25 phone, right?

Page 264 1 А No, I don't think so. 2 Okay. And to the extent you talked to 0 one lady lawyer out of Denver that asked you to be an 3 4 expert for plaintiffs, you said you would rather not 5 do that, right? 6 А Right. 7 0 You wanted to stay impartial and neutral, 8 didn't you? 9 That's the way I look at it, yes. А 10 0 Your science is what's important to you? 11 А Yes. Okay. Now, let's get over some of the 12 0 13 substance that was brought up by Monsanto's 14 attorneys. 15 One of the issues that he talked about, 16 and he showed you Exhibit 26, was an issue that 17 someone at IARC had e-mailed you about after -- is it 18 fair to say after IARC issued its report that probably -- that glyphosate probably caused 19 20 non-Hodgkin lymphoma, there was quite a bit of ruckus, if you will, about all that, wasn't there? 21 22 MR. LASKER: Objection to form. 23 THE WITNESS: Yes. 24 BY MR. MILLER: 25 Okay. And one of the issues was that 0

Page 265 there was this negative AHS study that you've been 1 talking about a lot with Monsanto's lawyers, right? 2 3 Yes. А 4 And there were the -- the positive 0 5 studies on non-Hodgkin lymphoma, right? 6 А Yes. 7 0 So the issue is we're weighing the positive case-control studies, more than a few of 8 9 them that the jury has heard of by now, that show the association statistically significant between 10 11 glyphosate and non-Hodgkin lymphoma, and the negative study, AHS, which really didn't show a statistically 12 significant association, right? 13 14 Correct. А 15 And you, Dr. Blair, are one of the 0 authors of that AHS study, right? 16 17 Α Yes. Yet when it came time to vote as a 18 0 volunteer scientist on the International Agency for 19 the Research for Cancer, you voted unanimously with 20 21 16 of your peers that there was a probable 22 association between glyphosate and non-Hodgkin 23 lymphoma, right? 24 Well, I voted that way. I think it was Α 25 unanimous. I don't actually remember.

Page 266 I understand. I understand. 1 0 2 And you're not the only author of the AHS 3 study that -- that thinks there is an association 4 between glyphosate and non-Hodgkin lymphoma, are you, 5 sir? 6 MR. LASKER: Objection to form. 7 THE WITNESS: I actually don't know the 8 answer to that. MR. MILLER: What's our next number 9 exhibit? 10 11 MR. LASKER: 36. 12 MR. MILLER: Thank you. 13 All right. 36. (Blair Exhibit No. 36 was marked for 14 15 identification.) 16 BY MR. MILLER: 17 And I might not be pronouncing this 0 right, but Michael Alavanja? 18 19 Alavanya (phonetic). А 20 Excuse me. Michael Alavanja is one of 0 the authors of the AHS study, isn't he? 21 22 Α He is. 23 No. 36. All right. Here is an article 0 24 that Dr. Alavanja wrote that came out -- let's make 25 sure we get the date right -- in 2013? Yes, okay.

Page 267 Which was about -- well, which was the same year as 1 you had your AHS data, right, that you talked about 2 3 so much --4 MR. MILLER: Excuse me, here's a copy for 5 counsel. 6 MR. LASKER: Thank you. BY MR. MILLER: 7 8 Q And here's a copy for you, Dr. Blair. 9 -- the same year that you had that --10 that AHS study, right? 11 Yes, this paper is in the same time А 12 frame, '13. 13 MR. LASKER: And I'm going to object to 14 form. Questioning a fact witness about a paper that he is not an author of. Lack of foundation. 15 16 BY MR. MILLER: 17 And here's what he says on page 5 in his 0 table about glyphosate --18 19 MR. LASKER: Where are you? 20 MR. MILLER: Table 5. 21 MR. LASKER: What page is it? 22 MR. MILLER: Let's count them out. Let's 23 count them out. One, two --24 MR. LASKER: That's not going to work. Ι thought there was a page number on the bottom. 25

Page 268 MR. MILLER: No, sir, I don't have one. 1 When you have -- when you have Table 5, let me know, 2 3 and we will get back to work here. 4 MR. LASKER: Table 5? BY MR. MILLER: 5 6 0 But this author of the AHS study in the same year that you have --7 8 MR. LASKER: I'm sorry. Is this the 9 glyphosate on the middle of the page? MR. MILLER: Table 5. Are you -- when 10 11 you've found Table 5, I'm going to ask my question. Are you ready, Counsel? 12 13 MR. LASKER: Okay. MR. MILLER: Okay. 14 15 BY MR. MILLER: 16 0 Table 5, this author of the AHS in the 17 same year that this so-called new data comes out in 18 2013 says: "Glyphosate is positively associated with non-Hodgkin lymphoma. That's the epidemiologic 19 20 evidence." 21 Do you see that, sir? 22 MR. LASKER: Objection to form. 23 Incomplete reading of the exact line that you're 24 looking at. BY MR. MILLER: 25

Page 269 You can answer, Doctor. 1 Q 2 All right. I'm actually trying to find А 3 it. Is it on the first page of the table or the 4 second? 5 I tell you what, it's easier if we all 0 look at the screen. 6 Oh, oh, sorry. All right. 7 Α I said Table 5, Dr. Alavanja savs 8 0 9 "epidemiologic evidence." Do you see that, sir? 10 А Yes. 11 0 And he lists --12 А Yeah. Okay. 13 MR. LASKER: 47. Reference Windstar. BY MR. MILLER: 14 And he says: "Glyphosate positively 15 0 associated with non-Hodgkin lymphoma." 16 17 MR. LASKER: Objection to form. 18 THE WITNESS: That's what he says. 19 BY MR. MILLER: 20 Yes, sir. And following up on counsel's 0 21 questions, you certainly never wrote a letter to Dr. Alavanja, your co-author, and said, Gee, you're 22 23 wrong when you say that glyphosate is positively associated with non-Hodgkin lymphoma, right? 24 25 Misrepresenting a document. MR. LASKER:

Page 270 1 Objection to form. BY MR. MILLER: 2 3 0 You can answer. 4 А I did not. 5 Okay. And I think -- well, the jury is 0 going to hear a lot about this, but I want to ask 6 7 you, this AHS study was a cohort study, right? 8 А Yes. 9 And these other studies, the case-Ο control studies upon which the positive association 10 11 with non-Hodgkin lymphoma, it's a different kind of epidemiological study, right, as compared to a cohort 12 13 study? 14 А Yes. 15 And that one of the problems -- all 0 16 studies have problems and no studies are perfect. Is that fair? 17 18 А Fair. Okay. One of the problems of cohort 19 0 studies is they've got to be powered up enough to 20 find statistically significant information that we as 21 scientists can rely upon, right? 22 23 True for all studies, yes. Α 24 Sure. But if they're not powered up 0 25 enough, the information comes back and it's not

Page 271 statistically significant, right? 1 2 Α Yes. 3 MR. LASKER: Objection to form. 4 THE WITNESS: It's harder to find 5 statistical significance, yes. BY MR. MILLER: 6 7 0 Sure. And a responsible scientist is not 8 going to rely upon information that is not 9 statistically significant when he has statistically significant information he can look at, right? 10 11 MR. LASKER: Objection to form. 12 THE WITNESS: Yes. BY MR. MILLER: 13 14 Sure. And one of the other problems with 0 15 cohort studies like the AHS study is loss to 16 follow-up. You've heard that phrase before, haven't 17 you? 18 А Yes. Tell the jury what "loss to follow-up" 19 0 20 means, Doctor. MR. LASKER: Objection to form. Calling 21 22 for expert opinion now. 23 BY MR. MILLER: 24 0 You can answer. А The --25

Page 272 1 MR. LASKER: Beyond the scope. 2 THE WITNESS: In the cohort studies, that 3 you have to keep following people, and in an open 4 society, it's hard to do. 5 BY MR. MILLER: 6 0 And, look, we know you and Dr. Alavanja 7 are hard-working scientists that are working on this 8 issue when you prepared that cohort study, the AHS 9 study, but the truth is you had loss to follow-up. We did. 10 А 11 0 Yeah. And the truth is the information that counsel kept asking about in a hundred different 12 13 ways for the last several hours was not statistically 14 significant, was it? 15 We can go back and look at a lot of 16 numbers, but that 2013 data was, by and large, not 17 statistically significant. 18 It was no excess, but it wasn't a А statistically significant deficit, I think. 19 20 0 Sure. 21 Is that correct. А 22 0 I think. I think that's a fair way to 23 put it, Doctor. 24 Let's look at the NAPP study. Now, the 25 NAPP study is the North American Pooled Project which

Page 273 is looking again scientifically at this issue of 1 glyphosate and non-Hodgkin lymphoma, right? 2 It's one of the pesticides that can be 3 А 4 looked at, yes. 5 And unlike the voluminous data in the AHS 0 study that had the problems of loss to follow-up that 6 7 was not statistically significant, the abstract for 8 the NAPP study shows statistically significant information, right, sir? 9 10 MR. LASKER: Objection to form, misstates 11 the document. 12 THE WITNESS: I -- I've seen a lot of 13 stuff. I sort of generally know what studies I've 14 been involved with show. I feel uncomfortable giving a "yes" or "no" answer without the evidence in front 15 16 of me to look at. I think that's correct. 17 BY MR. MILLER: Totally fair, Doctor. And let me then 18 0 show you that statistically significant information, 19 20 and we can look at it together, and I have a --21 MR. LASKER: May I have a document? 22 MR. MILLER: Of course. Of course, you 23 can. 24 MR. LASKER: What's the date of --25 MR. MILLER: 37.

Page 274 1 MR. LASKER: What is the date on this 2 one? 3 (Exhibit No. 37 was marked for 4 identification.) BY MR. MILLER: 5 6 0 All right. So here we are, Doctor. 7 Statistically significant information from a study that you authored with others. And this is an 8 9 abstract, right, sir? 10 Α Yes. 11 0 Explain to the jury what an abstract is. 12 Different scientific associations have А 13 meetings of their members, and at those meetings 14 there will be verbal presentations, and you get 15 accepted to be on the program by submitting an 16 abstract to decide who gets to be on the program. 17 And these are the abstracts. This is one of those 18 abstracts. 19 0 Sure. 20 It's not a full paper, but it's a -- a Α 21 synopsis of some work someone has done they're willing to talk about. 22 All right, sir. And it's presented at 23 0 24 the International Society for Environmental 25 Epidemiology. Right, sir?

Page 275 1 Α Yes. 2 And that was at their 2015 conference, 0 3 right, sir? 4 I think so, yes. А 5 0 All right, sir. And so the jury understands, it was an evaluation of glyphosate, 6 which is the active ingredient in Roundup, right? 7 8 А Yes. 9 And the risk of non-Hodgkin lymphoma --0 10 А Yes. 11 -- major histological subtypes in the 0 North American Pooled Project, right? 12 13 А Correct. And you are one of the authors, Aaron 14 0 15 Blair from the United States Cancer Institute, right? 16 А Yes. 17 And Dennis Weinberger -- I'm sorry, 0 Weisenburger from the City of Hope Hospital. Right? 18 19 Α Yes. 20 And among many others, right? Q A number of others. 21 А Yes, sir. 22 Q 23 And what you scientists found statistically significant and presented to the 24 25 International Society for Environmental Epidemiology

Page 276 was several findings, results. Cases who ever use 1 glyphosate had elevated non-Hodgkin lymphoma risk 2 overall, with an odds ratio of 1.51 statistically 3 4 significant. Right? 5 Α Yes. And as a scientist, statistical 6 0 7 significance is important, isn't it? 8 А Yes. 9 The highest risks were found for other 0 subtypes, "other" meaning other types of non-Hodgkin 10 11 lymphoma? It means if we looked at several 12 Α different subtypes, and the one that's sort of the 13 14 catchall category was the one that had a 15 statistically significant elevation. An odds ratio of 1.9 are almost a 16 Q 17 doubling of the risk, right? 18 А Correct. Statistically significant? 19 Q 20 А Yes. All right. Subjects who used glyphosate 21 0 for greater than five years had an increased odds 22 23 ratio that was higher, 2.58, right? 24 Α Yes. 25 And that shows as dose-dependent 0

Page 277 1 response, right? 2 That is -- you did say "subtype," right? А 3 Yes, sir. 0 4 Yeah, okay. Yes. Α 5 And dose-dependant response is strong 0 evidence of causality is what the preamble to the 6 IARC tells us, right? 7 8 А Yes. 9 MR. LASKER: Objection to form. Objection to the line of questioning to the extent 10 11 that plaintiffs now apparently are using or trying to use Dr. Blair as an expert witness. Beyond the scope 12 of the litigation. 13 MR. MILLER: Did you get the answer? 14 15 THE REPORTER: Yes. BY MR. MILLER: 16 17 0 Okay. "Compared to non-handlers, those who handled glyphosate for greater than two days/year 18 had significantly elevated odds of non-Hodgkin 19 20 lymphoma overall, odds ratio of 2.66." Was that statistically significant, 21 22 Doctor? 23 Yes. Α 24 And it goes on to tell us about various 0 25 subtypes of non-Hodgkin lymphoma, right?

		Page 278
1	А	Correct.
2	Q	What's FL?
3	А	Follicular lymphoma.
4	Q	Okay. And that odds ratio was 2.36?
5	А	Correct.
6	Q	And that's statistically significant?
7	А	Yes.
8	Q	And DLBCL, what's that?
9	А	Diffuse B-cell chronic leukemia.
10	Q	Trip triple the risk of diffuse B-cell
11	non-Hodgki	n lymph
12	А	Lymphoma, yeah.
13	Q	Right, sir?
14		Statistically significant?
15	А	Yes.
16	Q	As a result of exposure to glyphosate?
17	A	Yes.
18	Q	And this is information that was reported
19	out after	IARC found the positive association between
20	glyphosate	and non-Hodgkin lymphoma, right?
21	A	Yes.
22	Q	Okay. But you couldn't tell IARC about
23	this posit	ive finding from this NAPP study because it
24	hadn't bee	n published in March when you were in your
25	IARC meeti	ngs in Lyon, France, correct?

Page 279 1 Α Correct. 2 Scientists follow protocols, right? Q 3 Correct. Α 4 Do what you say, say what you do. Q 5 MR. LASKER: Object to form. THE WITNESS: Well, you want to make sure 6 7 that the analysis is complete and the interpretation 8 is the best you can make it. BY MR. MILLER: 9 You are not as quite as old as I, but do 10 0 11 you remember Paul Harvey? 12 I do. Α "The rest of the story," as he liked to 13 0 14 say. 15 Monsanto's lawyer showed you Exhibit 34, 16 a PowerPoint by Dr. -- is it Patchwa? 17 MR. LASKER: Pahwa. 18 THE WITNESS: Pahwa. BY MR. MILLER: 19 20 I'm sorry, I didn't mean to mispronounce Q 21 it. My apologies. 22 We will get this thing where you can look 23 at it. 24 (Counsel conferring.) BY MR. MILLER: 25

Page 280 1 0 So he showed you this, which is Exhibit 34, from the doctor --2 MR. MILLER: Well, I know it is. I know 3 4 it is. 5 (Counsel conferring. б BY MR. MILLER: Exhibit 16 is a detailed evaluation of 7 0 glyphosate using the risk of non-Hodgkin lymphoma in 8 9 the North American Pooled Project presented in June of 2015. Do you see that? 10 11 Α Yes. Okay. What counsel didn't show you was 12 0 in that PowerPoint there was in fact a statistically 13 14 significant increased risk for non-Hodgkin lymphoma 15 with use of glyphosate, right, sir? 16 MR. LASKER: Objection to form. 17 THE WITNESS: For some subtypes. 18 BY MR. MILLER: And that's for the diffuse B-cell --19 Q 20 А Yep. -- and others? 21 Ο And other. 22 А 23 Okay. For others, it was over double the 0 24 risk and statistically significant, right? 25 MR. LASKER: Objection to form,

Page 281 1 mischaracterizes the document. 2 THE WITNESS: Yes. BY MR. MILLER: 3 4 Also in that PowerPoint about this North 0 5 American Pooled Project was the frequency, that is the number of days a year, of glyphosate handling and 6 7 NHL risk. Do you see that, sir? 8 А Yes. 9 And what they're telling us is here that 0 there was overall almost a doubling of the risk 10 11 statistically significant if you handled a glyphosate for greater than two days; is that right, sir? 12 13 А Yes. And for diffuse B-cell, it was 2.49 14 0 15 statistically significant, right? 16 Α Correct. 17 0 What does the trend test tell us? It's a measurement across the different 18 Α exposure categories and whether or not that trend 19 20 line is statistically significant. Okay. What is the difference between 21 Ο 22 proxy and self-respondents? 23 Proxy would be someone else reporting for Α 24 the subject in the study where it's often the spouse or child or brother or sister. 25

Page 282 1 0 Because the person who got non-Hodgkin 2 lymphoma may not be alive to report. May not be alive or may be incapacitated 3 Α 4 and can't report. 5 Sure. So what would be the significance 0 in comparing in the North American Pooled Project 6 7 proxy information versus self-respondent information? 8 Well, the general assumption -- in fact, А 9 the data supported it -- that proxy respondents tend to make more errors and so would tend to drive the 10 11 risk down, where you get more accurate reporting and more accurate analyses based on information from the 12 13 individuals themselves. And so when proxies were compared to 14 0 15 self-respondents for frequency of greater than two days use, we had a statistical doubling of the risk 16 17 from proxy and self-respondents, right? 18 Α Yes. At one point --19 Q 20 Actually, sorry. Let me --Α 21 0 Sure, go ahead. That's one -- one component is proxies 22 А 23 can't tell you as much, which means more exposure misclassification, which drives the risk down. 24 The 25 other is the worry that proxies will remember things

Page 283 that aren't correct, and seize upon the topic of the 1 day and falsely report things in such numbers that 2 gives you a false positive. But the thing about 3 4 case-control studies is it can go in both directions. 5 And you did not find a problem with 0 self-reporting in the case-control studies when you 6 reviewed this for IARC. Fair enough? 7 8 MR. LASKER: Objection to form. 9 THE WITNESS: Well, we did some methodologic aspects to our studies to see if there 10 11 was case response bias. 12 BY MR. MILLER: 13 0 And what did you find? A We did not find case response bias. 14 You did not find a problem. Right? 15 0 16 Α With case response bias. 17 Okay. So -- and case response bias was 0 the allegation of bias against the case-control 18 studies, isn't it? 19 20 MR. LASKER: Objection to form. 21 THE WITNESS: It's one of them. 2.2 BY MR. MILLER: 23 And you didn't find it? 0 24 We did not find it. Α 25 And this PowerPoint supports the position 0

Page 284 of not finding that bias because in fact when you 1 compared self-respondents only, you got remarkably 2 similar to proxy and self-respondents, 1.98 and 2.05, 3 4 right? 5 MR. LASKER: Objection to form, incomplete discussion of the document. 6 7 THE WITNESS: Yes. 8 BY MR. MILLER: 9 Q Okay. I want to -- I want to go back to 10 Exhibit 27 that -- that Monsanto's counsel showed 11 you. It was a question and answer that was prepared 12 by IARC. 13 Do you remember generally speaking to him about this document? 14 15 (No response.) Α 16 Q Sir? 17 А Yeah. Do you generally remember speaking to 18 0 Monsanto's lawyer about this document? 19 20 А Yeah. 21 Okay. 0 22 Α Sorry. That's all right. It's a long day. 23 0 24 We're doing the best we can. 25 Let's go to page 2 of this document

	Page 285	
1	prepared by IARC in response to the allegations that	
2	this well, let's just ask about it.	
3	This question and answer: "Several of	
4	the epidemiological studies considered by the IARC	
5	expert working group showed increased cancer rates in	
6	occupational settings after exposure to glyphosate in	
7	herbicides. Can this be attributed to glyphosate as	
8	a single ingredient or could it be due to other	
9	other chemicals in the formulations? And that was	
10	the question.	
11	And the answer that IARC	
12	MR. LASKER: Objection to form, beyond	
13	the scope.	
14	BY MR. MILLER:	
15	Q And the answer that IARC was, quote:	
16	Real world exposures that people experience are to	
17	glyphosate in formulated products. Studies of humans	
18	exposed to different formulations in different	
19	regions at different times reported similar increases	
20	on the same type of cancer, non-Hodgkin lymphoma.	
21	That's what you saw, right, Doctor?	
22	MR. LASKER: Objection to form.	
23	THE WITNESS: Yes.	
24	BY MR. MILLER:	
25	Q And one of the questions that IARC wanted	

Page 286 a formal answer to was the question posed by 1 Monsanto's attorneys as to whether the Agricultural 2 3 Health Study was the most powerful study, and IARC 4 said no. Isn't that right, Doctor? 5 MR. LASKER: Objection to form. 6 THE WITNESS: It's -- it's a powerful 7 study. And it has advantages. I'm not sure I would 8 say it was the most powerful, but it is a powerful study. 9 BY MR. MILLER: 10 11 Sure. Unfortunately, not powered up 0 enough to get statistically significant information 12 13 in 2013. MR. LASKER: Objection to form. 14 In 2005 or 2013? 15 16 MR. MILLER: I said 2013. 17 MR. LASKER: 2013. Okay. Well, 18 that's --19 THE WITNESS: I would not say it in that 20 way because it assumes that if you make the study 21 bigger, you will get the same answer. And that's 22 not --23 BY MR. MILLER: 24 0 Oh. -- scientific. 25 А

Page 287 Oh, I --1 0 2 Whatever you find now with some study, Α you make it bigger, the relative risk may go in 3 4 either direction. 5 Understood. 0 So it's --6 А 7 0 I understand. 8 Power is power, but it doesn't direct Α where it's going to fall. 9 10 0 Absolutely. And what you're looking to 11 get is enough power to get statistically significant information --12 13 А Absolutely. 14 MR. LASKER: Objection to form. 15 THE WITNESS: Yes. BY MR. MILLER: 16 17 Okay. Let's go back to see what IARC's 0 18 official position is on whether the AHS was the most powerful study, and the answer provided is: 19 "The 20 Agricultural Health Study has been described as the most powerful study, but this is not correct." 21 22 That's --23 MR. LASKER: Objection to form. Can we 24 clarify which study you're talking about now? BY MR. MILLER: 25

Page 288 1 0 The official position of IARC, isn't it, 2 Doctor? You're asking me if that is the official 3 А 4 position --5 Yes, sir. 0 -- of IARC? 6 А 7 MR. LASKER: Objection to form. 8 THE WITNESS: Yes, apparently so. 9 MR. MILLER: All right, sir. All right. 10 (Counsel conferring.) 11 BY MR. MILLER: 12 Remember counsel for Monsanto spent a 0 long time talking to you about the draft of the AHS 13 14 study that you have not released because -- you explained to us, I guess, why. It -- it's still --15 this still hasn't been published, has it? 16 17 А Well, we published half of it. We published on the insecticides. 18 19 Q Sure. 20 But not on the herbicides. А 21 I understand. But in this -- yes, sir. 0 22 I understand. 23 In this draft that counsel talked to you 24 about, he didn't show you the sentence, you write in there --25

Page 289 1 MR. LASKER: Where are you? 2 MR. MILLER: On page 20, bottom of the 3 page. 4 BY MR. MILLER: 5 -- quote: Cautious interpretation of 0 these results is advised. Since the number of 6 exposed cases for each subgroup of NHL --7 8 MR. LASKER: Objection to form. Where 9 are you? BY MR. MILLER: 10 11 -- for each subgroup of NHL in the AHS is 0 still relatively small. 12 13 MR. MILLER: It's pages 20 and 21. BY MR. MILLER: 14 15 That's what you --0 MR. LASKER: Objection to form. 16 17 BY MR. MILLER: 18 That's what you wrote, right, Doctor? 0 MR. LASKER: Objection to form, 19 20 mischaracterizing the document. THE WITNESS: Well, this was in -- this 21 is in the document. 2.2 BY MR. MILLER: 23 24 Yes, sir. 0 25 Right, it was in the document. А

Page 290 1 Q That's right. 2 That's what that non-finished document Α 3 says. 4 Yes, I understand. Q 5 Α Yes. And the reason you caution people because 6 0 this is a draft document, isn't it, sir? 7 8 Yes. Yeah. А 9 MR. LASKER: Objection. BY MR. MILLER: 10 11 And the data in this document only goes 0 to 2008, right, sir? 12 13 I think that's correct. А 14 0 I understand. 15 А I don't remember for sure. 16 Q And I think you've -- I think you've 17 already said as much, but we're looking at an old 18 interview that you did --19 MR. LASKER: Do you have a document for 20 me? MR. MILLER: In a minute when I use one. 21 22 MR. LASKER: Okay. 23 BY MR. MILLER: Recall by -- recall bias, it doesn't add 24 0 25 up to much. Isn't that basically your experience?

Page 291 1 MR. LASKER: Objection to form, beyond the scope, calling for expert opinion. 2 3 THE WITNESS: In our evaluation of it, it 4 doesn't occur very often. 5 BY MR. MILLER: 6 Okay. And when it -- when it does 0 7 happen, it can cause the association between the 8 agent and the disease to actually look smaller than it really is or look a little larger than it really 9 It can go in either direction. 10 is. 11 It can go in either direction. Α MR. LASKER: Objection to form, calling 12 for an expert opinion, beyond the scope of the 13 14 deposition. BY MR. MILLER: 15 You know what SEER data is, right? 16 Q 17 Α Yes. In SEER data, since 1975 to present, the 18 0 number of cases of death by non-Hodgkin lymphoma in 19 20 this country have doubled, haven't they? MR. LASKER: Objection to form. 21 Objection, beyond the scope --22 23 BY MR. MILLER: 24 0 You can answer. 25 MR. LASKER: -- of the deposition as

Page 292 noticed, beyond the scope of my direct examination 1 2 and without a document. BY MR. MILLER: 3 4 You can answer. Q 5 А Both mortality and incidence has gone up. This, I believe, was Exhibit 13. Counsel 6 0 marked some notes from some other fellow that was 7 on -- invited to be a member of IARC. 8 9 Do you remember that general line of 10 questions? 11 Α Yes. Okay. So without any lawyers around, 12 0 this fellow made some notes. What was his name 13 14 again? 15 A It was Ross, I think. He said --16 Q 17 Α Last name Ross. He said: "Case-control glyphosate, 18 0 non-Hodgkin lymphoma." Right? 19 20 А Yes. 21 That wraps it up, doesn't it really? 0 22 MR. LASKER: Object to form. THE WITNESS: Well, that's what he 23 24 thought. BY MR. MILLER: 25

Confidential - Subject to Protective Order

Page 293 That's what the panel unanimously 1 0 thought, right? 2 3 MR. LASKER: Objection to form. 4 THE WITNESS: Yes. BY MR. MILLER: 5 6 Okay. Has anything you've been shown by 0 Monsanto's lawyers in the 3 hours and 40 minutes that 7 he questioned you changed the opinions that you had 8 9 at the IARC meeting about glyphosate and non-Hodgkin 10 lymphoma? 11 MR. LASKER: Objection to form, beyond 12 the scope. BY MR. MILLER: 13 14 0 You can answer. 15 А No. 16 MR. MILLER: I didn't even use an hour. 17 Thank you for your time. 18 MR. LASKER: I have like three questions, 19 but I will ask them from here. We don't have to go 20 off. MR. MILLER: Sure. Sure. If the doctor 21 is okay with it, I'm okay with it. 22 23 THE WITNESS: That's fine. 24 **RECROSS-EXAMINATION** 25 BY MR. LASKER:

Page 294 1 0 Dr. Blair, I just want to clarify 2 something. I believe you said in response to one of the questions from Mr. Miller that you don't look at 3 4 nonsignificant data. Is that what you said? 5 Α Well, if I did, it's wrong. 6 Okay. Clearly, you do look at 0 7 nonsignificant data in evaluating the scientific evidence, correct? 8 9 Absolutely. Α And epidemiological studies that do not 10 0 11 find a significant association are important studies 12 to consider in evaluating whether or not a substance can cause or is associated with an illness, correct? 13 Absolutely. They're -- all data are 14 А 15 useful to some extent. 16 Q And you were shown -- strike that. 17 Mr. Miller asked you about the 18 case-control studies and whether or not they found a positive association. And just so the record is 19 20 clear, the North American Pooled Project analysis that we've discussed a fair amount today is a pooling 21 of case-control studies, correct? 2.2 23 Α Correct. 24 In fact, it's a pooling of all the 0 case-control studies in North America, correct? 25

Confidential - Subject to Protective Order

Page 295 1 Α T think so. 2 And as we discussed in our 0 3 presentation -- in our questions --4 Α Of non-Hodgkin lymphoma. 5 0 Exactly. As we discussed in our questions and your 6 7 answers earlier, when the pooled data is looked at for all the case-control studies in North America for 8 9 non-Hodgkin lymphoma and that data is controlled for exposures to other pesticides, there is no 10 11 statistically significant positive association between glyphosate and non-Hodgkin lymphoma, correct? 12 13 А Well, it depends on what you actually look at. Overall, yes. Now, whether you look at 14 categories, whether you look at subgroups, it's not 15 that simplistic. 16 17 The yes/no, ever exposed versus exposed 0 analysis that was used in the meta-analyses, for 18 example, that you relied upon that I prepared show 19 20 that for all the case-control data in North America, when it's controlled for exposures to other 21 pesticides, there is no statistically significant 22 23 positive association between glyphosate and 24 non-Hodgkin lymphoma, correct? 25 I think that's right for ever/never Α

Page 296

1 exposure.

2	Q And Mr. Miller on redirect showed you
3	some presentation from the North American Pooled
4	Project, and the data that he showed you and let
5	me absolutely just go to this. This was plaintiffs'
6	exhibit or Exhibit 16, I'm sorry, and he went
7	through and showed certain data on he pointed out
8	certain numbers that were statistically significant
9	among the various evaluations that were presented in
10	this I'm sorry June 10, 2016 presentation. Do
11	you recall that?
12	A Yes.
13	Q And those data points that he was
14	pointing to you was of the analysis that was not
15	controlled for exposures to other pesticides,
16	correct?
17	A If you say so. I don't remember.
18	Q Okay. So you don't know when you were
19	looking at it, you didn't know if that data was
20	controlled or not controlled. You were just reading
21	what the numbers were on the page.
22	A Absolutely.
23	MR. LASKER: I have no further questions.
24	MR. MILLER: Just
25	MR. LASKER: Oh, that's the document.

Confidential - Subject to Protective Order

Page 297 1 MR. MILLER: Just one. 2 REDIRECT EXAMINATION 3 BY MR. MILLER: 4 So a person who ever used Roundup for one 0 5 time would be in the ever exposed group. 6 THE WITNESS: Yes. 7 MR. MILLER: Okay. Thank you for your 8 time. 9 MR. LASKER: No further questions. Thank 10 you, Dr. Blair. 11 MR. GREENE: Before we stop. Doctor, you have the right to read your deposition, and even 12 13 though I know that the reporter does a very good job 14 as far as taking down everything that was said and 15 all the questions asked, knowing how you are with 16 respect to accuracy, I would suggest in this case you 17 may want to read. 18 THE WITNESS: I think I would like that. MR. MILLER: Yeah, we'll send you a copy. 19 20 We'll send it to your counsel and --21 MR. LASKER: The court reporter can send 2.2 it to him. 23 MR. MILLER: There is a certain amount of 24 time involved. 25 THE WITNESS: Sure.

٦

	Page 298
1	MR. MILLER: Sure, absolutely, we'll
2	THE WITNESS: I have one other request.
3	Can I have a card from everybody in this room?
4	MR. MILLER: Sure. Absolutely.
5	THE VIDEOGRAPHER: The time is 3:58 p.m.,
6	March 20th, 2017. Going off the record, concluding
7	the videotaped deposition.
8	(Whereupon, at 3:58 p.m. the
9	deposition of AARON EARL BLAIR,
10	Ph.D. was concluded.)
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

1 _ _ _ _ _ _ ERRATA 2 _ _ _ _ _ _ 3 4 PAGE LINE CHANGE 5 _____ б REASON: 7 _____ 8 REASON: 9 ___ __ 10 REASON: _____ _____ 11 12 REASON: 13 _____ **REASON:** 14 15 _____ 16 REASON: _____ 17 _____ 18 REASON: 19 _____ 20 REASON: 21 _____ 22 REASON: 23 _____ 24 **REASON**: _____ 25

Confidential - Subject to Protective Order

ACKNOWLEDGMENT OF DEPONENT
I,, do
hereby certify that I have read the
foregoing pages, and that the same is
a correct transcription of the answers
given by me to the questions therein
propounded, except for the corrections o
changes in form or substance, if any,
noted in the attached Errata Sheet.
AARON EARL BLAIR, PH.D. DATE
Subscribed and sworn
to before me this
day of, 20
My commission expires:
Notary Public

1	CERTIFICATE OF NOTARY PUBLIC
2	
3	I, LESLIE ANNE TODD, the officer before whom the
4	foregoing deposition was taken, do hereby certify
5	that the witness whose testimony appears in the
6	foregoing deposition was duly sworn by me in
7	stenotype and thereafter reduced to typewriting under
8	my direction; that said deposition is a true record of
9	the testimony given by said witness; that I am neither
10	counsel for, related to, nor employed by and the
11	parties to the action in which this deposition was
12	taken; and, further, that I am not a relative or
13	employee of any counsel or attorney employed by the
14	parties hereto, nor financially or otherwise
15	interested in the outcome of this action.
16	
17	LESLIE ANNE TODD
18	Notary Public in and for the
19	District of Columbia
20	My commission expires:
21	November 14, 2017
22	
23	
24	
25	